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Malaria is one of the leading causes of deaths worldwide. Despite strategic 
implementations aimed at decreasing mortality and morbidity rates in recent decades, 
this plasmodial disease continues to impact public health and the economies of 
developing countries. Furthermore, the emergence of resistance toward current 
antimalarial treatments increases the necessity for the development of novel 
antimalarials. 
The benzimidazole scaffold is an extensively researched privileged scaffold in 
medicinal chemistry because of its capacity to interact with numerous biological 
systems in various diseases, including malaria. Based on previous metabolite 
identification studies in liver microsomes, a new series of pyrido[1,2-a]benzimidazole 
(PBI) metabolites containing Mannich base side-chains were designed and 
synthesized. Their in vitro parasite (Plasmodium falciparum) growth and β-hematin 
formation inhibition activities, turbidimetric solubility, cytotoxicity, and microsomal 
metabolic stability in mouse liver microsomes were evaluated. To investigate structure 
activity relationships (SARs), the study was broadly diversified into two series (SAR-1 
and SAR-2). Mannich base side-chains from SAR-1 were designed and synthesized 
as hypothesized N-dealkylated metabolites. In SAR-2, hypothesized N-dealkylated 
metabolites were compared with their respective parent compounds with a focus on 
modifications around the PBI core.  
The most potent analogues exhibited sub-micromolar activity (50% inhibitory 
concentration (IC50) < 1 µM) against the drug-sensitive NF54 strain of Plasmodium 
falciparum. Some compounds showed high activity against early- and late-stage 
gametocytes, the sexual stage transmissible forms of the parasite. Overall, 
compounds in this series were more active against early-stage gametocytes than late-
stage gametocytes, thus indicating stage-specificity. All but three of the analogues 
synthesized were potent inhibitors of β-hematin formation. Most compounds showed 
no cytotoxicity against HepG2 and Chinese hamster ovarian (CHO) cells. Inclusion of 
Mannich base side-chains influenced the in vitro microsomal metabolic stability of 
compounds. As expected, N-dealkylated (desethyl) metabolites showed greater 
metabolic stability relative to their equivalent parent compounds. 
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CHAPTER 1: Introduction and literature review 
1.1 Chapter overview 
In this chapter, a brief overview of malaria and its treatment is provided. Malaria is 
highlighted with respect to disease and burden, the life-cycle of Plasmodium 
falciparum, current antimalarial chemotherapies, and the hemoglobin degradation 
pathway. The importance of drug properties with regard to absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) is discussed with emphasis on metabolic 
bioactivation pathways. Background to the project is provided by highlighting the use 
of Mannich bases as antimalarials, as well as ongoing investigations into the potential 
of pyrido(1,2-a)benzimidazoles (PBIs) as antimalarials. To sum up the chapter, a 
research program is included, and study justifications, hypotheses, and study 
objectives are briefly mentioned. 
 
1.2 Malaria 
1.2.1 Malaria disease and burden 
Malaria as a human parasitic disease represents one of the most significant burdens 
in terms of its impact on both economies and public health, especially in low-income 
countries.1,2 Despite strategies implemented by the World Health Organisation (WHO) 
aiming to reduce mortality and morbidity rates in recent decades, 228 million malaria 
cases were recorded worldwide in 2018 (Figure 1.1).1  
The malaria burden is heaviest in the WHO African region, with 213 million cases 
(93%) in 2018, followed by the WHO South-East Asia region (3.4%), and the Eastern 
Mediterranean region (2.1%).1 P. falciparum is the pathogen responsible for disease 
associated with the highest rates of morbidity and mortality, although Plasmodium 
vivax is responsible for approximately 3.3% of all estimated cases, with 53% of these 
in the WHO South-East Asia region, and is the predominant parasite in the WHO 
region of the Americas (75%).1 Despite the unprecedented progress made towards 
lowering these alarming statistics, recent findings showed an increase of 









Figure 1.1: Mortality and incidence rates of malaria from 2010 to 2018 (World Health Organisation - 
World Malaria report 2019) 
 
The number of malaria cases peaked in 2017 (231 million cases) and has since then 
decreased to approximately 228 million in 2018. Although these statistics attest to 
successful global efforts made to control the disease, they do remain alarmingly high, 
thus highlighting impediments to disease treatment including the development of 
insecticide resistance in malaria vectors4 and reduced sensitivity to the first-line 
artemisinin combination therapy (ACT) regimen.5 Furthermore, the only licensed 
vaccine (RTS,S) is hindered by limited efficacy and is currently being introduced only 
as a pilot scheme in a few regions in sub-Saharan Africa.6 This situation urges the 
discovery of novel, safe, and effective therapeutic options to tackle this disease.7  
 
1.2.2 P. falciparum life-cycle 
Malaria is a parasitic disease that is transmitted via the bite of a female, Plasmodium-
infected Anopheles mosquito.8 Infection may be caused by five different species of the 
genus Plasmodium: P. falciparum, P. vivax, P. ovale, P.knowlesi and P. malariae. The 
most severe of these pathogens in terms of virulence and morbidity is P. falciparum,9 
although P. vivax also has a major impact on populations with regard to morbidity.10 
Understanding the life-cycle and transmission of P. falciparum may reveal the sites of 
action of potential drugs. The cycle has distinct stages that include both asexual and 




Figure 1.2: Life-cycle of the malaria parasite (Cowman, A; Healer, J; Marapana D et al. Malaria: Biology 
and Disease. Cell. 2016; 167(3):610-624) 
 
The life-cycle of P. falciparum is a continuous loop that relies on numerous biological 
and cellular changes and regulation in both the Anopheles mosquito and human hosts. 
Briefly, during a blood meal, a parasite-infected mosquito injects sporozoites into the 
human host from its salivary glands (Figure 1.2A).11 The motile sporozoites penetrate 
into small capillaries through the dermis of the human host, thus stimulating the host 
immune response.12 Circulating sporozoites quickly access the liver by a process 
known as traversal.13 Sporozoites are able to cross the sinusoidal barrier comprising 
fenestrated endothelial cells and are mopped up by Kupffer cells (macrophage-like 
immune cells) into the liver where the exo-erythrocytic or liver-stage cycle of growth 
occurs.14,15 Importantly, sporozoites are injected into the dermis in “migratory mode” 
and convert to “invasive mode” upon interaction with hepatocytes.13 Sporozoites 
penetrate hepatocytes and grow in size over a few days, developing into schizonts 
over the subsequent 2–10 days of the liver stage. Parasites remain within a 
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parasitophorous vacuole membrane into late liver-stage development (Figure 1.2B),13 
which culminates in the release of up to 40 000 merozoites per hepatocyte into the 
blood-stream by budding of parasite-filled merozoites16,17 These merozoites are 
carried into general circulation and eventually break apart, releasing invasive 
merozoites that attach to and invade red blood cells (RBCs) to start the erythrocytic 
cycle of infection, also known as the blood-stage cycle.15,18  
Erythrocyte invasion is a dynamic, multi-step process comprising pre-invasion, active 
invasion, and echinocytosis, and which is completed in 2 min.19 Pre-invasion involves 
the initial interaction of merozoites with RBCs and little is understood about the 
molecular details of this step. Merozoite surface protein 1 (MSP1) is a major 
glycophosphatidylinositol (GPI)-associated protein on the merozoite surface that is 
involved in erythrocyte binding, although it is not absolutely required for invasion of 
RBCs.20,21 Ultimately, pre-invasion involves robust interactions between merozoites 
and RBCs directed by a number of protein interactions and cellular signaling 
molecules resulting in parasite actomyosin motor-driven deformation of the host cell.19 
Following deformation of the erythrocyte, the apical end of the merozoite orientates 
itself to lean against the RBC membrane.22 A number of complex merozoite surface 
protein interactions are associated with an influx of Ca2+ into the host RBC.19,23 Tight 
junctions formed between parasite-derived proteins cause the irreversible attachment 
of merozoites to erythrocytes. Lipid-rich rhoptry contents form the parasitophorous 
vacuole membrane while the merozoite is propelled into the RBC using the force 
generated by the parasite actomyosin motor.24 After the active invasion phase, 
membranes at the posterior end of the merozoite fuse, thus sealing the parasite within 
the parasitophorous vacuole and erythrocyte, a process known as endocytosis. 
Echinocytosis follows, which causes RBC shrinkage and the formation of spiky 
protrusions.  
Following RBC infection, cell division (schizogony) occurs over the next 48 h and 
results in the formation of 16–32 merozoites that migrate when developed. Merozoites 
immediately differentiate into erythrocytic trophozoites.15 Trophozoites feed off the 
hemoglobin of invaded RBCs where mitotic growth causes the development of 
schizonts that continually divide by mitosis to form differentiated merozoites.25 
Approximately 48 h after intracellular growth, the host cell (RBC) membrane ruptures, 
5 
 
causing the release of merozoites that reattach and further invade healthy RBCs to 
continue the asexual blood cycle.15 During schizogony, some merozoites within 
schizonts differentiate into male and female micro- and macro-gametocytes 
respectively, instead of the asexual trophozoites, upon entering a new RBC (Figure 
1.2C).17,26  
The transmission of malaria from humans to mosquitoes is dependent on development 
of the sexual stages and this has been recognized as a potential intervention point, 
either with the use of transmission-blocking drugs or vaccines.27 Environmental 
stimuli, such as high parasitemia and exposure to drugs such as chloroquine (CQ), 
are associated with increased conversion to gametocyte production, indicating that 
parasites can sense their environment.27, 28 The mosquito sexual stage of the parasitic 
life-cycle begins when a feeding female takes up circulating gametocytes in its blood 
meal (Figure 1.2E). In the midgut of the mosquito, RBCs lose their membranes and 
expose gametocytes, which become sexually stimulated. The male gametocyte 
undergoes nuclear division and flagellation to prepare for fertilization of the female 
gametocytes.29 A diploid zygote is formed when a male gametocyte penetrates a 
female gametocyte. Further divisions allow for differentiation and growth of the zygote 
into elongated sporozoites.30 Following sporozoite maturation, the capsule bursts 
open, thus releasing hundreds of sporozoites into the hemocoel of the mosquito. 
These eventually migrate to and penetrate the salivary gland of the mosquito.30 When 
a mosquito in search of a blood meal penetrates the skin of a human, salivary fluid is 
released along with several hundred sporozoites, bringing the life-cycle of the 
mosquito back to its start.30  
Transmission is limited by environmental factors (primarily temperature) affecting the 
ability of the mosquito to sustain parasite development. Transmission is also linked to 
the frequency of contact between infected mosquitos and humans, which is affected 
by mosquito density, location, and feeding habits. As exposure rises, transmission 
becomes more consistent year to year, and exposed individuals begin to develop a 
degree of immunity. In contrast, areas where the risk of infectious bites is low and 
unpredictable, malaria is said to be unstoppable.27 Under such circumstances, 
patients of all ages are susceptible to infection, and infective episodes generally result 
in clinical disease. 
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1.2.3 Current antimalarial chemotherapies  
Considerable progress has been made towards reducing the malaria burden through 
vector control, diagnostic-led case management, and chemoprevention.31 
Preventative strategies include the use of long-lasting insecticide-treated nets, indoor 
residual spray, and intermittent preventative therapy for pregnant women.31 Over the 
last decade, technological progress in molecular platforms has stimulated tremendous 
advances in the research and development of novel drug candidates that may become 
viable alternatives to current clinically approved medicines. As malaria is an infectious 
disease, resistant parasite strains are continually emerging, requiring the constant 
development of new molecules. The last few years have seen a new generation of 
compounds with novel mechanisms of action entering clinical development.31,32  
Malaria incidence rates have significantly reduced over the last 15 years, mainly via 
the protection of at-risk populations with insecticide-treated bed nets and spraying with 
insecticides and larvicides.33 Perhaps the most exciting preventative strategy is the 
development of a malaria vaccine. The pre-erythrocytic vaccine RTS,S/AS01 offers 
the potential for a large-scale roll-out.34 However, RTS,S/AS01 shows limited efficacy 
against severe cases of malaria (18–36%) with reported short-lasting immunity, and is 
thus not effective enough to drive eradication alone.34 More vaccines are currently 
under evaluation, including an irradiated sporozoite vaccine that is approaching clinical 
phase III trials.35 P. falciparum’s complex life-cycle presents an array of targets in the 
parasite developmental stages that may be inhibited using various drugs or drug 
combinations to treat malaria.31 Burrows and colleagues recently profiled the ideal 
types of molecules (target candidates) and medicines (target product) for novel 
malaria therapy, thus helping to establish a crucial blueprint for malaria drug design 
by defining the minimum acceptable profiles for ideal candidate molecules and 
drugs.31,36 Considering the various stages of P. falciparum’s life-cycle, transmission 
blocking, efficacy, and exposure, target candidate profiles (TCPs) for new antimalarial 
drugs were defined.31  
Current antimalarials may be grouped into several classes: 4-aminoquinolines, 8-
aminoquinolines, arylamino alcohols, antifolates, artemisinins, antibiotics, and 
inhibitors of the bc1 complex in the parasite electron-transport chain. Artemisinin 
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combination therapy (ACT) is the current WHO-recommended treatment option for 
uncomplicated malaria.37  
Artemisinins, including synthetic derivatives such as artesunate (Figure 1.3 (1)), 
artemether (2), and dihydroartemisinin (3), act on both the early and late stages of the 
parasite’s life-cycle within the human host.38 ACT regimen is fast-acting and safe, and 
involves an artemisinin derivative combined with a long-acting partner antimalarial. 
Combination therapy aims to enhance the therapeutic effects of the treatment by 
lengthening drug exposure in a synergistic manner to delay the onset of resistance.31 
The antifolates sulfadoxine (4) and pyrimethamine (5) synergistically inhibit enzymes 
within the folate pathway and are currently recommended by the WHO as an 
intermittent preventative treatment in pregnant women (IPTp).39  
 
Figure 1.3: Current drugs used in artemisinin combination therapy (ACT) and intermittent preventive 
treatment in pregnant women (IPTp) 
1, artesunate; 2, artemether; 3, dihydroartemisinin; 4, sulfadoxine; 5, pyrimethamine 
 
Antibiotic antimalarials including doxycycline (Figure 1.4 (6)) and clindamycin (7) 
inhibit protein synthesis. Their slow onset means they have therapeutic potential for 
combination with fast-acting artimisinins.31 Quinine (8), mefloquine (9), lumefantrine 
(10), and halofantrine (11) are examples of aryl-amino alcohols. Both mefloquine (9) 
and lumefantrine (10) are used in combinations with artesunate (1) and artemether 
(2), respectively, whilst halofantrine (11) is not widely used because of severe 
concerns relating to cardiotoxicity.40 Atovaquone (12) is mostly used for 
chemoprevention in combination with proguanil (13), and for the treatment of 




Figure 1.4: Chemical structures of currently prescribed antibiotics, aryl amino alcohols, and respiratory 
chain inhibitors 
6, doxycycline; 7, clindamycin; 8, quinine; 9, mefloquine; 10, lumefantrine, 11, halofantrine, 12, 
Atovaquone and 13, proguanil. 
 
The only drug currently used for the treatment of infections with P. vivax and relapsing 
forms of malaria is the 8-aminoquinoline drug primaquine (Figure 1.5 (14)).41 
Tafenoquine (15) is an analogue of 14 that has undergone phase II and phase III 
clinical evaluation and shows signs of increased potency and decreased toxicity 
compared to that of 14.42,43 CQ (16) is the most widely known of the 4-aminoquinoline 
class and is used to treat uncomplicated P. vivax malaria. Following widespread 
resistance to 16, amodiaquine (17) was designed as an alternative, but presents 
limitations relating to agranulocytosis and hepatotoxicity. However, 17 is currently 
used in combination with 3 as part of the ACT-based treatment regimen. Piperaquine 
(18), another 4-aminoquinoline used in ACT treatment in combination with 3, shows 
excellent tolerability and high malaria cure rates and has promising potential to prevent 













Figure 1.5: Chemical structures of various currently used antimalarials 
14, primaquine; 15, tafenoquine; 16, chloroquine; 17, amodiaquine; 18, piperaquine 
 
Although many uncomplicated malaria infections are successfully treated, the above 
mentioned chemotherapies have limitations.3 Evidence of parasite tolerance towards 
ACT-based treatment heightens the urgency for novel antimalarial drug discovery and 
development. In order to fast track the eradication of malaria, Medicines for Malaria 
Venture (MMV)  have an open portfolio of all the projects they support from research 













Table 1.1: Drug development stages and Medicines for Malaria Venture (MMV) open labeled portfolio 
 
 












































































Target Candidate Profiles: 
 Asexual blood stages   Prophylaxis   Transmission reduction   Relapse prevention 
Target Product Profiles: 
3-day cure, ACTs    Uncomplicated malaria treatment for single-exposure radical cure and/or 
resistance management  Severe malaria treatment / pre-referral intervention  
Intermittent / seasonal malaria chemoprevention  Products targeting prevention of relapse for 
P. vivax  Single-exposure chemoprotection  
 paediatric formulation 
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The importance of this portfolio is the transparent progression of compounds through 
the drug development pipeline. Currently there are several compounds undergoing 
lead optimization strategies (not shown), which is encouraging since there is currently 
only one compound in the candidate profiling stage of the pipeline, namely 
MMV1581373 which is currently undergoing profiling at Sanofi.  
Furthermore, in order to support the malaria eradication campaign MMV has defined 
Target Candidate Profiles (TCPs) and Target Product Profiles (TPPs).46 These TCPs 
highlight the important features of the individual compounds and give an indication of 
the effect of the compounds on various stages of the life cycle of P. falciparum. The 
TPPs are used to characterize compounds in the human volunteer stages of 
development according to the type of malaria which the compounds are likely to 
combat.  
Briefly from Table 1.1, there are currently six preclinical candidates (MMV533, 
MMV370, MMV371, MMV183, MMV646 INE693 and UCT943) which are in the 
preclinical development phase all of which target the asexual blood stages. Additional 
to asexual blood stage activity MMV370 and MMV371 can be used for prophylaxis in 
order to prevent the disease. Furthermore, preclinical candidate MMV183 has the 
potential to reduce transmission of the disease.  
There are currently four compounds in human volunteer trials namely P218 (19), 
M5717 (20), MMV253 (21) and Atoguanil which contains the active pharmaceutical 
ingredients atovaquone (22) and proguanil (23) shown in Figure 1.6. Compound 19 is 
a P. falciparum dihydrofolate reductase (DHFR) inhibitor with a clinically validated 
pathway and proof of pharmacology has been confirmed in volunteer infection studies 
(VIS). Although it has good tolerability and pharmacokinetics in humans, it is limited 
by a short human half-life.47 Currently 19 is in VIS for prophylaxis which started in 
December 2018. Compound 20 is a P. falciparum translation elongation factor 2 (EF2) 
inhibitor which is a novel mechanism of action with comparable activity across all 
stages of the malaria parasite life-cycle. Currently 20 is undergoing a volunteer 
infection studies.48 Compound 21 has an unknown mechanism of action, however it 
has a low resistance potential from in vitro studies. It was approved as a preclinical 
candidate in 2014 and first-in-human studies started in February 2019.49   Atoguanil 
has the potential to provide a lower cost alternative, making such products more 
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accessible to people living in malaria endemic countries for prophylaxis and is 
currently under investigation by Ipca Laboratories.  
 
Figure 1.6: Chemical structures of compounds currently in the Human volunteer’s stage of research 
19, P218; 20, M5717; 21, MMV253 and Atoguanil which is made up of 22, atovaquone and 23, proguanil 
 
 
There are currently six treatments in the patient exploratory phase of development 
namely; Ferroquine/Artefenomel (24), Ganaplacide/Lumefantrine (25), Cipargamin 
(26), DSM265 (27) and MMV048 (28) shown in Figure 1.7. The Ferroquine/ 
Artefenomel (24) treatment makes use of Ferroquine which inhibits heme 
detoxification combined with the synthetic trioxolane mode of action of Artefenomel. 
The combination of these two drugs allows for long duration of plasma exposure 
(Ferroquine) with the fast killing of parasites as well as the possibility of transmission 
blocking.48 This combination treatment is currently undergoing phase IIb clinical 
studies. The combination therapy involving Ganaplacide and Lumefantrine (25) has 
the potential for prophylaxis and the treatment for uncomplicated malaria. 
Furthermore, Ganaplacide has a novel mechanism of action which shows activity to 
resistant strains of P. falciparum, with the rapid killing of parasites.50 This combination 
therapy is currently undergoing a phase IIb combination study. Cipargamin (26) aims 
to treat both uncomplicated cases of malaria as well as severe malaria with a novel 
mode of action by inhibiting the PfATP4 pathway of P. falciparum. 26 shows rapid 
killing of parasites and has the potential for transmission-blocking. 26 does however 
need further safety profiling and is therefore undergoing a phase II malaria patient 
study which started in February 2019 as well as Parenteral Glucagon-like peptide 
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(GLP) safety study which is currently in progress.51 DSM265 (27) is a Plasmodial 
dihydroorotate dehydrogenase inhibitor which is a novel mode of action. There is 
however a potential for resistance because it targets a single enzyme only.52 Currently 
27 has undergone phase IIa studies and controlled human malaria infection studies in 
combination with Artefenomel.53,54 UCT identified the aminopyridine  28 and revealed 
its novel mode of action which is by inhibiting the P. falciparum phosphatidylinositol 4-
kinase  (PfPI4K) enzyme. Encouragingly, there is a long half-life found in humans as 
well as the potential for transmission blocking. There are however safety concerns in 
pregnant women which is a challenge which needs to be addressed. 28 is currently 
undergoing phase IIa studies in Ethiopia.31 
 
Figure 1.7: Chemical structures of compounds currently in the patient exploratory stage of development; 




There are currently four treatment candidates in the patient confirmatory phase of 
development, namely; (29) Dihydroartemisinin-piperaquine dispersible, (30) 
Tafenoquine Paediatric, (31) Sulfadoxine-pyrimethamine and (32) Artemether-
lumefantrine shown in Figure 1.8. The combination therapy of Dihydroartemisinin-
piperaquine (29) aims to make use of a pharmacokinetic bridging strategy to establish 
a paediatric dose on an already used ACT treatment regime in adults.55 29 is 
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anticipated to have comparatively long post-treatment protection. There are however 
confirmed piperaquine resistance cases and there is a potential for cardiac monitoring 
restrictions.56,57 29 has undergone pharmacokinetic studies in children and a dossier 
is under development for submission to the European Medicines Agency. Tafenoquine 
paediatric (15) makes use of the already approved antimalarial Tafenoquine and using 
a pharmacokinetic bridging strategy to establish a paediatric dose. The efficacy in 
adults is already established and a single-dose treatment in children who cannot take 
the adult tablet is being developed.58 There are however challenges associated with 
glucose-6-phosphate dehydrogenase (G6PD) deficient patients which requires 
quantitative testing for G6PD deficiency in patients.59 Sulfadoxine-pyrimethamine (30) 
combination aims to cure intermittent and seasonal malaria by means of 
chemoprevention. Although the treatment is currently being used in adults in 
combination with amodiaquine, a treatment regime is being developed for sulfadoxine 
and pyrimethamine without any additional antimalarial compounds. Artemether-
lumefantrine (31) is an already approved combination therapy which is undergoing 
pharmacokinetic studies to tailor a dose for children that weigh less than 5 kg.  
 
Figure 1.8: Chemical structures of compounds currently in the patient confirmatory stage of 
development; 29, Dihydroartemisinin-piperaquine dispersible; 15, Tafenoquine Paediatric; 30, 
Sulfadoxine-pyrimethamine; 31, Artemether-lumefantrine <5Kg. 
 
The malaria drug development process highlights the need for a full understanding of 
drug and safety profiles to predict therapeutic effects expected in humans. By 
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understanding drugs that have been rejected in the late stages of development, 
possible liabilities that may be associated with new drug candidates based on 
chemotypes, specific MoAs, and modes of resistance can be flagged. One way to 
achieve this is by understanding the MoAs of established drugs as a starting point for 
the development of new drug candidates. Structural similarities with existing drug 
candidates displaying established MoAs could indicate that a particular scaffold may 
impact a specific pathway because of its similarity to other drug candidates. One such 
pathway is the hemoglobin degradation pathway, which is present in Plasmodium spp. 
and has been targeted by other prescribed antimalarials.60 
1.2.4 Hemoglobin degradation  
Hemoglobin degradation and formation is a part of the P. falciparum life-cycle that is 
an established target of certain antimalarial drugs such as CQ and AQ.61,62 The 
formation of hemozoin from toxic heme is a unique process that has been adopted by 
Plasmodium spp. for survival. As is outlined in Figure 1.9, P. falciparum relies on 
human hemoglobin for growth and division.60 Hemoglobin is catabolized into hemozoin 









Figure 1.9: Hemoglobin degradation pathway showing catabolism63 (aa – amino acids; PfDPAP1 – P. 
falciparum Dipeptidyl Aminopeptidases 1; PfAPP – P. falciparum aminopeptidase P; PfM1AAP - P. 
falciparum M1 alanyl aminopeptidase, PfM17LAP – P. falciparum M17 leucine aminopeptidase and 




Heme (or hematin, Figure 1.10) that is released during hemoglobin catabolism is toxic 
to vacuolar proteases and parasite membranes.62 Parasites have developed a non-
enzymatic strategy to detoxify free heme by converting it into an insoluble polymer 
called hemozoin, which aggregates in the digestive vacuole.64 Several antimalarial 
drugs are known to inhibit hemozoin formation by complexing with ferriprotoporphyrin 
IX (FPIX), thereby preventing polymerization to form hemozoin.62 Drugs that inhibit the 
formation of hemozoin include the 4-aminoquinolines CQ (16) and AQ.62,65 It was 
recently hypothesized that PBIs may adopt flat conformations to allow for - stacking 




Figure 1.10: The structure of hematin, a toxic molecule to P. falciparum that is detoxified by the parasite 
by converting to hemozoin 
 
1.3 ADME profiling in drug discovery and development 
Pharmacokinetics (PK) defines the processes that a drug undergoes after oral 
administration, and may be referred to as drug metabolism and pharmacokinetics 
(DMPK).67 After oral administration, the therapeutic effects of a drug may only be 
realized if the compound can successfully dissolve, cross the biological membranes 
of the gastrointestinal tract and surrounding tissues, and enter systemic circulation. 
This is vital for effective therapeutic control as target organs must be reached for 
maximum effect.68 The most common reason for the failure of orally administered 
drugs is low intestinal absorption and/or rapid clearance, drug-drug interactions, and 
the presence of reactive metabolites causing undesirably low and/or variable 
bioavailability.69 Understanding the DMPK properties of molecules is important in 
rational drug discovery as these predict human drug PK and metabolism, and help to 
reduce the number of unsuitable compounds being filtered out early in the drug 
development process.70 DMPK is determined and expressed by chemically modifiable 
factors that influence the ADME of drugs.71 A rational approach to drug discovery 




1.4 Bioactivation and metabolism in drug discovery 
Understanding bioactivation through drug metabolism is important as it is often 
suspected to be the event initiating drug toxicity. Metabolism is often an important 
contributor to drug clearance via the excretion of metabolized drugs.72 Drug 
metabolism also underlies drug-drug interactions, detoxification and excretion of toxic 
agents, drug activation or targeting, and has the potential to generate oxidative stress 
by producing reactive electrophiles or radical products.73 The two most common 
enzyme systems involved in bioactivation are the cytochrome P 450 (CYP450) and 
peroxidase enzyme systems.73 A third mechanism for the formation of chemically 
reactive species is the glucuronyl transferase enzyme system, which has been 
extensively reviewed with regard to carboxylic acids.74  
The CYP450 catalytic cycle is a monooxygenous heme-containing enzyme system 
that directly binds to the substrate. Following substrate binding, two single-electron 
reductions of the substrate by CYP450 itself and NAPDH occurs. However, this 
mechanism is not concerted and therefore depends on the substrate’s reduction 
potential. One-electron reductions could therefore occur at the substrate rather than 
the oxygen level, thereby allowing free-radical formation.73  
Peroxidases are involved in bioactivation in non-hepatic tissue in contrast with the full-
body distribution associated with the CYP450 enzyme system.75 Peroxidases usually 
act with electron-rich functional groups such as aromatic  systems, and this enzyme 
system differs from CYP450 in that the heme is attached to an apoprotein. 
Furthermore, the nature of the axial ligand is different.76 Peroxidase bioactivation 
results more frequently in radical formation without oxygen rebound.73 Peroxidases 
are associated with neutrophils, which are of interest as neutrophil infiltration occurs 
during the inflammatory response and is associated with many disease states. When 
infiltration into the liver occurs, the potential for peroxidase reactions to generate 
radical metabolites increases and drug metabolism in healthy and sick patients may 
therefore vary.73  
Glucuronyl transferases affect the transfer of glucuronic acid to mostly nucleophilic 
functional groups.77 Mechanisms by which these acyl glucuronides react have been 
extensively studied.78 Glucuronides are often stable enough to be characterized and 
challenges concerning bioactivation are thus easily overcome in drug design.79 
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Functional group bioactivation pathways have also been extensively reviewed.80 Such 
potential issues can be easily avoided, although this may not always be practical as a 
wide range of functional groups present bioactivation liabilities.73 
 
1.5 Project background 
1.5.1 Amodiaquine (AQ) 
AQ is a 4-aminoquinoline, Mannich base-containing CQ derivative that has been used 
as an antimalarial for more than 50 years in Africa and Asia.81 Compared to CQ, and 
other 4-aminoquinoline compounds, AQ showed greater efficacy and was better 
tolerated in outpatients with uncomplicated malaria.82 However, AQ was withdrawn 
from several countries or prohibited from use as a single administration because of 
severe toxicity relating to agranulocytosis and hepatotoxicity.3,83 Rapid bioactivation to 
form protein-reactive metabolites is thought to play a critical role in such toxicity.84  
After oral administration, AQ is rapidly metabolized to form the major metabolite N-
desethylamodiaquine (DEAQ), which shows 100–240-fold higher internal exposure 
than AQ in vivo.85 Other metabolites include N-bis-desethylamodiaquine (bis-DEAQ) 
and 2-hydroxyl-desmethylamodiaquine.86 DEAQ is rapidly formed and has a longer in 
vitro half-life than AQ so pharmacological studies for AQ may ultimately be influenced 
by DEAQ formation, even though the potency of AQ is 3-fold higher than that of 
DEAQ.86 Bioactivation of AQ to its metabolites occurs both in vitro and in vivo,86 and 
oxidative bioactivation is achieved via dehydrogenation of the 4-aminophenol moiety 
by CYP450 to obtain reactive AQ quinoneimine (AQ-QI; Figure 1.11). Cytotoxicity to 
neutrophils and hepatocytes is dependent on bioactivation to AQ-QI by cytochrome 
myeloperoxidase and CYP450s, respectively.87 Similarly, bioactivation of the major 
metabolite DEAQ via CYPs (Figure 1.11) also forms reactive quinoneimine. 
Hepatotoxicity may be explained by covalent binding of both AQ and DEAQ 
quinoneimines.86  
Genetic and non-genetic factors such as the expression of CYPs described in Figure 
1.11 also influence AQ-induced toxicity, as the expression of these isozymes 
influences bioactivation kinetics.86 Considering the liabilities associated with 
quinoneimine formed during AQ bioactivation, a literature search was conducted to 
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1.5.2 Strategies to mitigate rapid bioactivation  
The metabolic studies outlined previously showed that the rapid metabolism of AQ 
contributed importantly to its hepatotoxicity. It is therefore important to mitigate the 
rapid bioactivation and metabolism of this molecule to improve its PK properties and 
overall potency. Researchers have employed the following tactics to achieve this:80 
- Eliminating the suspect functional group 
- Inhibiting potential metabolism (e.g., by site fluorination) 
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- Lowering the potential for metabolism via steric hindrance or reducing oxidation 
potentials 
- Incorporating metabolic soft spots away from the suspect group 
However, this may not always be practical as the functional groups contributing toward 
metabolism may also be responsible for the compound’s biological activity and a 
balance between PK parameters and the biological activity should therefore be 
achieved. 
 
1.5.3 Pharmacological activity of PBI-Mannich base compounds 
The benzimidazole scaffold is privileged in medicinal chemistry because of its capacity 
to interact with numerous biological systems.88 The antibacterial, antifungal, antiviral, 
and antitumor activities of PBIs have been extensively researched.89 In light of the 
spread of drug-resistant parasites, researchers from Tropical Disease Research 
(TDR) in collaboration with Tibotec screened a small library of 2000 non-proprietary 
compounds donated by Specs against protozoa in vitro. This led to the identification 
of a PBI coded TDR15087  (Figure 1.12), which showed moderate activity against 
GHA and W2 strains of P. falciparum (IC50 = 0.17–0.37 M).90 This is significant since 
no prior published work suggested that PBIs displayed antimalarial activity. This 
prompted a medium throughput screening of 535 commercially available analogues 
which were selected on the basis of providing structural diversity around the PBI core. 
This led to the identification of 49 compounds with IC50 < 0.1 µg/mL; notably included 
the N-benzylpiperazinyl derivatives TDR35885 and TDR44047 seen in Figure 1.12. 
 




However, the original hit compounds (Figure 1.12) all proved inactive in a P. berghei 
mouse model which prompted Ndakala and co-workers to further investigate the 
structure-activity relationship (SAR) of PBIs in an extensive study. Further 
development and SAR exploration of PBIs by Ndakala and co-workers led to the 
identification of pyrido(1,2-a)benzimidazoles that combine good in vitro activity against 
P. falciparum with oral efficacy in the P. berghei mouse model. In vivo and in vitro 
activities were strongly influenced by metabolic stability, and therefore microsomal 
stability studies were performed to guide researchers in overcoming metabolic 
liabilities.66 Several PBI analogues were synthesized by Ndakala et al.66 and showed 
in vitro antiplasmodium activities comparable to CQ (IC50 = 0.17–0.20 M). In general, 
lipophilicity influences in vitro activity and selectivity, although structural features of the 
side-chains also play a role.66 The in vivo activity of compounds that were most active 
in vitro was assessed and the mean survival time of P. berghei infected mice increased 
significantly compared to that after CQ treatment.66 In vitro metabolic stability studies 
showed moderate to high rates of metabolic degradation, with the exception of a few 
compounds showing moderate metabolic degradation. Deamination, N-dealkylation, 
and ring cleavage was suggested to be responsible for this rapid metabolic 
degradation.66 The lead compound A (Figure 1.13) showed high antiplasmodium 
activity in vitro (IC50 in P. falciparum (Pf) NF54 = 0.11 M; IC50 in PfK1 = 0.12 M) as 
well as promising antimalarial oral efficacy in vivo (96% at 4  25 mg/kg per oral (p.o.)) 
in a P. berghei rodent model. However, PK studies indicated low solubility and 
saturation in absorption at low oral doses.66 
Further SAR studies conducted by Singh and co-workers based on the lead compound 
A (Figure 1.13) led to the identification of potent, metabolically stable compounds with 
improved in vivo oral efficacy in the P. berghei mouse model and additional activity 
against parasite liver and gametocyte stages, making them potential candidates for 
preclinical development.7 Among the most active compounds in vitro, B and C showed 




Figure 1.13: Original lead PBI compound A and subsequently identified lead compounds B and C, by 
SAR expansion showing activity against chloroquine-sensitive (NF54) and chloroquine/multidrug-
resistant (K1) Plasmodium falciparum strains as well as the in vivo mouse model efficacy studies. 7,66 




The most active compounds also showed good activity against gametocytes, 
indicative of potential as dual-acting antimalarials. Other analogues have shown 
activity against the liver stage of P. berghei. There is no conclusive evidence for their 
mode of action, although inhibition of Hemozoin formation is identified as a potential 
contributing factor. Mechanistic studies performed on PBIs have focused on the 
potential for inhibition of hemozoin formation, based on the hypothesis that the flat 
conformation of PBIs  would allow for - stacking with FPIX, thus leading to hemozoin 
formation inhibition and parasite death.7,66 Among the diverse mode of actions (MoAs) 
reported for PBIs is the inhibition of the pore-forming protein perforin in mammalian 
cells by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles. This is of interest as the P. 
falciparum proteome contains perforin-like proteins, which are involved in 
permeabilizing the erythrocyte membrane during egress of gametocytes and 
merozoites which is a potential target for parasite elimination.91 Because of the 
antimalarial activities described, PBIs have been extensively investigated.7,66  
1.6 Aims and objectives 
1.6.1 Objective 
a) Design and synthesize potential N-dealkylation metabolites of parent 
antimalarial PBIs containing Mannich base side-chains.  
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1.6.2 Specific aims 
i) Synthesize and characterize potential N-dealkylation metabolites of 
antimalarial PBIs and related compounds with Mannich base side-chains. 
ii) Profile synthesized compounds with respect to physico-chemical properties, 
antiplasmodium activity, cytotoxicity and microsomal metabolic stability. 
iii) Derive antiplasmodium SAR profiles. 
























CHAPTER 2: Design, synthesis, and characterization of pyrido(1,2-
a)benzimidazoles 
2.1 Chapter summary 
In this chapter, the design, synthesis, and spectroscopic characterization of pyrido(1,2-
a)benzimidazole-based compounds containing a phenolic Mannich base side-chain 
are discussed. This is preceded by a brief overview of prior work conducted by our 
research group at the University of Cape Town (UCT). 
 
2.2 Introduction and preliminary work 
Previous work on PBIs as antimalarial agents is well documented.92,7 A brief summary 
of the medicinal chemistry efforts made by the Chibale research group on the 
development of PBIs serves as a preface for this work. These analogues generally 
comprise a PBI core linked to a phenolic Mannich base side-chain via N-arylation 
(Table 2.1). Medicinal chemistry efforts led to the identification of compound KP84, a 
potent inhibitor of the growth of the chloroquine (CQ)-sensitive (NF54) and –multidrug-
resistant (K1) Plasmodium falciparum strains. Varying the position of the Mannich 
base substituent on the aromatic ring (Ar) and the substituents at the R and X-
positions of the pyridine and benzimidazole benzene rings influenced the 
antiplasmodium activity, cytotoxicity, and metabolic stability. Results for KP84, along 










Table 2.1: Phenolic Mannich base-containing pyrido(1,2-a)benzimidazoles evaluated by the Chibale 
research group 
 CHO, Chinese hamster ovarian cells; MLM, mouse liver microsomes.92 
 
All compounds were evaluated for in vitro antiplasmodium activity against the NF54 
and K1 strains. Antiplasmodium activity (IC50) ranged from 0.07 to 5.14 µM. 
Compound KP84 showed sub-micromolar in vitro activity against the K1 and NF54 
strains (NF54 IC50 = 0.11 µM, K1 IC50 = 0.18 µM). The replacement of the R-
substituent in KP94 from the para-trifluoromethyl phenyl (4-CF3Ph) substituent to 









In vivo  
antimalarial activity 































H 5.14 4.66 142 <10 - - 
LB88 
  
F 0.07 0.07 >100 30 ± 9.4 - - 
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loss of activity (NF54 IC50 = 0.89 µM, K1 IC50 = 1.0 µM). Interchanging the hydroxyl 
and Mannich base side group (KP87) or substituting the 4-hydroxyl with fluorine 
(KP98) was significantly detrimental to activity. However, an introduction of fluorine 
atoms at the X-positions on the left-hand side (LHS) of the PBI molecule while 
maintaining the para-trifluoromethyl phenyl (4-CF3Ph) substitution appeared to afford 
the most active compounds (represented by LB88). 
Furthermore, two compounds were prioritised for in vivo studies namely KP84 and 
KP94. KP84 exhibited high in vitro potency and resulted in in vivo parasitemia 
reduction of 94.5% at a dose of 4 × 50 mg/kg in mice, with a mean survival period of 
16 days post treatment. Replacement of the para-trifluoromethyl phenyl (4-CF3Ph) 
substituent with trifluoromethyl (CF3) whilst maintaining the aromatic Mannich base 
resulted in a loss of activity in the case of KP94 with less than 40% reduction in 
parasitemia at the same dose.  The in vivo efficacy of these phenolic Mannich-based 
derivatives may be ascribed to their active metabolites.92,66 It is this hypothesis that 
the compounds may be producing active metabolites which prompted metabolic 
stability studies and subsequent metabolite identification studies. 
Rapid metabolism of the parent compounds was observed in vitro for all analogues 
and <40% parent compound remained after 30 min when the compounds were 
incubated with liver microsomes. This was characterized by short degradation half-
lives, suggesting the compounds are significantly susceptible to hepatic metabolism 
regardless of the modifications on the Mannich base side group. Furthermore, 
Disubstitution with fluorine at the X-positions did not improve metabolic stability. Based 
on previous knowledge of the antimalarial amodiaquine (AQ) and its route of 
metabolism it was hypothesised that similar desethyl metabolites may be contributing 
to the activity of the parent compounds of these Mannich base containing PBIs.93 
There was no metabolism observed in the presence of NADPH which implies that the 
observed biotransformations is primarily a function of the p450 enzyme-mediated 
phase 1 metabolism with N-deethylation seemingly the predominant route of 
metabolism.92 To investigate reactive metabolite formation compounds were screened 
by LC-MS/MS in rat liver microsomes. The main biotransformation following incubation 
at 37 ˚C with human and/or mouse liver microsomes in the presence of phosphate 
buffer and NADPH as cofactor are highlighted in Figure 2.1. Using glutathione (GSH) 
27 
 
as a trapping agent GSH-drug adducts were detected in samples for KP84, KP94 and 
LB88 but were not detected in KP87 or KP98 shown in Figure 2.1.  
 
Figure 2.1: Proposed bioactivation of KP84, KP94, and LB88 and their putative conjugation with 
reduced GSH compared with the non adduct-forming KP87 and KP98 
 
Microsomal metabolic stability and metabolite identification studies performed 
suggested that the N-deethylated metabolite persists in systemic circulation long 
enough to suppress parasitemia, even after concentration of the parent compound 
decreased below the therapeutic threshold.92 Furthermore, formation of a 
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quinoneimine through a bioactivation pathway was confirmed via glutathione (GSH)-
trapping studies performed with compounds KP84, KP94, and LB88 (Figure 2.1).92  
Additional metabolic pathways such as oxidative quinoneimine formation result in the 
formation of highly reactive metabolites that are linked to toxic side-effects in vivo.73 
In order to avoid potential issues with quinoneimine formation, Mannich base regio-
isomer was developed for KP87 which resulted in N-deethylation and core oxidation 
as the main biotransformations, without the formation of GSH adducts which implies 
that the reactive quinoneimine does not form. Similarly, KP98 did not form any GSH 
conjugates and the main biotransformation is N-deethylation. However, these 
modifications were detrimental to in vitro antiplasmodium activity compared with that 
of KP84, KP94 and LB88.  
These findings compelled us to further explore the multi-parameter SARs and 
structure-property relationships (SPRs) of PBIs. The phenolic Mannich base PBI KP84 
was therefore used as a model hit compound. In this work, the R-position was either 
fixed to the trifluoromethyl group (as in KP94, KP87 and KP98) or to a methyl group. 
The group’s extensive experience on the synthesis of various PBI analogues thus 
informed the choice of scaffold and synthetic methods used in this work.  
Without providing a detailed account of the literature, this introduction reflects and 
builds on aspects of antiplasmodium activity and the merits of phenolic Mannich base-
containing PBIs. Synthesis has been divided into construction of the PBI core, 
preparation of phenolic Mannich base side-chains, and finally the coupling reaction 
between the PBI core and Mannich base side-chains to afford target compounds. Of 
note is the SAR studies, which have been split into SAR-1 and SAR-2 in this 
dissertation. In SAR-1, the parent compounds and their N-dealkylated counterparts 
were investigated. In this study, the parent compounds contain an N,N-diethylated 
terminal amine and their corresponding N-deethylated analogues are considered 
primary metabolites in vivo.92 SAR-2 was systematically mapped onto SAR-1 with 
structural modifications around the PBI core. SAR studies on the phenolic Mannich 




2.3 Design rationale and SAR development for new Mannich base PBIs 
One of the critical challenges in designing phenolic Mannich base PBI analogues was 
addressing microsomal stability. With this information, two points of SAR were 
investigated (Figure 2.2): (i) SAR-1, replacing the Ar fragment of KP84 with various 
structurally diverse phenolic Mannich base side-chains (with the exception of one 
analogue which possesses a only a phenolic group) guided by the commercial 
availability of substituted aminophenols. and (ii) SAR-2, introduction of substituents in 
the PBI core.  
 
 
Figure 2.2: Structure activity relationship design of SAR-1 and SAR-2 
 
It should be noted that SAR-2 was designed as an extension of SAR-1 and that N-
dealkylated analogues selected comprised of the Mannich base fragments that gave 
the most active compounds from SAR-1. Selected parent compounds and presumed 
N-dealkylated metabolites were synthesized and structural modifications made around 




2.4 Synthesis and characterization of Mannich base PBIs 
The overall procedure for the synthesis of all target compounds in both SAR-1 and 
SAR-2 is shown in Scheme 2.1. 
 
Scheme 2.1: General synthetic protocol for target compounds 4–28, according to the following steps: 
(i) synthesis of the pyrido(1,2-a)benzimidazole (PBI) core (1.1–1.3), (ii) synthesis of free phenolic 
Mannich base side-chain (2.1–2.2 and 3.1–3.3), and (iii) final coupling reaction b 
 
Briefly, substituents mentioned at positions R’ (CF3 or CH3) and X (H or F) were 
introduced during synthesis of the PBI core. Phenolic Mannich base side-chains were 
synthesized using the two synthetic pathways previously highlighted. Specifically, 
synthesis of 1,4-halogenated anilines (2.2a and 2.2b) began with commercially 
available 3-nitrobenzaldehydes. The N-dealkylated side-chain was introduced via 
reductive amination while subsequent reduction of the nitro group furnished the 
respective aniline necessary for the final coupling reaction. Synthesis of the second 
phenolic Mannich base side-chain began by protecting substituted aminophenols via 
an acetylation reaction. Acetylation of the amine is necessary to attenuate its reactivity 
so that polysubstitution products are avoided during electrophilic aromatic substitution. 
The R-substituent was introduced in a Mannich reaction as either the N-dealkylated 
(proposed metabolite) or diethyl (parent) side-chain specific to the desired phenolic 
Mannich base intermediates. Finally, deprotection of the aniline nitrogen was 
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necessary for the final coupling reaction. The final targeted compounds were obtained 
via a coupling reaction with the appropriate phenolic Mannich base side-chain-
containing phenol and PBI core to afford compounds 4-28. 
 
2.4.1 Synthesis and characterization of the PBI core  




Scheme 2.2: General procedure for the synthesis of the PBI core 
Reagents and conditions: (i) ethyl-cyanoacetate, dimethylformamide (DMF), 100 °C, 7 h, microwave 
radiation (MW); (ii) di-keto ester with appropriate R’ group, NH4OAc, 150 °C, 12 h; (iii) POCl3, 120 °C, 
12–15 h 
 
In order for the final coupling reaction to occur between the appropriate Mannich base 
side-chain-containing phenol and the PBI core, a chlorinated PBI intermediate (1.3a–
d) was synthesized (Scheme 2.2). A commercially available unsubstituted 
benzimidazole acetonitrile was used to synthesize unsubstituted keto-PBI 
intermediates (1.2a and 1.2b, where X = H) whereas synthesis of difluorinated keto-
PBI intermediates was achieved using commercially available 4,5-difluorobenzene-
1,2-diamine. Briefly, the difluorinated benzimidazole acetonitrile (1.1a) was 
synthesized using 4,5-difluorobenzene-1,2-diamine via cyclization with ethyl 
cyanoacetate. Keto-PBIs (1.2a–1.2d) were achieved via cyclization of commercially 
available benzimidazole acetonitrile or intermediate 1.1a. Deoxy-chlorination 
of intermediates 1.2a–1.2d was achieved using phosphorous oxychloride (POCl3) to 
obtain compounds 1.3a–1.3d. The synthesis and characterization of the PBI core 
intermediates are detailed here. Details of selected key reaction steps leading to the 
formation of critical PBI intermediates and the proton nuclear magnetic resonance (1H-
NMR) spectroscopic analyses of representative compounds are described here. 
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Preparation of benzimidazole acetonitrile 1.1a 
As previously mentioned, it was necessary to prepare the difluorinated benzimidazole 
acetonitrile (1.1a) as it was not available commercially unlike the unsubstituted 





Scheme 2.3: Reaction conditions for the preparation of difluorinated benzimidazole acetonitrile 
intermediate 1.1a 
 
The synthesis of 2-(5,6-difluoro-1H-benzo[d]imidazol-2-yl)acetonitrile (1.1a) was 
achieved via cyclization of commercially available 4,5-difluorobenzene-1,2-diamine 
and ethyl cyanoacetate in N,N-dimethyl formamide (DMF). The mixture was irradiated 
under microwave conditions at 100 °C for 7 h for formation of the desired product. A 
proposed mechanism for the formation of 1.1a is shown below (Scheme 2.4).   
 
Scheme 2.4: Proposed mechanism of the formation of 2-(1H-benzo[d]imidazole-2-yl)acetonitrile 1.1a 
 
The formation of 1.1a began with nucleophilic addition of the amino group to the 
electrophilic carbonyl carbon of ethyl cyanoacetate (1.1.1, Scheme 2.4). The ethoxide 
leaving group formed subsequently deprotonated the hydrogen of the positively 
charged nitrogen ion intermediate, resulting in the formation of the amide 1.1.2. As 
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shown (1.1.2, Scheme 2.4), potential exists for amide iminol tautomerism, however 
formation of the product that would result in the addition step at the carbon adjacent 
to the hydroxyl substituent (shown using *, 1.1.2, Scheme 2.4) was not observed. The 
intramolecular nucleophilic addition at the amide carbonyl leads to ring closure, and 
subsequent iminol formation and dehydration resulted in the formation of 2-(5,6-
difluoro-1H-benzo[d]imidazol-2-yl)acetonitrile (1.1a). To confirm the success of the 







Figure 2.3: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 1.1a 
 
The difluorinated benzimidazole diagnostic peaks for 1.1a showed characteristic 
splitting patterns and J coupling constants. A doublet of doublets integrating for two 
protons at δ 7.59 ppm, which looks like a triplet, was observed for protons H4 and H7. 
The splitting pattern was attributed to ortho and meta coupling to the fluorine atoms at 
positions C5 and C6 with respect to protons H4 and H7. Considering the symmetry of 
the molecule, the chemical environment surrounding H4 and H7 is identical due to 
tautomerism of the NH hydrogen with the other nitrogen. The remaining singlet at δ 
4.38 ppm integrates for 2 protons, confirming successful cyclization, and was assigned 
to H8.  
Mass analysis of compound 1.1a was performed using ESI in the positive mode (ESI+). 
The parent peak revealed an m/z of 194.1 [M+H]+, which was corroborated with the 
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calculated mass for C9H5F2N3 (193.05). Having successfully obtained intermediate 
1.1a, a second cyclization reaction was performed to obtain keto-PBIs 1.2a–1.2d from 
1.1a or the commercially available benzimidazole acetonitrile. 
Synthesis of keto-PBI intermediates 
The general cyclization procedure used to afford keto-PBI intermediates is shown in 






Scheme 2.5: General cyclization procedure used to afford keto-PBI intermediates 1.2a–1.2d 
 
Synthesis of keto-PBI intermediates 1.2a–1.2d was achieved via cyclization with either 
1.1a or commercially available 2-benzimidazole acetonitrile (1.1b) and the appropriate 
diketo-ester in the presence of NH4OAc at 150 °C for 12 h. The formation of the keto-
PBI intermediate 1.2b via cyclization of 2-benzimidazole acetonitrile with ethyl 3-













Scheme 2.6: Proposed method of cyclization to keto-intermediate 1.2b from 2-benzimidazole 
acetonitrile with ethyl 3-oxobutanoate 
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The reaction proceeds via deprotonation of the α-proton to the CN group by the basic 
(-OAc) to form a carbanion. The carbanion attacks the carbonyl centre of 3-
oxobutanoate, and this is followed by protonation of the oxygen anion to a hydroxyl 
group by NH4OAc.  A second addition reaction occurs at the carbonyl centre of ethyl 
3-oxobutanoate by the nucleophilic nitrogen of the benzimidazole acetonitrile. This 
subsequently causes an intramolecular proton transfer. Internal cyclization is achieved 
by elimination of ethanol as a result of the proton transfer during formation of the keto-
PBI intermediate.  
A second protonation of the OH group mediated by NH4OAc, which converts the 
hydroxy to a better leaving group occurs. Proton abstraction from the α-hydrogen to 
the carbonyl group is facilitated by NH4OAc to afford 1.2b. In order to confirm the 
success of the cyclization reaction, 1H-NMR analysis of 1.2b was performed (Figure 
2.4). The diagnostic peaks include the absence of an aromatic proton signal 
corresponding to the C4 position due to the CH2 protons similar to those in 
intermediate 1.1a. Furthermore, the singlet at δ 5.55 ppm integrating for a single 
proton corresponding to H2 supported the formation of a new aromatic ring. 
Cyclization of the benzimidazole scaffold to a PBI resulted in a loss of symmetry in the 
molecule and was evident with respect to the aromatic protons H7–H10. The rest of 
the aromatic signals were observed as a doublet (J = 8.0 Hz) and a triplet (J = 7.6 Hz), 
each integrating for one proton. H10 was assigned to a doublet at δ 8.49 ppm because 
of its high down-field chemical shift relating to the lack of electron density attributed to 
the tertiary amide of the imidazole. The H7 proton was assigned to a doublet at δ 7.48 
ppm. Finally, two remaining aromatic signals were observed as triplets at δ 7.33 ppm 
(J = 7.6 Hz) and at δ 7.12 ppm (J = 7.6 Hz), corresponding to H9 and H8, respectively. 
An additional singlet corresponding to the methyl peak at δ 2.31 ppm integrating for 
three protons also confirmed the presence of H13. The 1H-NMR data were backed-up 
























The 13C-NMR spectrum for 1.2b is shown in Figure 2.5 and peaks were assigned 
using diagnostic peaks identified in the 13C-NMR spectrum. These diagnostic features 
include the appearance of two carbon signals attributed to the carbonyl peak 
corresponding to C1 at δ 172.41 ppm and the methyl peak at δ 20.90 ppm 
corresponding to C13. The remaining peaks were assigned to 10 aromatic carbons 
corresponding to C2–C10 as well as the CN peak at δ 141.10 corresponding to C12, 
further supporting the success of the cyclization reaction to form 1.2b. The LC-MS 
(ESI+) analysis of compound 1.2b indicated a chemical purity of 94% (254 nm) and 
retention time of 2.36 min. The parent peak showed an m/z value of 224.2 [M+H]+, 
which was found to corroborate the calculated mass for C13H9N3O (223.07). 
Having successfully synthesized keto-PBI intermediates (1.2a–1.2d), chlorinated PBIs 
necessary for the final N-arylation coupling reaction were prepared via deoxy-






Scheme 2.7: General procedure for the deoxy-chlorination reaction used to afford chlorinated PBIs 
1.3a–1.3d 
 
The synthesis of chlorinated PBIs 1.3a–1.3d  (Scheme 2.7) was achieved by treating 
1.2a–1.2d with POCl3 at 130 °C for 12 h. The proposed reaction mechanism and 














Scheme 2.8: Proposed method of deoxy-chlorination to form chloro-intermediate PBI 1.3b 
 
Formation of the chlorinated PBI intermediate 1.3b using POCl3 is shown in Scheme 
2.8. The reaction is driven by the nucleophilic addition of electrons from the keto-
oxygen to the phosphorous centre which forms an irreversible O-P bond by addition-
elimination to POCl3, which results in free Cl- release in solution (Scheme 2.8: 1.2.1). 
The chloride anion attacks the electrophilic carbon of the phosphonate ester in an 
aromatic nucleophilic substitution reaction to afford compound 1.3b with release of 
PO2Cl and Cl-, which further drives the reaction.  
The 1H-NMR spectrum for keto-PBI intermediate 1.2b overlaid with that of chlorinated 



















Figure 2.6: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 1.2b (top) and 1.3b (bottom), stacked to show 
corresponding PBI intermediate peaks 
 
1H-NMR patterns indicating successful chlorination were readily observed in the 
downfield shift of H2 to a higher frequency compared to that in 1.2b (Figure 2.6), which 
was observed as a singlet integrating for one proton at δ 7.31 ppm. The remaining 
aromatic peaks identified for 1.2b are observed in the 1H-NMR spectrum for 1.3b 
(Figure 2.6).  
The 13C-NMR spectrum for 1.3b (Figure 2.7) further validates the success of the 
deoxy-chlorination reaction. Formation of 1.3b was confirmed by the absence of a 
carbonyl signal in the region of 150–180 ppm. Furthermore, there are 12 carbon peaks 
in the aromatic region corresponding to C1-C12 and a peak at 20.68 ppm 
corresponding to the methyl carbon C13, which are the peaks expected for 











Figure 2.7: 13C-NMR (DMSO-d6, 151 MHz) spectrum of 1.3b 
 
Mass analysis was done using ESI+. The parent peak indicated an m/z of 242.7 
[M+H]+, which was found to corroborate the calculated mass for C13H8ClN3 (241.68). 
Having successfully synthesized chlorinated PBIs (1.3a–1.3d), these intermediates 
were used in subsequent  coupling reactions with synthesized Mannich base side-
chain-containing phenols.  
 









Scheme 2.9: General synthetic route for the production of Mannich base side-chains 
Mannich base intermediates were synthesized using two distinct pathways (Scheme 
2.9): (i) 3-nitrobenzaldehydes were subjected to reductive amination in the presence 
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of ethylamine to afford intermediates 2.1a and 2.1b, and (ii) use of amine-protected 
aminophenols with acetic anhydride to form acetamides 3.1c–3.1h. A Mannich 
reaction was then used to form substituents designated as R-groups in 3.2a–3.2j. 
Deprotection of acetamides was achieved using 6 M aqueous hydrogen chloride 
solution in  to afford intermediates 3.3a–3.3j as HCl salts. The detailed synthesis and 
characterization of Mannich base side-chains as well as key intermediates along with 
1H-NMR spectroscopy analyses of representative compounds are described below. 
 
Reductive amination reaction  
Reductive amination was used to introduce the appropriate R substituent for 
intermediates 2.1a and 2.1b (Scheme 2.10) and was performed using the 
commercially available nitrobenzaldehydes 2-fluoro-5-nitrobenzaldehyde and 2-
chloro-5-nitrobenzaldehyde to obtain amino-alkylated intermediates 2.1a and 2.1b, 





Scheme 2.10: General procedure for the reductive amination reaction used to afford amino-alkylated 
intermediates 2.1a-2.1b 
 
The proposed reaction mechanism for the reductive amination of compound 2.1b is 
shown in Scheme 2.11.94 The reaction begins with the nucleophilic attack of the 
primary amine at the electrophilic carbonyl carbon in a protic solvent to form a 
tetrahedral transition-state intermediate. The protic solvent acts as a proton source 
and stabilizes the tetrahedral transition state. Nucleophilic addition of the amine group 
in the first step results in hydroxyl formation and subsequent proton transfer enables 
an iminol-dehydration process. This results in the loss of a water molecule and 
formation of the imine intermediate.  The imine nitrogen coordinates to a vacant boron 
orbital and this coordination subsequently encourages the release of a hydride ion 
from sodium borohydride in a concerted transition state. The hydride  adds to the 
electrophilic carbon of the imine intermediate whilst the pi-electrons of the imine bond 
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add to the vacant boron orbital forming a N-B bond. The N-B bond is broken due to 
protonation by methanol which causes the subsequent release of BH3 and the desired 
intermediate 2.1b. The success of the reductive amination reaction for compound 2.1b 










Scheme 2.11: Proposed mechanism for the reductive amination reaction used to afford 2.1b 
 
An illustrative example for all reductive amination reactions is shown in the 1H-NMR 
spectrum for compound 2.1b (Figure 2.8). Diagnostic peaks for successful reductive 
amination were new proton peaks corresponding to the ethylamine substituent and 
methylene carbon spacer. Ethylamine peaks (H7, N-H, H8, and H9) are shown as a 
broad N-H singlet at δ 4.81 ppm integrating for a single proton, another singlet 
integrating for two protons at δ 3.94 ppm corresponding to H7, a quartet at δ 2.72 ppm 
(J = 7.2 Hz) integrating for two protons corresponding to H8, and a triplet integrating 
for three protons at δ 1.19 ppm (J = 7.2 Hz) corresponding to H9. The aromatic region 
peaks displayed a doublet at δ 8.38 ppm (J = 2.8 Hz), showing meta coupling between 
H6 and H2 protons. A doublet of doublets integrating for one proton at δ 8.11 ppm was 
assigned to H6 because of H5 ortho (J = 8.7 Hz) and H2 meta coupling (J = 2.8 Hz) 
constants. H5 was represented by a doublet at δ 7.63 ppm (J = 8.8 Hz) integrating for 
a single proton. To further support these assignments, 13C-NMR was performed for 










Figure 2.8: 1H-NMR (MeOD-d4, 400 MHz) spectrum of 2.1b 
 
The 13C-NMR spectrum for compound 2.1b is shown in Figure 2.9. Diagnostic signals 
of 2.1b confirming successful completion of the reductive amination reaction include 
the appearance of three new signals in the aliphatic region corresponding to C7–C9. 
These peaks are attributed to the ethylamine chain and methylene linker, thus 
confirming the successful transformation expected in the reductive amination reaction. 
Furthermore, six aromatic peaks corresponding to C1–C6 of the substituted benzene 





















Figure 2.9: 13C-NMR (MeOD-d4, 151 MHz) spectrum of 2.1b 
 
Mass analysis of compound 2.1b was performed using ESI+. The parent peak 
indicated an m/z of 215.3 [M+H]+, which was obtained to corroborate the calculated 
mass for C9H11ClN2O2 (214.05). Having successfully synthesized the amino-alkylated 
nitrobenzene intermediates 2.1a and 2.1b, these were subjected to tin(II) chloride 
reduction to reduce the nitro group to a primary amine. This is necessary for the final 
coupling reaction between the Mannich base inputs and chlorinated PBI intermediates 
1.3a–1.3d as final coupling relies on the presence of a nucleophilic primary amine.  
 
Tin(II) chloride nitro reduction to primary amine 
Reduction of the nitro group in compounds 2.1a and 2.1b to the primary amine was 
achieved using Sn(II)Cl in tetrahydrofuran (THF) in the presence of 1 M HCl aqueous 
solution (Scheme 2.12). To confirm the success of the reduction reaction, 1H-NMR 
spectra were recorded for each compound and 2.2b will be used as a representative 










Scheme 2.12: General procedure for tin(II) chloride reduction from a nitro to a primary amine to afford 
2.2a and 2.2b 
 
The 1H-NMR spectrum of compound 2.2b is shown in Figure 2.10. One distinct 
change following the transformation of 2.1b to 2.2b was a upfield chemical shift in 
aromatic protons, which occurred as a result of the presence of the electron-donating 
NH2 substituent compared to the electron-withdrawing nitro group in 2.1b. Protons 
situated ortho to the NH2 substituent show a downfield shift compared to 2.1b, as 
exemplified by H2 and H6 appearing as a doublet at δ 6.75 (J = 2.8 Hz) and a doublet 
of doublets at δ 6.62 (J = 8.5, 2.8 Hz), each integrating for a single proton. H5 showed 
almost no downfield shift as a doublet integrating for a single proton at δ 7.09 (J = 8.4 
Hz) compared to that in 2.1b, which is expected for meta substituents to electron-
donating groups. The remaining peaks included a singlet integrating for two protons 
at δ 3.75 ppm corresponding to H7, a quartet integrating for two protons at δ 2.66 ppm 
(J = 7.2 Hz) corresponding to H8, and a triplet integrating for three protons at δ 1.15 
ppm (J = 7.1 Hz) corresponding to H9. It is also important to note the water peak 






Figure 2.10: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 2.2b 
 
 
Mass analysis for compound 2.2b was performed using ESI+ and the parent peak 
indicated an m/z of 185.1 [M+H]+, which was obtained to corroborate the calculated 
mass for C9H13ClN2 (184.08).  
Having successfully obtained the halogenated Mannich base intermediates 2.2a and 
2.2b, the last remaining step to produce the final compounds was a final coupling 
reaction with chlorinated PBI intermediate 1.3a. The second route for synthesizing 
Mannich base side-chain inputs involved a Mannich reaction following an acetylation 





Formation of acetamides from aminophenol intermediates 
Acetylation using acetic anhydride was performed to protect the free amine of 
aminophenols to obtain intermediates 3.1c–3.1h (Scheme 2.13). The compounds 






Scheme 2.13: General procedure for the formation of acetamide intermediates 3.1c–3.1h from 
commercially available aminophenols 
 
Intermediate compound 3.1e will be used as an illustrative example (Figure 2.11) for 
the acetylation reaction. Diagnostic features of the 1H-NMR spectrum of 3.1e include 
a signal arising from introduction of a methyl group. The methyl peak was assigned as 
a singlet at δ 2.18 ppm, which integrates for three protons and corresponds to H8. The 
remaining peaks are a doublet integrating for a single proton at δ 7.66 ppm (J = 8.6 
Hz) corresponding to H6, a doublet at δ 6.87 ppm (J = 2.3 Hz) integrating for a single 
proton corresponding to H3, and the final peak appearing at δ 6.81 ppm as a doublet 














Figure 2.11: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 3.1e 
 
Diagnostic features of the 13C-NMR spectrum for 3.1e (Figure 2.12) include the 
appearance of two new carbon signals corresponding to a carbonyl carbon and a 
methyl group. These peaks were assigned at δ 24.09 ppm, corresponding to C8, and 
the carbonyl carbon peak at δ 169.41 ppm corresponding to C7. The remaining signals 










Figure 2.12: 13C-NMR (DMSO-d6, 151 MHz) spectrum of 3.1e 
 
Mass analysis for compound 3.1e was performed using ESI+. The parent peak 
indicated an m/z of 186.2 [M+H]+, which was obtained to corroborate the calculated 
mass for C8H8ClNO2 (185.02).  
Having successfully obtained acetamides 3.1c–3.1h, the Mannich reaction was 
performed. Details of the Mannich reaction follow. 
 
Mannich reaction to afford amino-alkylated intermediates 
The general procedure used to synthesize amino-alkylated Mannich base 
intermediates 3.2a–3.2j is shown in Scheme 2.14. Synthesis began using synthesized 
acetamides 3.1c–3.1h or commercially available acetamides. The Mannich reaction 
was performed using formaldehyde and ethylamine or diethylamine depending on the 
desired amino-alkyl substituent (R-group). Yields of isolated intermediates 3.2a–3.2j 
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ranged from low to high. The lower yields obtained resulted from nucleophilic 
promiscuity, which is a mechanistic liability of the Mannich reaction. The electrophilic 
aromatic substitution step (Scheme 2.15) proceeds both at the ortho and para 
positions relative to the hydroxy substituent of the protected aminophenol. For 
intermediates in which the para position bears a substituent, higher yields were 
observed. Intermediate 3.2f is used as an illustrative example for the Mannich reaction 









Scheme 2.14: General procedure for the Mannich reaction used to synthesise amino-alkylated 
intermediates 3.2a-3.2j 
 
The proposed mechanism of the Mannich reaction used to convert compound 3.1f to 
the amino-alkylated intermediate 3.2f is represented in Scheme 2.15. This reaction 
relies on formation of the carbocation intermediate via nucleophilic addition of the 
ethylamine nitrogen at the electrophilic carbonyl of formaldehyde. The carbocation is 
quenched by the electrophilic aromatic substitution reaction which proceeds via 
Wheland intermediate, followed by re-aromatization of the molecule to afford 3.2f. To 
















Scheme 2.15: Proposed mechanism of the Mannich reaction used to afford compound 3.2f 
 
The diagnostic shifts indicating the successful transformation of 3.1f to intermediate 
3.2f include signals arising from addition of the ethylamine protons and methylene 
linker. These peaks are clearly seen in Figure 2.13 and were assigned as a singlet at 
δ 3.91 ppm integrating for two protons corresponding to the methylene linker H7. The 
remaining diagnostic ethylamine peaks appear as a quartet at δ 2.60 ppm (J = 7.2 Hz) 
integrating for two protons corresponding to H8, and a triplet at δ 1.08 ppm (J = 7.3 
Hz) integrating for 3 protons corresponding to H9. Another diagnostic feature is the 
loss of an aromatic proton at the C3 position of 3.1f. There are two aromatic signals 
which appear as two doublets at δ 7.94 ppm (J = 2.7 Hz) and δ 6.81 ppm (J = 2.7 Hz), 
both integrating for single protons corresponding to H6 and H4 respectively. The final 
peak for this intermediate is the appearance of a singlet at δ 2.10 ppm, integrating for 
three protons corresponding to the C(O)CH3 peak of H11. To further confirm the 
success of the Mannich reaction, 13C-NMR analysis was performed for 3.2f as shown 








Figure 2.13: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 3.2f 
 
Diagnostic features of the 13C-NMR spectrum include the appearance of three new 
carbon signals corresponding to the ethylamine chain and methylene linker. These 
peaks are clearly seen at δ 14.35 ppm corresponding to C9, δ 42.32 ppm 
corresponding to C8, and δ 50.88 ppm corresponding to C7. The remaining peaks 











Figure 2.14: 13C-NMR (DMSO-d6, 151 MHz) spectrum of 3.2f 
 
Mass analysis of compound 3.2f was performed using ESI+ and the parent peak 
indicated an m/z of 243.0 [M+H]+, which was obtained to corroborate the calculated 
mass for C11H15ClN2O2 (242.08).  
Having successfully obtained protected amino-alkylated acetamides 3.2a–3.2j, 
hydrolysis of the acetamide was performed under acidic conditions to obtain the 
deprotected Mannich base inputs necessary for the final coupling reaction.  
 
Hydrolysis of acetamides under acidic conditions 
Acetamide intermediates (3.2a–3.2j) were hydrolysed using 6 M aqueous hydrogen 
chloride solution at 100 °C to 3.3a–3.3j (Scheme 2.16). The compounds were isolated 
in low to high yields as dark oils. Compound 3.3i is shown below as an example for 











Scheme 2.16: General procedure for the hydrolysis of acetamides under acidic conditions to afford HCl 
Mannich base salts 3.3a–3.3j 
 
The 1H-NMR spectrum of the deprotected Mannich base input 3.3i is shown in Figure 
2.15. Features confirming the deacetylation reaction include the disappearance of the 
C(O)CH3 peak at approximately δ 2 ppm. The aromatic protons for 3.3i each integrate 
for one proton and are assigned as a doublet at δ 7.56 ppm (J = 2.6 Hz) corresponding 
to H2, a doublet of doublets at δ 7.34 ppm (J = 8.7, 2.6 Hz) corresponding to H6, and 
a doublet at δ 7.16 ppm (J = 8.7 Hz) corresponding to H5. As 3.3i was isolated as a 
2•HCl salt, it is expected that 3.3i is protonated at the tertiary and primary amine 
functionalities as these are the two most basic sites of the molecule. This was 
confirmed by the splitting observed for H7, which is a doublet integrating for two 
protons at δ 4.22 ppm (J = 4.6 Hz). Furthermore, splitting of the expected quartet in 
H8 to a doublet of quartets at δ 3.07 ppm (J = 13.9, 7.0 Hz) integrating for four protons 
further confirms protonation of the tertiary amine. The final peak is that of H9, which 




Figure 2.15: 1H-NMR (DMSO-d6, 400 MHz) spectrum of 3.3i 
 
The 13C-NMR spectrum for 3.3i is shown in Figure 2.16. Diagnostic features include 
the disappearance of two carbon signals attributed to the acetyl protecting group found 
in 3.2i, which are expected to appear at δ 20–25 ppm for the CH3 peak and δ 165–175 
ppm for the carbonyl peak. The remaining peaks are the six aromatic carbon peaks 
corresponding to C1-C6, a peak at δ 49.64 ppm corresponding to C7, and two peaks 







Figure 2.16: 13C-NMR (DMSO-d6, 151 MHz) spectrum of 3.3i 
 
Mass analysis of compound 3.3i was performed using ESI+. The parent peak indicated 
an m/z of 209.2 [M+H]+, which was obtained to corroborate the calculated mass for 
C11H18N2O (208.16) as the chloride counter-ions are not observed in LC-MS.  
Having successfully synthesized Mannich base inputs as 2•HCl salts (3.3a–3.3j), 
these were subjected to a final coupling reaction with the appropriate chlorinated PBI 






2.4.3 Synthesis of target compounds  
Synthesis of all final target compounds was achieved via a coupling reaction in which 
the appropriate chlorinated PBI intermediate (1.3a–1.3d) underwent a nucleophilic 
aromatic substitution reaction by the free primary amine of the Mannich base fragment 












Scheme 2.17: Reaction and conditions for the final coupling reaction performed to obtain SAR-1 and 
SAR-2 target compounds 4-16 
 
The same reaction conditions were used for the synthesis of SAR-1 and SAR-2 target 
compounds.  However, chlorinated PBI 1.3a was used for SAR-1 target compounds 
with the appropriate Mannich base inputs (2.2a–2.2b and 3.3a–3.3j) to deliver 
compounds 4-16 (Table 2.2) in low to moderate yields. For SAR-2, the various PBI 
modifications required use of different chlorinated PBI intermediates 1.3a–1.3d to 
allow synthesis of the desired analogues. The respective yields and associated 





Table 2.2: Isolated yields of target compounds 4-28 showing Mannich based fragments used in the final 






X, R’  
R1, R2, R3, R4, R5 Mannich Base  Yield 
(%) 
4 X = H, R’ = CF3 R1 = H, R2 = H, R3 = OH, R4 = H, R5 = H 4-aminophenol 38 
5 X = H, R’ = CF3 R1 = H, R2 = CH2NHEt, R3 = OH, R4 = H, R5 = 
H (M1) 
3.3a 37 
6 X = H, R’ = CF3 R1 = H, R2 = CH2N(Et)2, R3 = OH, R4 = H, R5 
= H (P1) 
3.3i 37 
7 X = H, R’ = CF3 R1 = H, R2 = OH, R3 = CH2NHEt, R4 = H, R5 = 
H 
3.3b 23 
8 X = H, R’ = CF3 R1 = H, R2 = CH2NHEt, R3 = F, R4 = H, R5 = H 2.2a 34 
9 X = H, R’ = CF3 R1 = H, R2 = CH2NHEt, R3 = Cl, R4 = H, R5 = 
H 
2.2b 18 
10 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = H, R4 = F, R5 = 
H 
3.3d 31 
11 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = Cl, R4 = H, R5 
= H 
3.3e 9 
12 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = H, R4 = Cl, R5 
= H 
3.3f 18 
13 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = H, R4 = H, R5 = 
Me 
3.3h 13 
14 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = H, R4 = Me, R5 
= H (M2) 
3.3g 32 
15 X = H, R’ = CF3 R1 = OH, R2 = CH2NHEt, R3 = H, R4 = H, R5 = 
H  
3.3c 26 
16 X = H, R’ = CF3 R1 = OH, R2 = CH2N(Et)2, R3 = H, R4 = Me, R5 
= H (P2) 
3.3j 26 
17 X = H, R’ = CH3 M1 3.3a 33 
18 X = H, R’ = CH3 M2 3.3g 34 
19 X = F, R’ = CH3 M1 3.3a 25 
20 X = F, R’ = CH3 M2 3.3g 39 
21 X = F, R’ = CF3 M1 3.3a 22 
22 X = F, R’ = CF3 M2 3.3g 29 
23 X = H, R’ = CH3 P1 3.3i 29 
24 X = H, R’ = CH3 P2 3.3j 25 
25 X = F, R’ = CH3 P1 3.3i 18 
26 X = F, R’ = CH3 P2 3.3j 12 
27 X = F, R’ = CF3 P1 3.3i 12 
28 X = F, R’ = CF3 P2 3.3j 25 
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The final compounds from SAR-1 were evaluated for antiplasmodium activity and 
results obtained used to select Mannich base side chain inputs for the synthesis of 
SAR-2 target compounds. Mannich base side chains present in the most active 
compounds selected from SAR-1 were used along with other modifications around the 
PBI core in SAR-2 as shown in Figure 2.17. More specifically, compounds 6 and 14 
showed promising potency against P. falciparum, and the Mannich base side-chains 
in these compounds were explored further in SAR-2. 
Compound 5 is the presumed metabolite (M1) of the parent compound 6 while 
compound 16 is the parent of the presumed metabolite 14.   
 
Figure 2.17: Lead compound parent-metabolite pairs 5 and 6 and 14 and 16 selected from SAR-1 and 
SAR-2. 
 
PBI core modifications in SAR-2 included modifications at positions R’ and X (Figure 
2.17). The final compounds were achieved through a coupling reaction with the 
appropriate Mannich base group and the appropriate chlorinated PBI intermediates 
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1.3b, 1.3c and 1.3d shown in Figure 2.18. The Mannich bases are maintained from 
SAR-1 and therefore modifications of the PBI core only will be discussed. 
 
Figure 2.18: Appropriate chlorinated PBI intermediates to diversify SAR-2 used in the final coupling 
reaction 
Three changes are employed for SAR-2 namely; (i) CF3/CH3 exchange at the R’ 
position (1.3b), (ii) difluorination at X (1.3c), and finally (iii) a combination of CF3/CH3 
exchange at R’ with fluorination at X (1.3d). For (i) exchanging CF3 for CH3 results in 
a significant decrease in molecular weight with little implications on electronic 
potentials of the compounds. The second modification was (ii) difluorination at position 
X, which was shown to improve the pharmacological activity and microsomal 
metabolic stability of PBIs in previous studies.92 The third and final modification 
explored in SAR-2 was (iii) a combination of CF3/CH3 exchange at R’ with 
difluorination at the X-position, combining the aforementioned modifications to develop 
a new PBI core scaffold and explore new chemical spaces.  
The previously discussed final coupling reaction between the appropriate Mannich 
base inputs and chlorinated PBI intermediates was utilised as shown in Scheme 2.17.  
The synthetic procedure and characterization of final compounds will be exemplified 
by compound 28 as an illustrative example for the final N-arylation coupling reaction 
between chlorinated PBI intermediates and MBFs. 
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Synthesis and characterization of target compounds from a coupling reaction 
between a Mannich base salt and PBI intermediate 
The synthesis of final compounds 4–28 was outlined in Scheme 2.17 earlier and the 
reaction mechanism is shown in Scheme 2.18. Synthesis of final compounds began 
with the appropriately substituted chlorinated PBI intermediates 1.3a–1.3d, which 
reacted with (i) free Mannich base inputs (1.2 eq) or (ii) [Mannich base ]•2HCl salts 
dissolved in EtOH (2 mL). It is important to note that the reaction favoured acidic 
conditions, and that the desired product was not formed unless HCl was present. It is 
for this reason that free Mannich bases 2.2a and 2.2b required the dropwise addition 
of 4 M HCl for formation of the product. For Mannich base inputs that were isolated as 
salts, there was dual protonation on the primary and secondary amines respectively 
and therefore addition of KH2PO4 was necessary to facilitate the aromatic nucleophilic 










Scheme 2.18: Proposed mechanism for the nucleophilic aromatic substitution reaction performed to 
afford final compound 28 
The formation of target compound 28 via nucleophilic aromatic substitution is shown 
in Scheme 2.18. The reaction proceeds via regioselective nucleophilic attack of the 
primary amine at the carbon of the chloro-position on the PBI. For Mannich base 
isolates which had a secondary amine on the Mannich base side chain, a 
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regioselective nucleophilic addition of the primary amine over the secondary amine 
occurred, as the less nucleophilic primary amine is sterically unhindered compared to 
the more nucleophilic secondary amine. The reaction mechanism proposed includes 
a nucleophilic aromatic substitution reaction, which begins with nucleophilic addition 
of the primary amine (aniline) at the carbon of the PBI core to which the chloro is 
attached. The cyano-substituent acts as an electron-sink. To confirm the success of 
the reaction, 1HNMR spectroscopy analysis of 28 was performed and the spectrum is 












The diagnostic peaks include key proton signals from the Mannich base (Ar) side-
chain and PBI core of the molecule. Successful substitution at the C1-position was 
confirmed by an upfield shift of proton H2 compared to that in 1.3c, which appeared 
as a singlet integrating for one proton at δ 5.63 ppm. Furthermore, protons belonging 
to the PBI core underwent ortho-fluorine coupling (J = 11.4 Hz) and meta-coupling (J 
= 8.1 and 7.4 Hz), and are assigned as two doublet of doublets at δ 8.72 ppm and δ 
7.51 ppm, each integrating for a single proton, corresponding to H10 and H7, 
respectively. The aromatic proton signals associated with the Mannich base side-chain 
(Ar) of the compound are two singlets, each integrating for a single proton at δ 6.86 
ppm and δ 6.80 ppm, corresponding to H19 and H17, respectively. The methylene 
linker was assigned to a singlet at δ 4.20 ppm integrating for two protons 
corresponding to H20. The diethylamine protons were assigned to two signals at δ 
3.10 ppm and δ 1.23 ppm as a quartet integrating for four protons (J = 7.2 Hz) and a 
triplet integrating for six protons corresponding to H21 and H22 respectively. The final 
peak in the 1H spectrum for 28 is that of H23 which appears as a singlet, integrating 






To further confirm the success of the reaction, 13C-NMR analysis was also performed 
(Figure 2.20). Characteristic features of the 13C-NMR spectrum include 19 carbon 
peaks in the aromatic region (89–155 ppm) corresponding to aromatic regions from 
both the PBI and Mannich base side-chain portions of the final compound and finally 
the CF3 carbon signal. The splitting pattern associated with the 13C-NMR spectrum of 
28 is attributed to fluorine atoms at C7, C8, C9, C10, and C13, as these have a nuclear 
spin of ½ and therefore split the carbon signals from singlets into doublets. Meta-
coupling to the fluorine atom in the PBI core was observed for C7 and C10.  Finally, 
the success of the reaction was confirmed by the remaining aliphatic 13C-NMR peaks 
attributed to the diethylamine chain at δ 51.17 ppm corresponding to C20, and two 
peaks remaining, each equivalent to two carbons at δ 47.14 ppm and δ 8.97 ppm 
corresponding to C21 and C22, respectively. The final remaining peak is that at δ 










Figure 2.20: 13C-NMR (DMSO-d6, 151 MHz) spectrum of 28 
Mass analysis of compound 28 was performed using ESI+ and the parent peak 
indicated an m/z of 504.20 [M+H]+, which was obtained to corroborate the calculated 
mass for C25H22F5N5O (503.17).  
 
2.5 Chapter conclusion 
This chapter described the synthesis and characterization of target compounds 
designed for SAR studies.  Furthermore, the parent and corresponding presumed N-
dealkylated metabolite pairs were selected from SAR-1 to investigate further in SAR-
2. The compounds were synthesized using standard protocols adapted from published 
synthetic methods. All compounds synthesized were fully characterized using NMR, 
and chromatographic methods including TLC and HPLC-MS, along with measurement 
of physical attributes such as melting point and appearance. The final target 
compounds were submitted for biological evaluation and physicochemical profiling as 
detailed in Chapter 3. In addition, data relating to the characterization of each of the 





CHAPTER 3: Biological results and discussion 
3.1 Chapter overview 
This chapter details the studies conducted to assess the antiplasmodium activity, β-
hematin inhibition potential, cytotoxicity, metabolic stability, and physicochemical 
properties of target PBIs. A simplified illustration of the test sequence used for 
biological and physicochemical profiling is included to highlight the key assays used. 
 
3.2 Screening cascade for target compounds 
The studies performed here followed the screening cascade shown in Figure 3.1, 
which lists the various assays and progression criteria (cut-off values) used. First, all 
compounds were initially screened to determine in vitro antiplasmodium activity 
against the NF54 (CQ-sensitive) asexual blood stage (ABS) strain of P. falciparum 
and sexual blood-stage gametocytes. The potential for compounds to inhibit -
hemozoin formation was evaluated using an in-house β-hematin inhibition cell-free 
assay. It is noteworthy that β-hematin is synthetic hemozoin. Emerging front-runner 
compounds exhibiting IC50 < 2 µM against ABS parasites were deemed active and 
were further tested for cytotoxicity and microsomal metabolic stability. Cytotoxicity was 
evaluated in both Caucasian hepatocellular carcinoma cells (Hep-G2) and Chinese 
hamster ovarian (CHO) cells to determine the compounds’ selectivity towards the 
parasite. Compounds displaying IC50 > 10 µM against mammalian cells were 
considered non-cytotoxic.  
Furthermore, two synthesized compounds were evaluated for microsomal metabolic 
stability in mouse liver microsomes (MLMs), towards identifying compounds for proof-
of-concept in vivo antimalarial efficacy studies in a mouse model.  Microsomal stability 
was determined via incubation with MLMs after which the percentage parent 
compound remaining after 30 min was  determined via LC-MS. 
The solubility of all target compounds was determined using the turbidimetric kinetic 





Figure 3.1: Screening cascade for various biological and physicochemical studies depicting cut-offs for 
the progression of compounds 
 
3.3 In vitro antiplasmodium activity  
The PBI analogues selected from SAR-1 and SAR-2 were evaluated in vitro for multi-
stage activity against the asexual erythrocytic CQ-sensitive (NF54) strain as well as 
early- and late-stage sexual stage parasites (gametocytes) using a modified luciferase 
assay (NF54-PfS16-GFP-Luc) for gametocyte viability determination.95 A discussion 
of the in vitro antiplasmodium activities of SAR-1 and SAR-2 compounds follows 
below. 
 
3.3.1 SAR-1  
The in vitro antiplasmodium activities of SAR-1 compounds were evaluated against 
asexual and sexual stages of P. falciparum. The mean values obtained for SAR-1 





Table 3.1: In vitro activity of SAR-1 compounds against asexual-stage (NF54) and gametocyte (NF54) 










% inhibition in 
early-stage 
gametocytes  
% inhibition in 
late-stage 
gametocytes  
X, Y, Z NF54 1 µM 5 µM 1 µM 5 µM 
4 X =H, Y =4-OH, Z = H 6.00 0 12 25 27 
5 X =H, Y =4-OH, Z = 3-CH2NHEt 6.00 33 14 26 41 
6 X =H, Y =4-OH, Z = 3-CH2N(Et)2 1.60 19 29 60 60 
7 X =H, Y =3-OH, Z = 4-CH2NHEt 6.00 0 0 66 67 
8 X =H, Y =4-F, Z = 3-CH2NHEt 5.82 16 49 77 43 
9 X =H, Y =4-Cl, Z = 3-CH2NHEt 6.00 - - - - 
10 X =5-F, Y =2-OH, Z = 3-CH2NHEt 6.00 - - - - 
11 X =4-Cl, Y =2-OH, Z = 3-CH2NHEt 6.00 - - - - 
12 X =5-Cl, Y =2-OH, Z = 3-CH2NHEt 2.56 - - - - 
13 X =6-Me, Y =2-OH, Z = 3-CH2NHEt 5.78 - - - - 
14 X =5-Me, Y =2-OH, Z = 3-CH2NHEt 0.81 - - - - 
15 X =H, Y =2-OH, Z = 3-CH2NHEt 4.86 2.0 4.5 14.9 0.9 
16 X =5-Me, Y =2-OH, Z = 3-CH2N(Et)2 1.18 6.6 84.6 0 12.5 
a
 Mean values were calculated from at least two independent experiments (individual values within ± 2-fold). 
Artesunate (IC50 = 0.007 μM) and chloroquine (IC50 = 0.012 μM) were used as reference drugs. 
 
For the purpose of this study, compounds were classified as showing high activity (IC50 
≤ 2 µM), moderate activity (2 < IC50 < 6 µM), or poor activity (IC50 ≥ 6 µM). For SAR-
1, all compounds synthesized contained the same PBI-core and are therefore 
discussed in terms of their substituents at the X, Y, and Z positions of the phenolic 
Mannich base side-chain (Table 3.1). The presence or absence of the monoethylated 
Mannich side chain was not critical for antiplasmodium activity as highlighted by the 
4-hydroxy aromatic (Ar) group in 4 (IC50 = 6.00 µM), and 5 (IC50 = 6.00 µM). The 
diethylated Mannich side chain was crucial as exemplified by the activity of compound 
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6. The substituent at the 3rd position (Z = 3-CH2N(Et)2) of the Mannich base side-chain 
drastically improved activity as exemplified by compound 6 (IC50 = 1.60 µM), which 
showed a 4-fold increase in activity compared to that of desethyl metabolite 5. One of 
the structural modifications implemented to overcome the liabilities associated with 
quinone-imine formation included swapping the position of the substituents at the 3rd 
and 4th positions of the Mannich base side-chain. Unfortunately, this resulted in loss 
of activity as shown for compound 7 (IC50 = 6.00 µM). Another strategy involving 
substituting the hydroxyl group at the 4th position of the Mannich base side-chain with 
a halogen (F or Cl) was detrimental to activity as shown by the poor activities of 
analogues 8 and 9 (IC50 = 5.82 and 6.00 µM, respectively).  
Exploitation of the 2nd and 3rd positions of the Mannich base side-chain was 
investigated for the remaining SAR-1 compounds. Compounds 10–16 all contained a 
Mannich base side-chain with the 2nd position occupied by a hydroxyl substituent (Y = 
2-OH). Compounds 10–12 are the halogenated analogues of SAR-1. Addition of a 
fluorine substituent at the 5th position (X = 5-F) and a chlorine substituent at the 4th 
position (X = 4-Cl) led to loss of antiplasmodium activity as shown by 10 and 11 ( (IC50 
= 6.00 µM). The presence of a chlorine atom in the 5th position (X = 5-Cl) was 
somewhat tolerated, as represented by the moderate activity of compound 12 (IC50 = 
2.56 µM).  
The position of the methyl substituent influenced antiplasmodium activity, as was 
shown by both analogues 13 and 14. Compound 13 containing a methyl substituent 
at the 6th position (IC50 = 5.78 µM), was significantly less active compared to 
compound 14 (IC50 of 0.81 µM), which contains a methyl substituent at the 5th position. 
When there is no substituent present (i.e., X = H, as in 15), activity decreased 6-fold 
(IC50 = 4.86 µM) compared to that of 14, thus highlighting the importance of a 5-methyl 
substituent. High antiplasmodium activity was observed for compound 16 (IC50 = 1.18 
µM) in which a diethylaminomethylene group is at position 3 (Z = 3-CH2N(Et)2). When 
compared to the monoethylated analogue 14  (IC50 = 0.81 µM), it appears 
monoethylation has similar activity compared to diethylation. 
In summary, eight compounds (4, 5, 7, 8, 9, 10, 11, and 13) from the SAR-1 series 
showed poor antiplasmodium activity, IC50 = 6.00 µM. In comparison, analogue 6 
showed an IC50 of 1.60 µM. The most active compounds from SAR-1 were 6, 14, and 
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16. These active compounds were used as a starting point in the rationalization of 
compounds selected for SAR-2. Of the remaining compounds, 12 (IC50 = 2.56 µM) 
and 15 (IC50 = 4.86 µM) showed moderate antiplasmodium activity. 
From SAR-1, seven compounds were selected for testing against both late- and early-
stage gametocytes. For the purpose of discussion, compounds were classified as 
indicated below: 
• High activity: >70% inhibition at 5 μM and >50% inhibition at 1 μM 
• Moderate activity: >70% inhibition at 5 μM and <50% inhibition at 1 μM, <70% 
inhibition at 5 μM and >50% inhibition at 1 μM, or 50–70% inhibition at 5 μM 
and <50% inhibition at 1 μM 
• No/ minimal activity: <50% inhibition at 5 μM and <50% inhibition at 1 μM 
Based on these criteria, all compounds selected for gametocyte testing, with the 
exception of 16, showed no/minimal activity against early-stage gametocytes. 
Compound 16 exhibited moderate activity against early-stage gametocytes with 
84.6% inhibition at 5 μM. Compounds 6, 7, and 8 showed moderate activity against 
late-stage gametocytes while compounds 4, 5, 15, and 16 showed minimal activity 
against late-stage gametocytes. Compounds 6 and 16 were considered active against 
both sexual and asexual stage parasites and analogues containing the Mannich base 
side-chains present in these active compounds were evaluated in SAR-2. The 
relationships between parent and desethyl metabolites were explored in SAR-2 with 
respect to antiplasmodium activity and metabolic stability. A brief comparison of the 
parent compounds and desethyl metabolites is provided using representative 
compounds from SAR-1 (compounds 5, 6, 14, and 16). 
 
3.3.2 Selection of parent and desethyl metabolite pairs from SAR-1 for 
exploration in SAR-2 
In SAR-1, only compounds 6 and 16 contained a diethylamine group at the 3rd position 
(Z = 3-CH2N(Et)2). These were classified as parent compounds based on the 
assumption that they will undergo metabolism to the corresponding desethyl 
metabolites based on previous metabolite identification studies.92 Desethyl 
metabolites of 6 and 16 were synthesized and evaluated in SAR-1, and these 
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contained an ethylamine substituent at the 3rd position (Z = 3-CH2NHEt), as 
represented by 5 and 14, respectively. Noticeably, when comparing the activity of 
parent and desethyl metabolite pairs 6 and 5, the parent compound 6 (IC50 = 1.60 µM) 
was active against asexual-stage parasites and moderately active against late-stage 
gametocytes (60% inhibition at 1 µM), although the desethyl metabolite (5) showed no 
activity against sexual or asexual parasites (IC50 = 6 µM). In comparison, the desethyl 
metabolite 14 (IC50 = 0.81 µM) showed similar activity against asexual-stage parasites 
compared to that of the parent 16. The parent was still considered active against 
asexual-stage parasites (IC50 = 1.18 µM) as well and moderately active against early-
stage gametocytes (84.6 % inhibition at 5 µM).  
Based on the antiplasmodium activity data described in SAR-1, the comparison 
between the antiplasmodium activities of parent compounds and desethyl metabolites 
was further investigated in SAR-2. The selection criteria used for SAR-2 analogues is 





Figure 3.2: Mannich base fragments used for all SAR-2 compounds 
 
The Mannich base side-chains selected for SAR-2 are highlighted in Figure 3.2. 
Briefly, the first metabolite-parent pair, desethyl metabolite 5 and parent 6,  contain 
Mannich base side-chains M1 and P1, respectively. The second metabolite-parent pair 
is desethyl metabolite 14 and parent 16, which contain Mannich base side-chains M2 
and P2, respectively. The two parent-metabolite pairs maintained their respective 
Mannich base side-chains whilst three changes were made to the PBI core, including 
a CF3/CH3 exchange at the R′ position, difluorination at the X-position, and a 
combination of CF3/CH3 substitutions and difluorination at the R′- and X-positions 
respectively. While the CF3 and CH3 substitutions were intended to broaden the SAR, 
introduction of fluorine atoms in the left hand side of the PBI core was designed to 
improve metabolic stability as fluorination is known to improve metabolic stability in 
phase I oxidation metabolism.96 The parent-metabolite pairs synthesized are shown in 




3.3.3 SAR-2 in vitro antiplasmodium activity  
The in vitro antiplasmodium activities of SAR-2 compounds were evaluated against 
asexual stages of P. falciparum (NF54 strain) and selected compounds evaluated 
against early- and late-stage gametocytes. The mean values obtained for SAR-2 






Table 3.2: In vitro activity of SAR-2 compounds against asexual-stage and gametocyte P. falciparum 




PBI core Mannich Base Fragments 








Early stage Late stage 
Compound X, R’ 
M1, P1, 
M2, P2 
NF54 1 µM 5 µM 1 µM 5 µM 
5 
X = H 
R’ = CF3 
M1 6.00 33 14 26 41 
6 
X = H 
R’ = CF3 
P1 1.60 19 29 60 60 
14 
X = H 
R’ = CF3 
M2 0.81 - - - - 
16 
X = H 
R’ = CF3 
P2 1.18 6.6 84.6 0 12.5 
17 
X = H 
R’ = CH3 
M1 3.70 0 57.5 0 14.8 
18 
X = H 
R’ = CH3 
M2 1.20 0 90.3 0 9.8 
19 
X = F 
R’ = CH3 
M1 0.59 0 77.1 0 10.2 
20 
X = F 
R’ = CH3 
M2 0.63 17.9 92.8 0 3.6 
21 
X = F 
R’ = CF3 
M1 3.06 0 23.2 0 0 
22 
X = F 
R’ = CF3 
M2 2.08 0 29.3 0 8.9 
23 
X = H 
R’ = CH3 
P1 1.50 0 30.9 0 1.7 
24 
X = H 
R’ = CH3 
P2 0.64 52.8 88.7 0 9.3 
25 
X = F 
R’ = CH3 
P1 0.47 0 52.6 0 0 
26 
X = F 
R’ = CH3 
P2 0.54 81.4 84.6 0 7.8 
27 
X = F 
R’ = CF3 
P1 2.31 0 17.1 0 12.2 
28 
X = F 
R’ = CF3 
P2 0.35 0 0 0 41.9 
aMean values were calculated from at least two independent experiments (individual values within ± 2-fold). 
Artesunate (IC50 = 0.007 μM) and chloroquine (IC50 = 0.012 μM) were used as reference drugs. bReference 
compounds typically produce the following average % inhibition of gametocyte viability at 1 μM: methylene blue, 
95% in early gametocytes and 92% in late gametocytes), MMV390048 (UCT MMV internal reference), 56% in early 




Compounds 5, 6, 14, and 16 have already been discussed in SAR-1 but are included 
in Table 3.2 for comparison purposes. Overall, SAR-2 compounds showed higher 
antiplasmodium activity than SAR-1 compounds. Six compounds from SAR-2 showed 
sub-micromolar antiplasmodium activity, including both parent compounds and 
desethyl metabolites. The desethyl metabolites showing sub-micromolar activity 
contain Mannich base side-chains M1 and M2, 19 (IC50 = 0.59 µM) and 20 (IC50 = 0.63 
µM), respectively. The four parent compounds with sub-micromolar activity are: 24 
(IC50 = 0.64 µM), 25 (IC50 = 0.47 µM), 26 (IC50 = 0.54 µM), and 28 (IC50 = 0.35 µM) 
containing Mannich base side-chains P2, P1, P2, and P2, respectively.  
The SAR for modifications made to the PBI-core will be highlighted using selected 
representative compounds based on CF3/CH3 substitutions and other modifications of 
the PBI-core. These modifications will be compared to SAR-1 compounds with an 
unmodified PBI core, as represented by compounds 5 (IC50 = 6.00 µM), 6 (IC50 = 1.60 
µM), 14 (IC50 = 0.81 µM), and 16 (IC50 = 1.18 µM).  
Overall, replacement of the CF3 substituent with a CH3 group either resulted in an 
increase in activity  for the desethyl metabolites 17 (IC50 = 3.70 µM, ) or in comparable 
activity as in 18 (IC50 = 1.20 µM,). In case of the parent compounds, there was 
comparable activity in case of 23 (IC50 = 1.50 µM) and an increase in activity in case 
of 24 (IC50 = 0.64 µM). In general, difluorination at the X-position resulted in an 
increase in activity as shown by desethyl metabolites 21 (IC50 = 3.06 µM, ) and 22 
(IC50 = 2.08 µM) and parent compound 28 (IC50 = 0.35 µM) but a slight decrease in 
activity for parent compounds 27 (IC50 = 2.31 µM). Simultaneous replacement of the 
CF3 substituent with a CH3 group with difluorination at the X-position resulted in an 
increase in activity for both parents and desethyl metabolites, as exemplified by 
desethyl metabolites 19 (IC50 = 0.59 µM) and 20 (IC50 = 0.63 µM,) and parent 
compounds 25 (IC50 = 0.47 µM), and 26 (IC50 = 0.54 µM). 
In summary, all structural modifications to the PBI core at positions X and R′ with 
respect to replacement of the CF3 substituent with a CH3 group and difluorination 
improved antiplasmodium activity across all Mannich base side-chains (M1, M2, P1, 
and P2), with the exception of difluorination at the X-position for Mannich base side-
chains M2 and P1, as exemplified by 22 and 27, respectively, which was detrimental 
to antiplasmodium activity.  
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All 12 compounds from SAR-2 were selected for testing against both late- and early-
stage gametocytes. Two compounds showed high activity against early stage 
gametocytes: these were parent compounds 24 and 26, which showed 52.8% and 
81.4%, inhibition, respectively, at 1 µM. Three desethyl metabolites showed moderate 
activity against early-stage gametocytes: 18 (90.3% inhibition at 5 µM), 19 (77.1% 
inhibition at 5 µM), and 20 (92.8% inhibition at 5 µM). The remaining seven compounds 
from SAR-2 (17, 21, 22, 23, 25, 27, and 28) showed minimal inhibition of early-stage 
gametocytes. No clear trend towards early-stage gametocyte activity was observed 
across transformations made around the PBI-core. All compounds from SAR-2 
showed minimal inhibition of late-stage gametocytes. Overall, compounds showed a 
preference for early-stage gametocytes, which suggests stage-specificity.  
 
3.4 β-hematin inhibition studies and turbidimetric solubility studies for final 
compounds 
The mechanistic potential of analogues synthesized in SAR-1 and SAR-2 to inhibit 
hemozoin formation was evaluated in vitro by investigating their ability to inhibit β-
hematin formation. A Nonidet-P-40 (NP-40) detergent-mediated assay was performed 
in acetate buffer (pH 4.8) at 37 °C, with the activity cut-off set at IC50 < 100 μM. The 
approximate aqueous solubility of the compounds synthesized was measured using 
turbidimetric kinetic solubility assay. The turbidimetric solubility assay relies on the 
appearance of turbidity in solution once a compound exceeds its solubility limit in the 
assay and generally results in an over-estimated solubility compared to HPLC-based 
methods. Compound solubility was determined as the concentration value (IC50) 
above which the compounds precipitated out of an aqueous buffer (phosphate-
buffered saline, pH 7.4). Results of the β-hematin inhibition and turbidimetric solubility 











X, R’  







X = H 
R’ = CF3 
R1 = H, R2 = H, R3 = OH, R4 = H, R5 = H 241 200 
5 
X = H 
R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = OH, R4 = H, 
R5 = H (M1) 
14.68 160 
6 
X = H 
R’ = CF3 
R1 = H, R2 = CH2N(Et)2, R3 = OH, R4 = H, 
R5 = H  (P1) 
6.502 5 
7 
X = H 
R’ = CF3 
R1 = H, R2 = OH, R3 = CH2NHEt, R4 = H, 
R5 = H 
43.86 10 
8 
X = H 
R’ = CF3 




X = H 
R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = Cl, R4 = H, 
R5 = H 
111.4 5 
10 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = H, R4 = F, 
R5 = H 
8.341 10 
11 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = Cl, R4 = H, 
R5 = H 
10.75 20 
12 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = H, R4 = Cl, 
R5 = H 
7.77 40 
13 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = H, R4 = H, 
R5 = Me 
10.39 40 
14 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = H, R4 = Me, 
R5 = H (M2) 
13.44 40 
15 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = H, R4 = H, 
R5 = H  
14.17 20 
16 
X = H 
R’ = CF3 
R1 = OH, R2 = CH2N(Et)2, R3 = H, R4 = 
Me, R5 = H (P2) 
182.4 20 
17 
X = H 
R’ = CH3 
M1 59.58 80 
18 
X = H 
R’ = CH3 
M2 33.56 80 
19 
X = F 
R’ = CH3 




X = F 
R’ = CH3 
M2 16.41 40 
21 
X = F 
R’ = CF3 
M1 7.84 20 
22 
X = F 
R’ = CF3 
M2 8.21 10 
23 
X = H 
R’ = CH3 
P1 71.08 200 
24 
X = H 
R’ = CH3 
P2 56.66 <5 
25 
X = F 
R’ = CH3 
P1 >200 <5 
26 
X = F 
R’ = CH3 
P2 5.86 20 
27 
X = F 
R’ = CF3 
P1 >200 10 
28 
X = F 
R’ = CF3 
P2 >200 <5 
 
For the purpose of discussion, Mannich base side-chains (Ar) maintained from SAR-
1 and carried through to SAR-2 are highlighted in Table 3.3. Compounds 5, 6, 14, and 
16 contain Mannich base side-chains M1, P1, M2, and P2, respectively. These 
abbreviated Mannich base side-chains are used to describe the Ar groups for 
compounds 17–28 from SAR-2. Most compounds were shown to be active inhibitors 
of β-hematin formation (Table 3.3). To illustrate how PBI core modifications influenced 




Figure 3.3: Graphical representation of β-hematin inhibition (IC50) and turbidimetric solubility (μM) for 
all compounds 
 
The most potent inhibitor of synthetic hemozoin formation was 26 (IC50 = 5.86 µM). 
However, there were 16 compounds that inhibited hemozoin formation with an IC50 < 
50 µM. Of these 16 compounds, 10 were from SAR-1 (5–8 and 10–15), and six were 
from SAR-2 (18–22 and 26). Interestingly, although compound 26 was the most potent 
inhibitor of the β-hematin pathway, parent MBFs (6, 16, and 23–28) overall exhibited 
low β-hematin inhibition when compared to desethyl analogues, with the exception of 
6 and 26. Although substitutions made around the PBI core were envisaged to 
potentially have an influence on β-hematin activity, there was no obvious correlation. 
Rather, the potential to inhibit the β-hematin pathway seems to correlate more closely 
with the Mannich base side-chains selected. Compounds 4, 9, 16, 25, 27, and 28 
showed minimal inhibition of β-hematin with IC50 values > 100 µM. In summary, of the 
25 PBI analogues, 16 displayed strong potential (IC50 < 50), three displayed moderate 
potential (50 < IC50 < 100), and six compounds showed minimal potential to inhibit the 
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β-hematin formation pathway. There was a correlation between the inhibition of the β-
hematin inhibition and the antiplasmodium activity of compounds. Compounds with 
potent antiplasmodium activity (IC50 < 2 µM) showed the highest inhibition of the β-
hematin formation. Exceptions of this trend are compounds 16, 25, and 28, which have 
good antiplasmodium activity with poor inhibition of the β-hematin formation, which 
may indicate an alternative mechanism of action for these compounds.  
As mentioned, the solubility of compounds was tested via a turbidimetric solubility 
assay. The solubility concentration values obtained are shown in Table 3.3 and are 
graphically presented in Figure 3.4. Turbidity was detected by measuring the 
ultraviolet-visible (UV-VIS) absorbance of the suspension at 620 nm as most 
compounds, including those synthesized, do not absorb light in this region. The 
positive control used was a solution of the compound in dimethyl sulfoxide (DMSO). 
The aqueous solubility of compounds was defined as a point of inflection from the 
baseline of a graph (DMSO plot) showing corrected absorbance at 620 nm and 
compound concentration, as shown for compounds 17 and 21 in Figure 3.4.  
 
Figure 3.4: Representative graphical plots depicting the relative aqueous solubility of PBI analogues 17 
and 21 
 
The majority of the compounds showed low (<20 μM) or moderate solubility (20–100 
μM; Table 3.3). Three compounds (4, 5, and 23) did, however, display high solubility. 
Compound 4 (200 μM) is used as a reference compound as it is the only analogue 




Figure 3.5: Plot of Log[Solubility] vs β-Hematin inhibition assay IC50. 
In an attempt to correlate the potential for a compound to inhibit synthetic hemozoin 
formation with solubility, a graph of the β-hematin inhibition assay (BHIA) vs 
Log(Solubility) was plotted (Figure 3.5). It is expected that increased solubility 
correlates with a decrease in the IC50 value determined for the BHIA, relating to more 
soluble compound’s ability to inhibit the beta-hematin formation pathway than 
insoluble ones which are likely to aggregate in solution. From the figure above, there 
is evidently no correlation between the BHIA and solubility for this series of compounds 
with an R2 value of <0.01. This could be due to the similarity of all the compounds 
across the series, since modest modifications are introduced focusing on microsomal 
metabolic liabilities, rather than an exploration of various solubilizing groups as in a 
structure-property relationship (SPR) guided project. This results in a flat series of 
compounds with little chemical diversity which could be addressed by introducing 
substituents from various regions of a Craig-plot to gauge the correlation between 





























3.5 Cytotoxicity evaluation  
 






X, R’  






4 X = H, R’ = CF3 
R1 = H, R2 = H, R3 = OH, R4 = 
H, R5 = H 
-156.3  
5 X = H, R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = 
OH, R4 = H, R5 = H (M1) 
-97.3 41.71 
6 X = H, R’ = CF3 
R1 = H, R2 = CH2N(Et)2, R3 = 
OH, R4 = H, R5 = H  (P1) 
-148.7  
7 X = H, R’ = CF3 
R1 = H, R2 = OH, R3 = 
CH2NHEt, R4 = H, R5 = H 
-13.9  
8 X = H, R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = F, 
R4 = H, R5 = H 
- 55.9  
9 X = H, R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = Cl, 
R4 = H, R5 = H 
-  
10 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = F, R5 = H 
-  
11 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
Cl, R4 = H, R5 = H 
-  
12 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = Cl, R5 = H 
-  
13 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = H, R5 = Me 
-  
14 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = Me, R5 = H (M2) 
17.3  
15 X = H, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = H, R5 = H  
-  
16 X = H, R’ = CF3 
R1 = OH, R2 = CH2N(Et)2, R3 = 
H, R4 = Me, R5 = H (P2) 
49.7 29.84 
17 X = H, R’ = CH3 
R1 = H, R2 = CH2NHEt, R3 = 
OH, R4 = H, R5 = H (M1) 
0 - 
18 X = H, R’ = CH3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = Me, R5 = H (M2) 
24.2 29.07 
19 X = F, R’ = CH3 
R1 = H, R2 = CH2NHEt, R3 = 




20 X = F, R’ = CH3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = Me, R5 = H (M2) 
22.3 30.67 
21 X = F, R’ = CF3 
R1 = H, R2 = CH2NHEt, R3 = 
OH, R4 = H, R5 = H (M1) 
37.8 - 
22 X = F, R’ = CF3 
R1 = OH, R2 = CH2NHEt, R3 = 
H, R4 = Me, R5 = H (M2) 
26.5 - 
23 X = H, R’ = CH3 
R1 = H, R2 = CH2N(Et)2, R3 = 
OH, R4 = H, R5 = H  (P1) 
100 > 50 
24 X = H, R’ = CH3 
R1 = OH, R2 = CH2N(Et)2, R3 = 
H, R4 = Me, R5 = H (P2) 
100 > 50 
25 X = F, R’ = CH3 
R1 = H, R2 = CH2N(Et)2, R3 = 
OH, R4 = H, R5 = H  (P1) 
56.1 > 50 
26 X = F, R’ = CH3 
R1 = OH, R2 = CH2N(Et)2, R3 = 
H, R4 = Me, R5 = H (P2) 
83.1 28.06 
27 X = F, R’ = CF3 
R1 = H, R2 = CH2N(Et)2, R3 = 
OH, R4 = H, R5 = H  (P1) 
37.8 - 
28 X = F, R’ = CF3 
R1 = OH, R2 = CH2N(Et)2, R3 = 
H, R4 = Me, R5 = H (P2) 
3.7 > 50 
 
Synthesized analogues from SAR-1 and SAR-2 were evaluated for in vitro cytotoxicity 
against HepG2 cells as a single-point concentration assay at 2 μM, and selected 
compounds were evaluated against CHO cells to determine the compound 
concentration value detrimental to cell survival. For HepG2 cytotoxicity studies, a 
compound leading to >50% cell death was regarded as cytotoxic and in CHO studies 
compounds which had an IC50 < 20 µM were regarded as cytotoxic (Table 3.4). All 
SAR-1 compounds evaluated against HepG2 cells were non-cytotoxic at 2 μM. The 
negative cytotoxicity values (Table 3.4) indicate treated cells that proliferated, in 
comparison to the control cell line (untreated), thus confirming the compounds are 
non-cytotoxic. Furthermore, compounds 5 and 16 showed no cytotoxicity against CHO 
cells. 
SAR-2 compounds were generally non-cytotoxic in both HepG2 and non-cytotoxic in 
all CHO cells. Cytotoxicity was observed for compounds 23 (100% HepG2 toxicity), 
24 (100% HepG2 toxicity), 25 (56.1% HepG2 toxicity) and 26  (83.1% HepG2 toxicity).  
in HepG2 cells. Compounds 23 – 26 showed cytotoxicity against HepG2 but not CHO 
cells. These observations highlight the importance of testing across multiple cell lines, 
as susceptibility across various cell lines may vary.  
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3.6 Microsomal stability studies on SAR-2 compounds 
The most potent (IC50 < 2 µM) PBIs were selected for in vitro microsomal metabolic 
stability. This assay was conducted by Dr Mathew Njoroge at the UCT Drug Discovery 
and Development Centre, H3D. The protocol used for the microsomal stability assay 
is described in detail in Chapter 5. The LC-MS/MS mass peak readout was used to 
determine the percentage remaining compound after 30 min incubation with MLMs 
(Table 3.5). For illustrative purposes, microsomal stability is also graphically presented 




















PBI core MBF Microsomal stability in MLMs 
X, R’ M1, P1, M2, P2 % remaining after 30 min 
5 
X = H 
R’ = CF3 
M1 - 
6 
X = H 
R’ = CF3 
P1 12.05 
14 
X = H 
R’ = CF3 
M2 >99 
16 
X = H 
R’ = CF3 
P2 28.91 
17 
X = H 
R’ = CH3 
M1 - 
18 
X = H 
R’ = CH3 
M2 34.96 
19 
X = F 
R’ = CH3 
M1 >99 
20 
X = F 
R’ = CH3 
M2 63.19 
21 
X = F 
R’ = CF3 
M1 - 
22 
X = F 
R’ = CF3 
M2 - 
23 
X = H 
R’ = CH3 
P1 60.35 
24 
X = H 
R’ = CH3 
P2 7.58 
25 
X = F 
R’ = CH3 
P1 51.18 
26 
X = F 
R’ = CH3 
P2 17.48 
27 
X = F 
R’ = CF3 
P1 - 
28 
X = F 
R’ = CF3 
P2 5.20 




Figure 3.6: SAR-2 selected compounds evaluated for microsomal stability in mouse liver microsomes 
(MLMs) 
Two PBI analogues from SAR-2 displayed high stability in MLMs, showing >99% 
remaining after 30 min incubation. The poor microsomal stability shown by compound 
16 is likely a result of the metabolically labile N,N-diethyl moiety, which undergoes 
rapid mono-desethylation. Similarly, compound 25 showed moderate microsomal 
stability (51.18% remaining), which is likely also due to mono-desethylation.  
When comparing the parent and desethyl metabolite of compounds containing the 
same PBI core, the most metabolically stable compounds contained the 
monoethylated desethyl metabolite Mannich base side-chain as opposed to the 
diethylated parent Mannich base side chain. Exemplified by monoethylated compound 
14,  the most stable compound (X = H, R’ = CF3, blue bar, notably from SAR-1) with 
>99% parent compound remaining after 30 min. Conversely, diethylated compound 
18 (X = H, R’ = CH3; orange bar) exhibited overall reduced metabolic stability through 
with approximately 35% remaining. Difluorination (where X = F and R’ = CH3, yellow 
bar;) improved metabolic stability with compound 20 showing approximately 60% 
parent compound remaining after 30 min, an improvement from 18. A similar trend 
was observed for analogues 16, 24, 26 and 28, with the most stable PBI core 
containing X = H and R’ = CF3 observed for 16 (28.91% remaining), followed by a drop 
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in microsomal stability for compound 24 (7.58% remaining) and a slight increase 
through difluorination as in compound 26 (17.48% remaining) and low microsomal 
stability for 28 (5.20% remaining).  
In contrast to these trends observed for 14 and 16, the most stable compound of the 
P1 analogues was compound 23 (60.35% remaining), where X = H and R’ = CH3. 
Furthermore, the effect of simultaneous difluorination  and methyl substitution resulted 
in a decrease in metabolic stability as seen in compound 25 (51% remaining). 
Although compound 19 (X = F and R’ = CH3) showed very high microsomal stability, 
with >99% parent compound remaining after 30 min, there were no analogues 
containing the M1 Mannich base side-chain showing potent antiplasmodium activity to 
prioritize microsomal stability testing. 
In summary, the nature of the Mannich base side chain, when comparing the same 
PBI-core, influenced the in vitro microsomal stability of compounds with desethyl 
metabolites showing greater stability than their corresponding parent compounds. The 
effects of PBI core modification on microsomal metabolic stability were not obvious 
and would need to be investigated further as part of future work.  
Compounds 14 and 19 exhibited high microsomal metabolic stability and are potential 
candidates for in vivo antimalarial efficacy studies. It is important to note that 
compounds 14 and 19 are hypothesized desethyl metabolites of parent compounds 
16 and 25 respectively (Figure 3.7). The rapid metabolism of both these parent 
compounds is likely due to the metabolically labile N,N-diethyl moiety, which 
undergoes rapid mono-desethylation. This hypothesis would need to be investigated 
through metabolite identification studies of parent compounds to confirm the presence 










Figure 3.7: Compounds 14 and 19 exhibiting high microsomal metabolic stability and their respective 
parent compounds 16 and 25. 
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CHAPTER 4: Summary, conclusions, and recommendations for future work 
4.1 General summary and conclusions 
Two series of PBI compounds containing various Mannich base side-chains were 
successfully synthesized for antiplasmodium structure-activity relationship studies.  
They were characterized using spectroscopic (1H-NMR, 13C-NMR, and LC-MS), and 
melting point determination. 
SAR-1 specifically investigated the activity of hypothesized N-dealkylated metabolites, 
which were further investigated in SAR-2 alongside their corresponding parent 
compounds, whilst simultaneously investigating the effect of modifications around the 
PBI core. SAR-2 modifications included systematic changes at the R’- and X-positions 
(Figure 4.1) via difluorination (X = F) to improve microsomal metabolic stability and 
antiplasmodium potency, and replacement of the CF3 substituent with a CH3 group, 
along with a combination of both difluorination and replacement of the CF3 substituent 
with a CH3 group. The antiplasmodium activities of all synthesized compounds were 
evaluated against the NF54 strain of P. falciparum, as was their ability to inhibit the 
formation of β-hematin. Solubility was also determined using the turbidimetric kinetic 
solubility assay. Finally, the cytotoxicity of compounds showing high antiplasmodium 
activity (IC50 < 2 µM) was evaluated in HepG2 and CHO cell lines and their microsomal 
















Figure 4.1: Summary of antiplasmodium activity, β-hematin inhibition, and turbidimetric solubility for 
final compounds from SAR-1 and SAR-2 
 
In summary, the following observations were made with regard to SAR-1 compounds: 
• Three compounds showed high antiplasmodium activity (IC50 < 2 µM). 
• The hydroxyl group on the Mannich base side-chain appears to be crucial for 
antiplasmodium activity since its replacement with a halogenation was 
detrimental to activity. 
• Analogues containing 1,4-aminophenol and 1,2-aminophenol moieties both 
showed high antiplasmodium activity, as exemplified by 6, 14, and 16. 
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• Most compounds potently inhibited the formation of synthetic hemozoin (β-
hematin) and are therefore likely inhibitors of the hemoglobin degradation 
pathway. 
• Only two compounds showed high solubility, whereas poor and moderate 
solubility was observed for the remaining 11 analogues. 
• This series of compounds showed no cytotoxicity against HepG2 cells. 
The MBFs of compounds that showed high antiplasmodium activities (4, 6, and 16) 
were investigated further in parent-desethyl metabolite pairs in SAR-2, with 
simultaneous modifications around the PBI core. 
In summary, the following observations were made with regard to SAR-2 compounds: 
• Eight compounds showed high antiplasmodium activity (IC50 < 2 µM). 
• High antiplasmodium activity was observed in both parent and hypothesized 
metabolite regardless of modifications made around the PBI core. 
• A combination of difluorination and substitution of the CF3 with a methyl group 
resulted in the most potent compounds. 
• Most compounds potently inhibited the formation of synthetic hemozoin and are 
likely inhibitors of the hemoglobin degradation pathway. 
• In general, synthesized desethyl metabolites were more soluble than their 
corresponding parent compounds. 
• All compounds showed poor or moderate solubility, with the exception of one 
compound that was highly soluble. 
• Four compounds showed cytotoxicity against HepG2 and CHO cells. 
• Three compounds showed moderate microsomal stability while two compounds 
showed high stability (> 99% remaining after 30 min) when incubated in MLMs  
• In general, synthesized desethyl metabolites showed greater stability in MLMs 
than their corresponding parent analogues, presumably due to rapid N-





4.2 Future outlook and recommendations 
• Metabolite identification should be performed on potent parent analogues to 
confirm the hypothesis that rapid N-dealkylation is responsible for the poor 
microsomal stability observed in parent analogues and also identify other 
metabolic soft spots. 
• Strategies aiming to improve the solubility of compounds should be employed 
to enhance the physicochemical profiles of compounds in this series for 
progression to in vivo animal model studies. The recommended changes to 


















Figure 4.2: Recommended future work to improve aqueous solubility of compounds. 
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CHAPTER 5: Experimental  
5.1 Chapter overview 
This chapter supplements the results from chapters 2 and 3 by describing the detailed 
experimental protocols involved, particularly those that have not been outlined in the 
main text. In addition, this chapter provides characterization data for all compounds 
synthesized. 
5.2. Biology 
5.2.1. In vitro antiplasmodium evaluation protocols 
Lactate dehydrogenase assay for asexual blood-stage parasites  
Samples were tested in triplicate on one occasion against the CQ-sensitive NF54 
strain of P. falciparum. Continuous in vitro cultures of asexual erythrocyte-stage P. 
falciparum were maintained using a modified version of the method described by 
Trager and Jensen.97 In vitro antiplasmodial activity was quantitatively determined via 
a parasite lactate dehydrogenase assay. Test samples were prepared as 20-mg/mL 
stock solution in 100% DMSO or were tested as suspensions if not completely 
dissolved. Stock solutions were stored at low temperatures of -20 °C. Further dilutions 
were prepared on the day of the experiment. CQ and artesunate served as reference 
drugs in all experiments. A full dose-response analysis was performed on all test 
compounds to determine the concentration inhibiting 50% parasite growth (IC50). 
Compounds were initially tested at a concentration of 100 μg/mL, which was then 
serially diluted 2-fold to produce 10 solutions (0.2 μg/mL being the lowest 
concentration). The same dilution technique was used for all samples. Reference 
drugs were tested at a starting concentration of 1000 ng/mL. The highest 
concentration of solvent to which the parasites were exposed had no measurable 
effect on parasite viability. IC50 values were obtained using a non-linear dose-






Luciferase reporter assay for early and late gametocyte parasites  
A luciferase reporter assay95 was established to enable accurate, reliable, and 
quantifiable investigations of the stage-specific action of gametocytocidal compounds 
in the early- and late-stage gametocyte marker cell line NF54-PfS16-GFP-Luc. Drug 
assays were set up on days 5 and 10 (representing >90% of early stage II/III or mature 
stage IV/V gametocytes, respectively). In each instance, assays were set up using 
parasite culture containing 2–3% gametocytemia and 1.5% hematocrit, which were 
incubated for 48 h under drug pressure in a gas chamber (90% N2, 5% O2, and 5% 
CO2) at 37 °C. Luciferase activity was determined in 30 μL parasite lysates by adding 
30 μL luciferin substrate (Promega Luciferase Assay System) at room temperature 
and the resultant bioluminescence was detected at an integration constant of 10 s 
using the GloMax® Explorer Detection System and Instinct® Software. Methylene 
blue (5 μM) and internal project specific controls (MMV390048, 5 μM) are routinely 
included as controls. Dual point screens are routinely performed as technical triplicates 
for a single biological assay.  
 
β-hematin inhibition assay 
This assay quantifies the inhibition of β-hematin formation at a particular drug 
concentration. It involves the addition of pyridine solution, which complexes with free 
heme (absorbance at 405 nm) but not β-hematin, thus allowing for quantification of 
hemozoin formation. The controls used were CQ and AQ, both known β-hematin-
inhibiting antimalarials, and the non-inhibitor pyrimethamine. Stock solutions of 
controls and test compounds (20 mM) were prepared in DMSO. A solution containing 
water/305.5 μM NP40/DMSO at a v/v ratio of 70%/20%/10% respectively, was added 
to every well in columns 1-11 while 140 μL water and 40 μL 305.5 μM NP40 were 
added to column 12 to mediate the formation of β-hematin. Drug (20 µL, 20 mM) was 
added to column 12 and 100 μL of this solution was serially diluted to column 2, with 
column 1 left as the blank (no compound). In case the compound was colored, the 
absorbance was pre-measured at 405 nm on a SpectraMax plate-reader. A 178.8-μL 
aliquot of hematin stock was suspended in 20 mL 1 M acetate buffer (pH 4.9) and 100 
μL of this hematin suspension was added to each well. Plates were then incubated for 
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5 h at 37 °C after which 32 μL pyridine solution (20% water, 20% acetone, 10% 2 M 
HEPES buffer (pH 7.4), 50% pyridine) was added. This was followed by addition of 60 
μL acetone to all wells. Plate absorbance was measured again at 405 nm and IC50 
values were plotted using GraphPad 6 software. 
 
3.6.2 Cytotoxicity evaluation protocols 
Cytotoxicity evaluation in CHO cells 
The in vitro cytotoxicity of the compounds synthesized was evaluated in CHO cancer 
cells using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), a 
colorimetric assay based on assessing cellular metabolic activity.98 The compounds 
synthesized were assayed in triplicate. Stock solutions of test samples (2 mg/mL) were 
prepared in DMSO and poorly soluble samples were tested as suspensions. The 
compounds were stored at -20 °C until use. In all experiments, emetine was used as 
a reference drug. Starting with an initial concentration of 100 μg/mL, 10-fold serial 
dilutions were made in complete medium to obtain six solutions (lowest concentration 
= 0.001 μg/mL). Cell viability was not affected by the highest concentration of solvent 
used. Full dose-response curves were plotted using a non-linear dose-response curve 
fitting analysis in GraphPad Prism v.4 software and the minimum concentration 
required for 50% inhibition (IC50) was determined for each compound. 
 
Cytotoxicity evaluation in HepG2 cells 
The compounds’ cytotoxicity was determined in HepG2 cells using a CytoSelect™ 
LDH Cytotoxicity Assay Kit (Cell Biolabs Inc., CBA-241) at 2 μM for 48 h. Screens 
were performed as technical duplicates for three biological assays. HepG2 cells were 
maintained as previously described99 in Dulbecco’s modified Eagle’s medium (DMEM, 
HyClone) supplemented with 5% heat-inactivated fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Sigma-Aldrich) at 37 °C in 5% CO2. Cell viability was 
monitored microscopically using 0.2% Trypan blue. Cells were treated with trypsin (1× 
Trypsin-EDTA, Sigma) and approximately 1×105 cells were plated in 96-well plates 
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and incubated for 24 h. The cells were treated with 2 μM compound and incubated for 
a further 48 h at 37 °C in 5% CO2. Cytotoxicity was determined using a CytoSelect™ 
LDH Cytotoxicity Assay Kit and the reagent was added to the supernatant before 
measuring absorbance at 450 nm. Data obtained were analyzed in Excel and 
experiments were performed in technical duplicates for one biological repeats (n = 1). 
 
3.7 Metabolic stability  
This assay was conducted by Dr Mathew Njoroge at the Division of Clinical 
Pharmacology, UCT. In this study, MLMs were selected as it was anticipated that in 
vivo PK and efficacy studies would be conducted in mouse models, if compounds were 
to be progressed to in vivo studies. Briefly, a single time-point (30-min) assay protocol 
was used. Test compounds were appropriately diluted to 0.1 μM using phosphate 
buffer at pH 7.4 in a 96-well microtiter plate. MLMs (0.4 mg/mL) were then added into 
the wells along with NADPH, which served as an enzyme cofactor for initiation of the 
enzymatic reactions involved. This mixture was then incubated at 37 ºC for 30 min, 
with shaking, and the reaction was stopped by the addition of ice-cold acetonitrile. The 
mixture was then centrifuged to remove proteins as sediments, while the supernatant 
was analyzed via LC-MS/MS. This readout was used to determine the percentage 
intact compound remaining after 30 min of incubation with MLMs. 
 
5.3 Chemistry 
5.3.1 Reagents and solvents 
All commercially available chemicals and reagents were purchased from either Sigma-
Aldrich or Combi-Blocks Limited (USA), and were used without prior purification. 
Anhydrous solvents such as 1,4-dioxane, acetonitrile, and DMF were purchased as such 
from Sigma-Aldrich. In addition, column chromatography solvents such as ethyl acetate, 
DCM, hexane (Hex), and methanol were purchased as analytical reagent (AR)-grade 
solvents from Kimix Chemicals, South Africa, and used directly. HPLC-grade acetonitrile 




5.3.2 Physical and spectroscopic characterization 
Reported compounds were characterized via 1H-NMR, 13C-NMR, HPLC-MS (ESI+), 
and melting point determination. Melting points were determined using a Lasec Stuart 
SMP40 hot-stage microscope and are reported as uncorrected values.  
NMR spectra were recorded on a Varian Mercury spectrometer (1H, 300 MHz; 13C, 75 
MHz), Bruker Ultrashield-Plus Spectrometer (1H, 400 MHz;  13C, 101 MHz), or Bruker 
Ascend™-600 spectrometer (1H, 600 MHz; 13C, 150 MHz). Samples for NMR 
spectroscopy were prepared by dissolving in deuterated DMSO (DMSO-d6), or 
methanol (methanol-d4). Chemical shifts (δ) are reported in parts per million (ppm) and 
are rounded to two decimal places, while coupling constants (J) are reported in Hz 
and are rounded to one decimal place. Abbreviations used to describe 1H-NMR signal 
multiplicities include: d (doublet), dd (doublet of doublets), ddd (doublet of doublet of 
doublets), dt (doublet of triplets), dtd (doublet of triplet of doublets), hept (heptet), m 
(multiplet), q (quartet), s (singlet), t (triplet), td (triplet of doublets), tdd (triplet of doublet 
of doublets), and tt (triplet of triplets). 13C-NMR spectra were recorded in complete 
proton-decoupled mode and chemical shifts are listed without assigning to the 
corresponding carbon atoms, a format accepted by most international journals. The 
splitting patterns observed in the 13C-NMR spectra as a result of fluorine splitting were 
reported as either a doublet (d) or quartet (q) and J values were not recorded but were 
reported in the form d or q, CJF. 
 
5.3.3 Chromatography 
Target compound peak purity, retention time, and molecular ions were determined 
using an Agilent HPLC system equipped with Agilent 1260® Infinity Binary Pump, 
Agilent 1260® Infinity Diode Array Detector (DAD), Agilent 1290® Infinity Column 
Compartment, Agilent 1260® Infinity Autosampler, Agilent 6120® Quadrupole LC/MS, 
and Peak Scientific® Genius 1050 Nitrogen Generator. The column used was an X-
bridge® C18, 2.5 µm, 3.0 mm (ID) × 50 mm (length) maintained at 35 °C. The 
composition and gradient conditions of the mobile phase used at a flow rate of 0.9 
mL/min are listed in Table 5.1. The injection volume was 2 µL and mass spectra were 
obtained both via ESI+ and atmospheric pressure chemical ionization (APCI). All 
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reported LC-MS (ESI+) purity values were based on maximum chromatograms 
resulting from DAD (210–640 nm) scans. 
Table 5.1: HPLC gradient conditions 
Time (min) %A %B 
0.00-1.00 90 10 
1.00-3.00 5 95 
3.00-5.00 5 95 
5.00-6.50 90 10 
6.50-7.00 90 10 
A, 10 mM NH4OAc in buffer (0.4% acetic acid); B, 10 mM NH4OAc (0.4% acetic acid) in 90% HPLC 
grade CH3OH in H2O 
Reactions were monitored via analytical TLC using Fluka or Merck F254 aluminium-
backed pre-coated silica gel plates, which were visualized under UV light at a 
wavelength of 254 or 366 nm. Staining was performed in some instances to facilitate 
direct visualization. Gravity column chromatography was performed using Merck 
Kieselgel® 60 (70–230 mesh) silica gel, while Biotage SNAP® cartridges were packed 
with 40–65 μm diameter KP-Sil silica gel for flash column chromatography on a 










5.4 Synthesis and characterization 
5.4.1 Synthesis and characterization of PBI intermediates  
2-(5,6-difluoro-1H-benzo[d]imidazol-2-yl)acetonitrile (1.1a) 
A mixture of commercially available 4,5-difluorobenzene-1,2-
diamine (0.500 g, 1.0 eq) and ethyl carbonocyanidate (1.11 
mL, 3.0 eq) was dissolved in anhydrous DMF (5 mL). The 
mixture was irradiated in a microwave reactor at 100 °C for 7 
h. The reaction mixture was left to cool to 23 °C. Cold ethyl 
acetate (20 mL) was added to the reaction mixture and transferred to a separating 
funnel. The organic layer was washed with water (4 × 30 mL) to remove residual DMF. 
The organic layer was dried using magnesium sulphate, filtered and reduced in vacuo 
to isolate 1.1a as a brown solid (0.605 g, 90%), Rf = 0.61 (5% MeOH/DCM);  1H-NMR 
(400 MHz, DMSO-d6) δ 7.59 (m, 2H, H7/ H4), 4.38 (s, 2H, H8); 13C-NMR (101 MHz, 
DMSO-d6) δ 157.88, 149.58, 139.15, 123.69, 121.19, 114.58, 105.57 (d, CJF), 102.47, 
101.56 (d, CJF); LC-MS (ESI+): Purity 82% (tR 1.18 min), m/z 194.1 [M + H]+. 
 
General procedure for cyclocondensation to afford intermediate compounds 1.2a-1.2d 
The appropriately substituted or unsubstituted 2-benzimidazole acetonitrile (1.0 eq),  
appropriate diketo-ester (1.2 eq), and NH4OAc (2.0 eq) were stirred at 150 °C under 
pressure for 12 h. The reaction mixture was left to cool to 23 °C. Cold MeCN (20 mL) 
was added to the mixture and left to cool to 0 °C on ice. The cold mixture was then 
filtered, the residue washed with cold acetonitrile (4 × 10 mL), and dried in vacuo to 









Obtained from commercially available 2-benzimidazole 
acetonitrile (0.800 g, 1.0 eq), ethyl 4,4,4-trifluoro-3-
oxobutanoate (0.89 mL, 1.2 eq), and NH4OAc (0.785 g, 2.0 
eq) to isolate intermediate 1.2a as a brown powder (1.20 g, 
86%), Rf = 0.70 (50% EtOAC/Hex); 1H-NMR (400 MHz, 
DMSO-d6) δ 8.61 (dd, J = 8.2, 1.9 Hz, 1H, H10), 7.65 (dd, J 
= 8.1, 1.8 Hz, 1H, H7), 7.45 (td, J = 8.3, 1.2 Hz, 1H, H9), 7.25 (td, J = 8.3, 1.1 Hz, 1H, 
H8), 6.03 (s, 1H, H2); 13C-NMR (101 MHz, DMSO-d6) δ 158.35, 148.52, 138.70, 
133.89, 128.18, 127.43, 124.07, 123.01, 121.34, 116.64, 115.02, 112.83, 102.10; LC-
MS (ESI+): Purity 95%, (tR 2.97 min), m/z 278.2 [M + H]+. 
3-methyl-1-oxo-1,5-dihydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (1.2b) 
Obtained from commercially available 2-benzimidazole 
acetonitrile (500 mg, 1.0 eq), ethyl 3-oxobutanoate (0.48 mL, 
1.2 eq) and NH4OAc (491 mg, 2.0 eq) to isolate intermediate 
1.2a as a brown powder (0.650 g, 92%), Rf = 0.39 (50% 
EtOAC/Hex); 1H-NMR (400 MHz, DMSO-d6) δ 8.49 (d, J = 
8.0 Hz, 1H, H10), 7.48 (d, J = 8.0 Hz, 1H, H7), 7.33 (t, J = 7.6 
Hz, 1H, H9), 7.12 (t, J = 7.6 Hz, 1H, H8), 5.55 (s, 1H, H2), 2.31 (s, 3H, H13); 13C-NMR 
(101 MHz, DMSO-d6) δ 172.41, 160.28, 151.37, 150.48, 141.10, 130.05, 124.81, 
119.54, 115.82, 114.76, 100.03, 71.52, 20.90; LC-MS (ESI+): Purity 90%, (tR 2.36 










Obtained from 1.1a (1.2 g, 1.0 eq), ethyl 4,4,4-trifluoro-3-
oxobutanoate (1.82 mL, 2.0 eq), and NH4OAc (0.959 g, 2.0 
eq) to isolate intermediate 1.2c as a brown powder (0.831 g, 
43%), Rf = 0.86 (10% MeOH/DCM);  1H-NMR (400 MHz, 
DMSO-d6) δ 8.48 (dd, J = 10.3, 7.4 Hz, 1H, H10), 7.66 (dd, 
J = 10.1, 7.0 Hz, 1H, H7), 6.37 (s, 1H, H2);  13C-NMR (101 
MHz, DMSO-d6) δ 157.88, 149.58, 147.28, 139.15, 138.84, 129.92, 123.69, 121.19, 
114.58, 105.57 (d, CJF), 102.47, 101.56 (d, CJF), 65.45; 19F NMR (377 MHz, DMSO-
d6) δ -62.98, -136.59 (d, J = 21.8 Hz), -142.25 (d, J = 21.5 Hz). LC-MS (ESI+): Purity 
94%, (tR 2.47 min),  m/z 314.1 [M + H]+. 
7,8-difluoro-3-methyl-1-oxo-1,5-dihydrobenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (1.2d) 
Obtained from 1.1a (0.600 g, 1.0 eq), ethyl 3-oxobutanoate 
(0.79 mL, 2.0 eq) and NH4OAc (0.479 g, 2.0 eq) to isolate 
intermediate 1.2d as a brown powder (0.742 g, 86%), Rf = 
0.63 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 
8.35 (dd, J = 11.1, 8.1 Hz, 1H, H10), 7.95 (s, 1H, H2), 7.43 
(dd, J = 11.8, 7.5 Hz, 1H, H7), 2.29 (s, 3H, H13); 13C-NMR 
(101 MHz, DMSO-d6) δ 157.04, 142.27, 135.84, 128.16, 125.61, 118.91, 115.54, 
112.16, 109.54, 105.97, 102.47, 101.56, 20.68; LC-MS (ESI+): Purity 85% (tR 2.82 
min), m/z 260.1 [M + H]+. 
 
General procedure for chlorination to afford intermediate compounds 1.3a–1.3d 
The appropriate intermediates 1.2a-1.2d (1.0 eq) were mixed with excess 
phosphorous oxychloride (POCl3, 20 eq) and heated to 130 °C under reflux for 12 h. 
Excess POCl3 was removed under reduced pressure and the solution was neutralized 
with NaHCO3 in cold water (50 mL) to a pH of 7-8. The cold mixture was then filtered, 
and the residue washed with cold water (4 × 10mL). The residue was dried of residual 
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water by using anhydrous magnesium sulphate in 10% methanol/DCM, then filtered 
and reduced in vacuo to isolate intermediates 1.3a–1.3d. 
1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (1.3a)  
Obtained from 1.2a  (1.0 g, 1 eq) and POCl3 (6.75 mL, 20 eq) 
to isolate 1.3a as a yellow powder (956 mg, 90%), Rf = 0.65 
(50% EtOAC/Hex); 1H-NMR (400 MHz, DMSO-d6) δ 8.76 (dd, 
J = 8.7, 0.9 Hz, 1H, H10), 8.10 (dd, J = 8.3, 1.3 Hz, 1H, H7), 
7.81 – 7.74 (m, 2H, H2 & H9), 7.62 (td, J = 8.4, 1.2 Hz, 1H, 
H8); 13C-NMR (101 MHz, DMSO-d6) δ 158.37, 146.65, 
145.30, 137.25, 129.79, 128.31, 127.42, 123.99, 122.99, 120.66, 116.68, 112.90, 
107.76; LC-MS (ESI+): Purity 94%, (tR 2.42 min), m/z 296.0 [M + H]+. 
1-chloro-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (1.3b) 
Obtained from 1.2b  (0.650 g, 1.0 eq) and POCl3 (5.45 mL, 
20 eq) to isolate 1.3b as a brown powder (652 mg, 93%), Rf 
= 0.74 (5% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 
8.58 (d, J = 8.6 Hz, 1H, H10), 7.93 (d, J = 8.3 Hz, 1H, H7), 
7.63 (t, J = 8.2 Hz, 1H, H9), 7.45 (t, J = 8.7, Hz, 1H, H8), 7.31 
(s, 1H, H2), 2.62 (s, 3H, H13); 13C-NMR (101 MHz, DMSO-
d6) δ 150.29, 147.62, 144.65, 134.22, 129.89, 127.08, 122.47, 120.01, 116.03, 115.03, 
114.10, 98.35, 20.68; LC-MS (ESI+): Purity 95%, (tR 2.45min), m/z 242.5 [M + H]+. 
1-chloro-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (1.3c) 
Obtained from 1.2c  (0.890 g, 1.0 eq) and POCl3 (5.16 mL, 
20 eq) to isolate 1.3c as a brown powder (0.784 g, 83%), Rf 
=  0.81 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 
8.79 (dd, J = 11.1, 7.4 Hz, 1H, H10), 8.19 (dd, J = 10.8, 7.6 
Hz, 1H, H7), 7.82 (s, 1H, H2); 13C-NMR (101 MHz, DMSO-
d6) δ 157.67, 149.10, 147.97, 136.83, 114.23, 112.38, 
108.29 (d, CJF), 107.71 (d, CJF), 105.69 (d, CJF), 105.22 (d, CJF), 103.26 (d, CJF), 




Obtained from 1.2d  (0.600 g, 1.0 eq) and POCl3 (4.23 mL, 
20 eq) to isolate 1.3d as a brown powder (0.544 g, 85%), Rf 
= 0.72 (5% MeOH/DCM). 1H-NMR (400 MHz, DMSO-d6) δ 
8.59 (dd, J = 11.2, 7.5 Hz, 1H, H10), 7.98 (dd, J = 11.0, 7.7 
Hz, 1H, H7), 7.35 (s, 1H, H2), 2.62 (s, 3H, H13); 13C-NMR 
(101 MHz, DMSO-d6) δ 150.64, 140.77, 133.73, 125.03, 
124.91, 114.68, 114.55, 107.10, 106.90, 104.69, 104.44, 98.41, 20.69; LC-MS (ESI+): 
Purity 98%, (tR 2.45 min), m/z 278.1 [M + H]+. 
 
5.4.2 Synthesis and characterization of Mannich base intermediates 
Reductive amination reaction to form intermediates 2.1a and 2.1b 
N-(2-fluoro-5-nitrobenzyl)ethanamine (2.1a)  
2-Fluoro-5-nitrobenzaldehyde (500 mg, 1.0 eq) and 
ethylamine (0.25 mL, 1.5 eq) in methanol (10 mL) were stirred 
at 23 °C for 3 h (monitored via TLC). The reaction mixture was 
cooled to 0 °C and NaBH4 (559 mg, 5 eq) was added. The 
reaction mixture was stirred at 23 °C for 3 h. The reaction 
mixture was neutralized using 1 M hydrogen chloride solution 
to pH 7 and reduced in vacuo. The residue was recrystallized using DCM to isolate 
compound 2.1a (545 mg, 95%) as a black oil, Rf = 0.16 (1% Hex/ EtOAc); 1H-NMR 
(400 MHz, DMSO-d6) δ 8.41 (dd, J = 6.3, 2.9 Hz, 1H, H2), 8.23 (ddd, J = 9.1, 4.4, 2.9 
Hz, 1H, H6), 7.35 (dd, J = 10, 8.6 Hz, 1H, H5), 4.82 (s, 2H, H7), 2.72 (q, J = 7.2 Hz, 
2H, H8), 1.19 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 204.96, 144.51, 
126.37 (d, CJF), 125.24 (d, CJF), 117.03 (d, CJF), 94.68, 45.11, 43.29, 14.87; 19F-
NMR (377 MHz, DMSO-d6) δ -107.97; LC-MS (ESI+): Purity 84%, (tR 0.137 min), m/z 





N-(2-chloro-5-nitrobenzyl)ethanamine (2.1b)  
2-Chloro-5-nitrobenzaldehyde (500 mg, 1.0 eq) and 
ethylamine (0.183 mL, 1.2 eq) in methanol (10 mL) were 
stirred at 23 °C for 3 h (monitored using TLC). The reaction 
mixture was cooled to 0 °C and NaBH4 (559 mg, 5 eq) was 
added. The reaction mixture was stirred at 23 °C for 1 h. The 
reaction mixture was neutralized using 1 M hydrogen chloride 
solution to pH 7-8 and reduced in vacuo. The residue was recrystallized using DCM 
to isolate compound 2.1b (547 mg, 95%) as a yellow oil, Rf = 0.73 (1%  MeOH/ DCM); 
1H-NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 2.8 Hz, 1H, H2), 8.10 (dd, J = 8.7, 2.8 
Hz, 1H, H6), 7.71 (d, J = 8.8 Hz, 1H, H5), 3.84 (s, 2H, H7), 2.72 (q, J = 7.2 Hz, 2H, 
H8), 1.19 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 146.96, 141.31, 
139.68, 130.76, 124.27, 123.29, 49.88, 43.58, 15.58; LC-MS (ESI+): Purity 81%, (tR 
0.167 min), m/z 215.1 [M + H]+. 
 
Reduction of nitro group using stannous chloride to form intermediates 2.2a and 2.2b 
3-((ethylamino)methyl)-4-fluoroaniline (2.2a)  
SnCl2 (1.91 g, 4 eq) in THF (5 mL) was added to compound 
2.1a (500 mg, 1.0 eq) and stirred at room temperature while 
adding 1 M aqueous hydrogen chloride solution (7.8 mL, 3.1 
eq). The solution was refluxed at 70 °C for 12 h. The reaction 
mixture was allowed to cool and reduced in vacuo. The 
reaction mixture was neutralized using saturated sodium 
bicarbonate to pH 9. The compound was extracted using 10% MeOH:EtOAc and the 
organic layer dried using MgSO4, filtered, and concentrated to isolate compound 2.2a 
(547 mg, 95%) as a black oil, Rf = 0.15 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-
d6) δ 6.77 (dd, J = 10, 8.6 Hz, 1H, H5), 6.62 (dd, J = 6.5, 2.9 Hz, 1H, H2), 6.41 (ddd, 
J = 8.6, 4.3, 2.9 Hz, 1H, H6), 3.59 (s, 2H, H7), 2.65 (q, J = 7.2 Hz, 2H, H8), 1.03 (t, J 
= 7.1 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 153.05 (d, CJF), 145.25, 127.87 
(d, CJF), 115.34 (d, CJF), 115.08, 113.31 (d, CJF), 46.57, 43.38, 15.48; 19F-NMR (377 
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MHz, DMSO-d6) δ -136.16; LC-MS (ESI+): Purity 70%, (tR 0.137min), m/z 169.1 [M + 
H]+. 
4-chloro-3-((ethylamino)methyl)aniline (2.2b)  
SnCl2 (1.77 g, 4 eq) in THF (5 mL) was added to compound 
2.1b (500 mg, 1.0 eq) and stirred at room temperature while 
adding 1 M hydrogen chloride solution (7.2 mL, 3.1 eq). The 
solution was stirred at 70 °C for 12 h. The reaction mixture 
was allowed to cool and reduced in vacuo. The reaction 
mixture was neutralized using saturated sodium bicarbonate 
to pH 9. The compound was extracted using 10% EtOAc:MeOH and the organic layer 
dried using MgSO4, filtered, and concentrated to isolate compound 2.2b (390.8 mg, 
91%) as a yellow oil, Rf = 0.16 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 
6.98 (d, J = 8.4 Hz, 1H, H5), 6.72 (d, J = 2.8 Hz, 1H, H2), 6.43 (dd, J = 8.5, 2.8 Hz, 
1H, H6), 3.61 (s, 2H, H7), 2.55 (q, J = 7.0 Hz, 2H, H8), 1.04 (t, J = 7.1 Hz, 3H, H9); 
13C-NMR (101 MHz, DMSO-d6) δ 148.13, 138.55, 129.45, 118.87, 115.45, 113.89, 
50.76, 43.50, 15.60; LC-MS (ESI+): Purity 75%, (tR 0.157 min), m/z 185.1 [M + H]+. 
 
General procedure for the acetylation reaction to form intermediate compounds 3.1c–
3.1g 
The appropriate aminophenol (1.0 eq) was dissolved in THF and acetic anhydride (1.2 
eq) added. The reaction mixture was stirred at 60 °C under pressure for 1 h, using 
TLC to monitor the progress of the reaction. The reaction mixture was allowed to cool 









Obtained from commercially available 2-aminophenol (1.00 
g, 1.0 eq) and acetic anhydride (1.04 mL, 1.2 eq) in THF (5 
mL) to isolate 3.1 as a white powder (1.325 g, 96%), Rf = 
0.41 (20% MeOH/DCM); 1H-NMR (400 MHz, MeOH-d4) δ 
7.56 (dd, J = 7.9, 1.6 Hz, 1H, H6), 6.98 (td, J = 7.5, 1.6 Hz, 
1H, H4), 6.85 (dd, J = 8.0 Hz, 1.4, 1H, H3), 6.79 (td, J = 7.6, 
1.4 Hz, 1H, H5), 2.16 (s, 3H, H8); 13C-NMR (101 MHz, 
MeOH-d4) δ 172.2, 149.7, 127.1, 126.8, 124.0, 120.6, 117.3, 23.4; LC-MS (ESI+): 
Purity 95%, (tR 0.23 min), m/z 152.2 [M + H]+. 
N-(5-fluoro-2-hydroxyphenyl)acetamide (3.1d)  
Obtained from commercially available 2-amino-4-
fluorophenol (320 mg, 1.0 eq) and acetic anhydride (0.30 mL, 
1.2 eq) in THF (2 mL) to isolate 3.1d as an off-white powder 
(374 mg, 88%), Rf = 0.4 (8% MeOH/DCM); 1H-NMR (400 
MHz, DMSO-d6) δ 7.75 (dd, J = 11.0, 3.1 Hz, 1H, H6), 6.83 
(dd, J = 8.9, 5.5 Hz, 1H, H3), 6.73 (td, J = 8.5, 3.2 Hz, 1H, 
H4), 2.12 (s, 3H, H8); 13C-NMR (101 MHz, DMSO-d6) δ 
169.52, 155.35 (d, CJF), 143.84, 127.85 (d, CJF), 115.93 (d, CJF), 110.04 (d, CJF), 
108.55 (d, CJF), 24.27; LC-MS (ESI+): Purity 77%, (tR 0.335 min), m/z 170.1 [M + H]+. 
N-(4-chloro-2-hydroxyphenyl)acetamide (3.1e)  
Obtained from commercially available 2-amino-5-
chlorophenol (1.0 g, 1.0 eq) and acetic anhydride (0.84 mL, 
1.2 eq) in THF (2 mL) to isolate 3.1e as a brown powder 
(1.254 g, 97%), Rf = 0.85 (5% MeOH/DCM); 1H-NMR (400 
MHz, DMSO-d6) δ 7.78 (d, J = 8.6 Hz, 1H, H6), 6.90 (d, J = 
2.4 Hz, 1H, H3), 6.80 (dd, J = 8.6, 2.4 Hz, 1H, H5), 2.10 (s, 
3H, H8); 13C-NMR (101 MHz, DMSO-d6) δ 169.41, 149.30, 
128.11, 126.15, 123.69, 119.07, 115.83, 24.09; LC-MS (ESI+): Purity 87%, (tR 0.873 
min), m/z 186.5 [M + H]+. 
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N-(5-chloro-2-hydroxyphenyl)acetamide (3.1f)  
Obtained from commercially available 2-amino-4-
chlorophenol (500 mg, 1.0 eq) and acetic anhydride (0.42 mL, 
1.2 eq) in THF (3 mL) to isolate 3.1f as a light brown powder 
(639 mg, 99%), Rf = 0.23 (5% MeOH/DCM);  1H-NMR (400 
MHz, DMSO-d6) δ 7.94 (d, J = 2.6 Hz, 1H, H6), 6.95 (dd, J = 
8.6, 2.6 Hz, 1H, H4), 6.86 (d, J = 8.6 Hz, 1H, H3), 2.11 (s, 3H, 
H8); 13C-NMR (101 MHz, DMSO-d6) δ 169.51, 146.72, 
128.28, 123.92, 122.61, 121.49, 116.89, 24.24; LC-MS (ESI+): Purity 90%, (tR 0.841 
min), m/z 186.1 [M + H]+.  
N-(2-hydroxy-5-methylphenyl)acetamide (3.1g) 
Obtained from commercially available 2-amino-4-
methylphenol (1.0 g, 1.0 eq) and acetic anhydride (0.92 mL, 
1.2 eq) in THF (3 mL) to isolate 3.1g as a light brown powder 
(1.29 mg, 96%), Rf = 0.87 (8% MeOH/DCM); 1H-NMR (600 
MHz, MeOH-d4) δ 7.35 (d, J = 2.0 Hz, 1H, H6), 6.80 (dd, J = 
2.2, 8.1 Hz, 1H, H4), 6.73 (d, J = 8.1 Hz, 1H, H3), 2.22 (s, 3H, 
H7), 2.15 (s, 3H, H9); 13C-NMR (151 MHz, MeOH-d4) δ 172.2, 
147.4, 130.1, 127.3, 126.8, 124.3, 117.3, 23.4, 20.7; LC-MS (ESI+): Purity 90%, (tR 
0.64 min), m/z 166.0 [M + H]+. 
N-(2-hydroxy-6-methylphenyl)acetamide (3.1h)  
Obtained from commercially available 2-amino-3-
methylphenol (1 g, 1.0 eq) and acetic anhydride (0.92 mL, 1.2 
eq) in THF (4 mL) to isolate 3.1h as orange needle-like 
crystals (1.29 g, 96%), Rf = 0.20 (5% MeOH/DCM); 1H-NMR 
(400 MHz, DMSO-d6) δ 6.96 (t, J = 7.8 Hz, 1H, H4), 6.69 (dd, 
1H, J = 8.2, 1.4 Hz H3), 6.66 (dd, J = 8.2, 1.4 Hz, 1H, H5),  
2.10 (s, 3H, H9), 2.04 (s, 3H, H8); 13C-NMR (101 MHz, 
DMSO-d6) δ 169.10, 153.10, 136.54, 127.14, 124.60, 120.97, 114.20, 23.25, 18.51; 
LC-MS (ESI+): Purity 90%, (tR 0.26 min) m/z 166.2 [M + H]+. 
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General procedure for the Mannich reaction used to afford compounds 3.2a–3.2j 
The appropriate acetanilide (1.0 eq) was dissolved in ethanol and a mixture of 
formaldehyde (1.5 eq) and ethylamine (1.5 eq) were added. The reaction mixture was 
stirred at 85 °C while monitoring with TLC for formation of product for approximately 3 
h. The reaction mixture was cooled to 23 °C and reduced in vacuo. The compound 
was dissolved in DCM (15 mL) and acidified using 1 M aqueous hydrogen chloride 
solution (15 mL), causing the compound to be extracted from DCM into the aqueous 
layer as a salt. The solution was then neutralized using 1 M aqueous NaOH solution 
to pH 8-10 and partitioned using DCM (3 × 15 mL). The organic layer was dried using 
MgSO4 and reduced in vacuo to isolate intermediates 3.2a–3.2j.  
N-(3-((ethylamino)methyl)-4-hydroxyphenyl)acetamide (3.2a) 
Obtained from commercially available (4-
hydroxyphenyl)acetamide  (300 mg, 1.0 eq), formaldehyde 
(0.09 mL, 1.5 eq), and ethylamine (0.17 mL, 1.5 eq) as a 
brown oil (0.242 g, 59%), Rf = 0.17 (EtOAc); 1H-NMR (400 
MHz, DMSO-d6) δ 7.28 (d, J = 2.6 Hz, 1H, H2), 7.23 (dd, J = 
8.6, 2.6 Hz, 1H, H6), 6.61 (d, J = 8.5 Hz, 1H, H5), 3.78 (s, 2H, 
H7), 2.56 (q, J = 7.3 Hz, 2H, H8), 1.98 (s, 3H, H11), 1.05 (t, J 
= 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 169.34, 158.54, 130.23, 126.42, 
122.51, 119.56, 117.04, 106.41, 51.85, 45.67, 13.99; LC-MS (ESI+): Purity 81%, (tR 
0.217 min),  m/z 209.0 [M + H]+. 
N-(4-((ethylamino)methyl)-3-hydroxyphenyl)acetamide (3.2b)  
Obtained from commercially available (3-hydroxyphenyl) 
acetamide  (1.4 g, 1.0 eq), formaldehyde (0.39 mL, 1.5 eq), 
and ethylamine (0.787 mL, 1.5 eq) to isolate 3.2b as a brown 
oil (911 mg, 47%), Rf = 0.17 (20% MeOH/DCM); 1H-NMR 
(400 MHz, DMSO-d6) δ 7.56 (d, J = 8.1 Hz, 1H, H5), 7.07 (d, 
J = 2.2 Hz, 1H, H2), 6.98 (dd, J = 8.1, 2.2 Hz, 1H, H6), 4.24 
(s, 2H, H7), 3.14 (q, J = 7.4 Hz, 2H, H8), 2.00 (s, 3H, H11), 
1.37 (t, J = 7.3 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) 
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δ 168.46, 158.09, 139.54, 128.82, 119.16, 109.74, 106.91, 49.06, 42.75, 24.44, 14.91; 
LC-MS (ESI+): Purity 80%, (tR 0.237 min), m/z  209.1 [M + H]+. 
N-(3-((ethylamino)methyl)-2-hydroxyphenyl)acetamide (3.2c)  
Obtained from 3.1c (1.0 g, 1.0 eq), formaldehyde (0.27 mL, 
1.5 eq), and ethylamine (0.560 mL, 1.5 eq) to isolate 3.2c as 
a purple solid  (106 mg, 8%), Rf = 0.14 (20% MeOH/DCM); 
1H-NMR (400 MHz, DMSO-d6) δ 7.61 (dd, J = 8.0, 1.6 Hz, 1H, 
H6), 6.94 (dd, J = 7.6, 1.6 Hz, 1H, H4), 6.61 (t, J = 7.8 Hz, 1H, 
H5), 3.89 (s, 2H, H7), 2.59 (q, J = 7.3 Hz, 2H, H8), 2.08 (s, 
3H, H11), 1.06 (t, J = 7.2 Hz, 3H, H9);  13C-NMR (101 MHz, 
DMSO-d6) δ 196.40, 177.67, 156.46, 148.41, 126.39, 125.35, 119.51, 52.28, 42.40, 
24.18, 14.36; LC-MS (ESI+): Purity 65%, (tR 0.179 min), m/z 209.1 [M + H]+. 
N-(3-((ethylamino)methyl)-5-fluoro-2-hydroxyphenyl)acetamide (3.2d)  
Obtained from 3.1d (350 mg, 1.0 eq), formaldehyde (0.09 mL, 
1.5 eq), and ethylamine (0.176 mL, 1.5 eq) to isolate 3.2d as 
a white powder (381 mg, 81%), Rf = 0.14 (5% MeOH/DCM); 
1H-NMR (400 MHz, DMSO-d6) δ 7.76 (dd, J = 11.1, 3.2 Hz, 
1H, H6), 6.63 (dd, J = 8.8, 3.1 Hz, 1H, H4), 3.89 (s, 2H, H7), 
2.58 (q, J = 7.2 Hz, 2H, H8), 2.12 (s, 3H, H11) 1.08 (t, J = 7.0 
Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 169.27, 154.44 
(d, CJF), 145.01, 127.59 (d, CJF), 123.49 (d, CJF), 109.06 (d, CJF), 106.43 (d, CJF), 









N-(4-chloro-3-((ethylamino)methyl)-2-hydroxyphenyl)acetamide (3.2e)  
Obtained from 3.1e (1 g, 1.0 eq), formaldehyde (0.23 mL, 1.5 
eq) and ethylamine (0.459 mL, 1.5 eq)  to isolate 3.2e as a 
brown oil (541.3 mg, 41%), Rf = 0.13 (20% MeOH/DCM); 1H-
NMR (400 MHz, MeOH-d4) δ 7.83 (d, J = 8.7 Hz, 1H, H5), 
6.57 (d, J = 8.6 Hz, 1H, H6), 4.28 (s, 2H, H7), 2.93 (q, J = 7.3 
Hz, 2H, H8), 2.18 (s, 3H, H11), 1.27 (t, J = 7.2 Hz, 3H, H9); 
13C-NMR (101 MHz, MeOH-d4) δ 169.91, 156.05, 128.35, 
126.92, 120.58, 116.86, 114.45, 46.60, 41.65, 22.51, 11.27; LC-MS (ESI+): Purity 
98%, (tR 1.765 min), m/z 243.1 [M + H]+. 
N-(5-chloro-3-((ethylamino)methyl)-2-hydroxyphenyl)acetamide (3.2f)  
Obtained from 3.1f (500 mg, 1.0 eq), formaldehyde (0.11 mL, 
1.5 eq) and ethylamine (0.22 mL, 1.5 eq) to isolate 3.2f as a 
yellow solid (343 mg, 52%), Rf = 0.11 (20% MeOH/DCM); 1H-
NMR (400 MHz, DMSO-d6) δ 7.94 (d, J = 2.7 Hz, 1H, H6), 
6.81 (d, J = 2.7 Hz, 1H, H4), 3.91 (s, 2H, H7), 2.60 (q, J = 7.2 
Hz, 2H, H8), 2.10 (s, 3H, H11), 1.08 (t, J = 7.2 Hz, 3H, H9); 
13C-NMR (101 MHz, DMSO-d6) δ 169.13, 149.03, 128.31, 
123.60, 122.57, 120.29, 119.05, 50.88, 42.32, 24.37, 14.35; LC-MS (ESI+): Purity 
79%, (tR 0.195 min), m/z 243.1 [M + H]+. 
N-(3-((ethylamino)methyl)-2-hydroxy-5-methylphenyl)acetamide (3.2g) 
Obtained from previously synthesised N-(2-hydroxy-5-
methylphenyl)acetamide (500 mg, 1.0 eq), formaldehyde 
(0.13 mL, 1.5 eq) and ethylamine (0.26 mL, 1.5 eq) to isolate 
3.2g as an orange oil (560.7 mg, 83%), Rf = 0.1 (5% 
MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 7.59 (d, J = 
2.2 Hz, 1H, H6), 6.61 (d, J = 2.2 Hz, 1H, H4), 3.84 (s, 2H, 
H7), 2.56 (q, J = 7.2 Hz, 2H, H8), 2.19 (s, 3H, H10), 2.08 (s, 
3H, H12), 1.07 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 168.84, 
146.59, 126.56, 126.44, 124.17, 123.10, 121.03, 51.36, 42.62, 24.27, 20.97, 14.77; 




N-(3-((ethylamino)methyl)-2-hydroxy-6-methylphenyl)acetamide (3.2h)  
Obtained from 3.1h (1.20 g, 1.0 eq), formaldehyde (0.27 mL, 
1.5 eq) and ethylamine (0.55 mL, 1.5 eq) to isolate 3.2h as 
an off-white solid (788 mg, 49%), Rf = 0.17 (20% 
MeOH/DCM); 1H-NMR (400 MHz, MeOH-d4) δ 7.11 (d, J = 
7.7 Hz, 1H, H4), 6.78 (d, J = 7.7 Hz, 1H, H5), 4.11 (s, 2H, 
H7), 2.99 (q, J = 7.3 Hz, 2H, H8), 2.23 (s, 3H, H10), 1.91 (s, 
3H, H12), 1.29 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, 
MeOH-d4) δ 172.10, 152.39, 137.01, 128.68, 123.76, 120.64, 118.44, 42.05, 22.71, 
21.35, 16.88, 10.79; LC-MS (ESI+): Purity 65%, (tR 0.140 min), m/z 223.1 [M + H]+. 
N-(3-((diethylamino)methyl)-4-hydroxyphenyl)acetamide (3.2i) 
Obtained from 3.1i (1.00 g, 1.0 eq), formaldehyde (0.27 mL, 
1.5 eq) and diethylamine (1.03 mL, 1.5 eq) to isolate 3.2i as 
a white solid (0.560 g, 36%), Rf = 0.18 (5% MeOH/DCM); 1H-
NMR (400 MHz, MeOH-d4) δ 7.23 (d, J = 2.6 Hz, 1H, H2), 
7.18 (dd, J = 8.6, 2.6 Hz, 1H, H6), 6.66 (d, J = 8.6 Hz, 1H, 
H5), 3.75 (s, 2H, H7), 2.63 (q, J = 7.2 Hz, 4H, H8), 2.07 (s, 
3H, H11), 1.10 (t, J = 7.2 Hz, 6H, H9); 13C-NMR (101 MHz, 
MeOH-d4) δ 169.91, 154.69, 129.95, 122.31, 121.30, 120.91, 115.30, 56.14, 46.16 
(2C), 22.10, 10.20 (2C); LC-MS (ESI+): Purity 84%, (tR 0.136 min), m/z 237.3 [M + H]+. 
N-(3-((diethylamino)methyl)-2-hydroxy-5-methylphenyl)acetamide (3.2j) 
Obtained from 3.1j (0.700 g, 1.0 eq), formaldehyde (0.18 mL, 
1.5 eq) and diethylamine (0.66 mL, 1.5 eq) to isolate 3.2j as 
a white solid (0.521 g, 49%), Rf = 0.18 (5% MeOH/DCM); 1H-
NMR (600 MHz, MeOH-d4) δ 7.61 (d, J = 2.0 Hz, 1H, H6), 
6.61 (d, J = 2.0 Hz, 1H, H4), 3.76 (s, 2H, H7), 2.64 (q, J = 7.2 
Hz, 4H, H8), 2.20 (s, 3H, H10), 2.14 (s, 3H, H12), 1.11 (t, J = 
7.2 Hz, 6H, H9); 13C-NMR (151 MHz, MeOH-d4) δ 171.6, 
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148.0, 128.5, 126.7, 125.9, 122.9, 122.8, 57.6, 47.4 (2C), 23.8, 20.9 and 11.5 (2C); 
LC-MS (ESI+): Purity 98%, (tR 0.151 min), m/z 251.2 [M + H]+. 
 
General procedure for the deacetylation reaction used to form intermediates 3.3a–3.3j 
The appropriate protected Mannich base/-protected amine (1.0 eq) was stirred in 6 M 
hydrogen chloride solution (4 eq) at 100 °C for 2 h. The reaction mixtures were allowed 
to cool, triturated with diethyl ether or DCM and reduced in vacuo to isolate [Mannich 
base]•[2HCl] salts of intermediate compounds 3.3a–3.3j. 
 
4-amino-2-((ethylamino)methyl)phenol (3.3a) 
Obtained from compound 3.2a (0.360 g, 1.0 eq) and 
6M hydrogen chloride solution as a brown oil (0.241 g, 
84%), Rf = 0.1 (15% MeOH/DCM); 1H-NMR (400 MHz, 
DMSO-d6) δ 7.44 (s, 1H, H2), 7.29 (d, J = 8.7 Hz, 1H, 
H5), 7.09 (d, J = 8.6 Hz, 1H, H6), 4.05 (s, 2H, H7), 2.95 
(q, J = 6.6 Hz, 2H, H8), 1.24 (t, J = 7.2 Hz, 3H, H9); 
13C-NMR (101 MHz, DMSO-d6) δ 158.42, 132.64, 
130.48, 124.20, 119.71, 115.42, 44.35, 42.16, 11.22; LC-MS (ESI+): Purity 99%, (tR 
0.142 min), m/z  167.1 [M + H]+. 
5-amino-2-((ethylamino)methyl)phenol (3.3b)  
Obtained from compound 3.2b (200 mg, 1.0 eq) and 6 
M hydrogen chloride solution as a brown oil (120.4 mg, 
75%), Rf = 0.13 (20% MeOH/DCM); 1H-NMR (400 MHz, 
DMSO-d6) δ 7.50 (d, J = 8.1 Hz, 1H, H5), 7.08 (d, J = 
2.0 Hz, 1H, H2), 6.84 (dd, J = 8.1, 2.1 Hz, 1H, H6), 3.85 
(s, 2H, H7), 2.93 (q, J = 6.5 Hz, 2H, H8), 1.23 (t, J = 7.3 
Hz, 3H, H9); 13C-NMR (101 MHz, DMSO-d6) δ 157.32, 
134.60, 132.98, 118.20, 113.71, 110.40, 44.35, 42.16, 11.22; LC-MS (ESI+): Purity 
99%, (tR 0.122 min), m/z 167.1 [M + H]+. 
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2-amino-6-((ethylamino)methyl)phenol (3.3c)  
Obtained from compound 3.2c (100 mg, 1.0 eq) and 6 
M hydrogen chloride solution (4 eq) as a brown oil (65.1 
mg, 81%), Rf = 0.10 (20% MeOH/DCM); 1H-NMR (400 
MHz, MeOH-d4) δ 7.86 (dd, J = 7.9, 1.8 Hz, 1H, H6), 
6.77 (dd, J = 7.5, 1.8 Hz, 1H, H4), 6.32 (t, J = 7.7 Hz, 
1H, H5), 3.71 (s, 2H, H7), 2.62 (q, J = 7.2 Hz, 2H, H8), 
1.12 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 MHz, MeOH-
d4) δ 174.11, 149.44, 127.07, 123.70, 120.64, 117.49, 51.13, 42.59, 14.79; LC-MS 
(ESI+): Purity 94%, (tR 0.126 min), m/z 167.1 [M + H]+. 
2-amino-6-((ethylamino)methyl)-4-fluorophenol (3.3d)  
Obtained from compound 3.2d (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (65 mg, 
80%), Rf = 0.08 (10% MeOH/DCM); 1H-NMR (400 MHz, 
MeOH-d4) δ 7.72 (dd, J = 10.7, 3.2 Hz, 1H, H6), 6.58 
(dd, J = 9.1, 3.2 Hz, 1H, H4), 3.88 (s, 2H, H7), 2.73 (q, 
J = 7.2 Hz, 2H, H8), 1.20 (t, J = 7.6 Hz, 3H, H9); 13C-
NMR (101 MHz, MeOH-d4) δ 156.09 (d, CJF), 145.20, 
123.09 (d, CJF), 117.58–116.85 (m) (2C), 111.99 (d, CJF), 44.96, 42.89, 10.09; LC-
MS (ESI+): Purity 83%, (tR 0.149 min), m/z 185.1 [M + H]+. 
2-amino-4-chloro-6-((ethylamino)methyl)phenol (3.3e)  
Obtained from compound 3.2e (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (75.6 
mg, 91%). Rf = 0.06 (8% MeOH/DCM); 1H-NMR (400 
MHz, MeOH-d4) δ 7.51 (d, J = 8.5 Hz, 1H, H5), 7.30 (d, 
J = 8.6 Hz, 1H, H6), 4.51 (s, 2H, H7), 3.25 (q, J = 7.3 
Hz, 2H, H8), 1.42 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 
MHz, MeOH-d4) δ 150.90, 136.27, 126.15, 122.43, 
120.52, 120.41, 43.31, 42.68, 9.99; LC-MS (ESI+): Purity 72%, (tR 0.180 min), m/z 
201.0 [M + H]+.  
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2-amino-4-chloro-6-((ethylamino)methyl)phenol (3.3f)  
Obtained from compound 3.2f (150 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (92.1 
mg, 74%). Rf = 0.44 (20% MeOH/DCM); 1H-NMR (400 
MHz, DMSO-d6) δ 7.27 (d, J = 2.5 Hz, 1H, H6), 7.20 (d, 
J = 2.5 Hz, 1H, H4), 4.13(s, 2H, H7), 2.98 (q, J = 6.5 
Hz, 2H, H8), 1.24 (t, J = 7.2 Hz, 3H, H9); 13C-NMR (101 
MHz, DMSO-d6) δ 145.86, 125.74, 125.65, 123.96, 
123.11, 120.76, 44.77, 42.46, 11.32; LC-MS (ESI+): Purity 87%, (tR 0.180 min), m/z 
201.1 [M + H]+.  
2-amino-6-((ethylamino)methyl)-4-methylphenol (3.3g)  
Obtained from compound 3.2g (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a red oil (65.1 mg, 
81%). Rf = 0.12 (15% MeOH/DCM); 1H-NMR (400 MHz, 
MeOH-d4) δ 7.95 (d, J = 2.8 Hz, 1H, H6), 6.75 (d, J = 
2.8 Hz, 1H, H4), 4.91 (s, 2H, H7), 2.61 (q, J = 7.1 Hz, 
2H, H8), 2.18 (s, 3H, H10), 1.13 (t, J = 7.2 Hz, 3H, H9); 
13C-NMR (101 MHz, MeOH-d4) δ 146.59, 126.56, 
126.44, 124.17, 123.10, 121.03, 51.36, 42.62, 20.97, 14.77; LC-MS (ESI+): Purity 
82%, (tR 0.124 min), m/z 181.2 [M + H]+. 
2-amino-6-((ethylamino)methyl)-3-methylphenol (3.3h)  
Obtained from compound 3.2h (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (76.2 
mg, 92%). Rf = 0.44 (27% MeOH/DCM); 1H-NMR (400 
MHz, MeOH-d4) δ 7.21 (d, J = 7.8 Hz, 1H, H4), 6.84 (d, 
J = 7.7 Hz, 1H, H5), 4.19 (s, 2H, H7), 3.10 (q, J = 7.0 
Hz, 2H, H8), 2.26 (s, 3H, H10), 1.35 (t, J = 7.3 Hz, 3H, 
H9); 13C-NMR (101 MHz, MeOH-d4) δ 172.39, 151.52, 
137.53, 129.35, 121.32, 117.41, 46.32, 42.20, 16.94, 10.10; LC-MS (ESI+): Purity 




Obtained from compound 3.2i (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (79.0 
mg, 96%). Rf = 0.15 (15% MeOH/DCM); 1H-NMR (400 
MHz, DMSO) δ 7.56 (d, J = 2.6 Hz, 1H, H2), 7.34 (dd, 
J = 8.7, 2.6 Hz, 1H, H6), 7.16 (d, J = 8.7 Hz, 1H, H5), 
4.22 (d, J = 4.6 Hz, 2H, H7), 3.07 (dq, J = 13.9, 7.0 Hz, 
4H, H8), 1.27 (t, J = 7.2 Hz, 6H, H9); 13C-NMR (101 
MHz, DMSO) δ 158.75, 131.29, 128.04, 126.79, 123.84, 118.22, 115.90, 49.64, 45.67 
(2C), 7.11(2C);. LC-MS (ESI+): Purity 99%, (tR 0.116 min), m/z 209.2 [M + H]+. 
2-amino-6-((diethylamino)methyl)-4-methylphenol (3.3j) 
Obtained from compound 3.2j (100 mg, 1.0 eq) and 6M 
hydrogen chloride solution (4 eq) as a brown oil (71.0 
mg, 85%). Rf = 0.14 (15% MeOH/DCM); 1H-NMR (400 
MHz, MeOH-d4) δ 7.44 (d, J = 1.9 Hz, 1H, H6), 7.33 (d, 
J = 1.8 Hz, 1H, H4), 4.43 (s, 2H, H7), 3.24 (m, 4H, H8), 
2.35 (s, 3H, H10), 1.37 (t, J = 7.2 Hz, 6H, H9); 13C-NMR 
(101 MHz, MeOH-d4) δ 148.6, 134.9, 133.6, 127.6, 
122.7, 122.1, 52.1, 48.5 (2C), 20.4, 9.2 (2C); LC-MS (ESI+): Purity 95%, (tR 0.14 min), 
m/z 209.2 [M + H]+.  
 
5.4.3 Synthesis and characterization of final compounds 
General procedures and characterization of final compounds 4, 5, 8, and 9 
The appropriate amine/Mannich base (1.2 eq) was dissolved in EtOH (2 mL) and 
added to compound 1.3a (1.0 eq), followed by the dropwise addition of 4 M hydrogen 
chloride solution (1 eq) and allowed to stir at 23 °C for 10 min. The mixture was 
irradiated in a microwave reactor at 80 °C for 1.5 h. Once cooled to 23 °C, the mixture 
was dissolved in EtOH (5 mL) and reduced in vacuo. The resulting residue was purified 
using column chromatography (DCM/MeOH) and reduced in vacuo. The residue was 




carbonitrile (4)  
Obtained from commercially available 4-aminophenol (34 
mg, 1.2 eq) and intermediate 1.3a (75 mg, 1 eq) as a yellow 
solid (35 mg, 38%), M.P. > 350 °C, Rf = 0.83 (20% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 9.35 (s, 1H, 
NH), 8.75 (d, J = 8.4 Hz, 1H, H10), 7.86 – 7.77 (m, 2H, 
H16/H18), 7.62 (t, J = 7.7 Hz, 1H, H9), 7.43 (t, J = 7.9 Hz, 1H, 
H8), 7.16 – 7.08 (m, 2H, H15/H19), 6.89 (d, J = 8.5 Hz, 1H, 
H7), 6.15 (s, 1H, H2); 13C-NMR (151 MHz, DMSO-d6) δ 
156.02, 149.65, 148.66 (2C), 143.96, 142.31, 135.79, 128.68 (2C), 128.21, 125.47, 
123.65, 122.21, 121.83, 120.01, 116.91, 116.84, 114.91, 70.34; LC-MS (ESI+): Purity 
98%, (tR 2.734 min), m/z 369.0 [M + H]+. 
 1-((3-((ethylamino)methyl)-4-hydroxyphenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (5)  
Obtained from 3.3a (42 mg, 1.5 eq) and 1.3a (50 mg, 1 eq) 
as a brown solid (26 mg, 37%), M.P. 380–382 °C, Rf = 0.48 
(20% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 10.15 
(s, 1H, NH), 8.79 (d, J = 8.8 Hz, 1H, H10), 8.79 – 8.77 (m, 
1H, H18), 7.69 (d, J = 7.2 Hz, 1H, H7), 7.55 (t, J = 7.9 Hz, 
1H, H9), 7.36 (t, J = 7.9 Hz, 1H, H8), 7.25 – 7.07 (m, 1H, 
H15), 7.07 – 6.93 (m, 1H, H19), 6.11 (s, 1H, H2), 4.09 (s, 
2H, H20), 2.97 (q, J = 7.7 Hz, 2H, H21), 1.23 (t, J = 7.2 Hz, 
3H, H22); 13C-NMR (101 MHz, DMSO-d6) δ 187.19, 
162.35, 153.49, 149.06, 142.37, 134.84, 128.87, 126.86, 126.21, 124.22, 123.29, 
122.15, 121.49, 119.74, 117.17 115.57, 115.38, 92.77, 70.27, 44.77, 42.03, 11.20; 






(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (8)  
Obtained from 2.2a (60 mg, 1.5 eq) and 1.3a (70 mg, 1 
eq) as an orange-brown solid (34 mg, 34%), M.P. 235–
237 °C, Rf = 0.63 (20% MeOH/DCM); 1H-NMR (400 
MHz, DMSO-d6) δ 8.80 (dd, J = 8.1, 1.1 Hz, 1H, H10), 
7.57 (dd, J = 7.9, 1.8 Hz, 1H, H7), 7.34 (td, J = 7.2, 1.2 
Hz, 1H, H9), 7.30 – 7.24 (m, 1H, H18), 7.17 (dd, J = 6.8, 
2.7 Hz, 1H, H15), 7.11 (td, J = 7.4, 1.2 Hz, 1H, H8), 7.05 
(ddd, J = 8.7, 4.7, 2.6 Hz, 1H, H19), 5.72 (s, 1H, H2), 
4.20 (s, 2H, H20), 3.05 (q, J = 7.3 Hz, 2H, H21), 1.23 (t, 
J = 7.3 Hz, 3H, H22); 13C-NMR (101 MHz, DMSO-d6) δ 157.45, 155.06, 151.81, 
151.02, 148.01, 145.42, 134.98 (q, CJF), 130.98, 125.39 (d, CJF), 125.31, 124.68 (d, 
CJF), 124.51, 120.23 (d, CJF), 119.03, 118.61, 117.00, 116.78 (d, CJF), 116.36, 
87.87, 43.68, 42.72, 11.38; LC-MS (ESI+): Purity 97%, (tR 2.382 min), m/z 428.1 [M + 
H]+. 
1-((4-chloro-3-((ethylamino)methyl)phenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (9)  
 Obtained from 2.2b (66 mg, 1.5 eq) and 1.3a (77 mg, 1 
eq) as a yellow solid (19.3 mg, 18%), M.P. 273–275 °C, Rf 
= 0.22 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) 
δ 8.83 (dd, J = 8.0, 1.6 Hz, 1H, H10), 7.58 (dd, J = 8.1, 1.7 
Hz, 1H, H7), 7.49 (d, J = 8.5 Hz, 1H, H18), 7.35 (td, J = 
8.2, 1.3 Hz, 1H, H9), 7.26 (d, J = 2.5 Hz, 1H, H15), 7.11 
(td, J = 8.3, 1.2 Hz, 1H, H8), 7.07 (dd, J = 8.5, 2.5 Hz, 1H, 
H19), 5.74 (s, 1H, H2), 4.14 (s, 2H, H20), 3.03 (q, J = 7.2 
Hz, 2H, H21), 1.24 (t, J = 7.2 Hz, 3H, H22); 13C-NMR (101 
MHz, DMSO-d6) δ 151.74, 150.97, 150.84, 145.56, 135.25, 134.96, 131.27, 130.95, 
130.81, 125.74, 125.57, 125.28, 124.62, 119.07, 118.51, 117.01, 116.50, 87.63, 




General synthetic procedures and characterization for final compounds 6, 7, and 10-
16 
The appropriate [Mannich base]•2HCl salt (1.2 eq) was dissolved in EtOH (2 mL) and 
added to a mixture of compound 1.3a (1.0 eq),and KH2PO4 (10 eq) and allowed to stir 
at 23 °C for 10 min. The mixture was irradiated in a microwave reactor at 80 °C for 1.5 
h. Once cooled to 23 °C, the mixture was dissolved in EtOH (5 mL) and reduced in 
vacuo. The resulting residue was purified using column chromatography 
(DCM/MeOH) and reduced in vacuo. The residue was then triturated using pentane or 
diethyl ether to isolate final compounds. 
1-((3-((diethylamino)methyl)-4-hydroxyphenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6)  
Obtained from 3.3i (136 mg, 3 eq) and 1.3a (50 mg, 1 
eq) as a brown solid (26 mg, 37%), M.P. 244 – 245 °C, 
Rf = 0.838 (20% MeOH/DCM); 1H-NMR (600 MHz, 
DMSO-d6) δ 8.81 (dd, J = 8.1, 0.9 Hz, 1H, H10), 7.58 
(dd, J = 8.1, 1.0 Hz, 1H, H7), 7.36 (td, J = 8.2, 1.3 Hz, 
1H, H9), 7.14 (td, J = 8.3, 1.2 Hz, 1H, H8), 7.02 – 7.01 
(m, 1H, H18), 6.94 – 6.93 (m, 2H, H19/H15), 5.84 (s, 
1H, H2), 4.16 (s, 2H, H20), 3.07 (q, J = 7.2 Hz, 4H, 
H21), 1.28 – 1.19 (m, 6H, H22); 13C-NMR (151 MHz, 
DMSO-d6) δ 152.33, 151.57, 150.77, 144.52, 142.10, 134.81, 133.07, 130.77, 126.61, 
125.60, 124.73, 122.97, 121.15, 119.39, 118.97, 118.12, 117.04, 116.06, 89.24, 









(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (7)  
Obtained from 3.3b (42 mg, 1.5 eq), compound 1.3a (50 mg, 
1.5 eq) and 4M Hydrogen chloride solution (0.1 mL, 1 eq) to 
isolate 7 as a brown solid (16.9 mg, 23%), M.P. 274 – 276 
°C, Rf = 0.15 (10% MeOH/DCM); 1H-NMR (400 MHz, DMSO-
d6) δ 8.81 (d, J = 8.2 Hz, 1H, H10), 7.62 (d, J = 8.2 Hz, 1H, 
H7), 7.42 (t, J = 7.8 Hz, 1H, H9), 7.30 (d, J = 7.8 Hz, 1H, 
H18), 7.21 (t, J = 7.9 Hz, 1H, H8), 6.60-6.63 (m, 2H, H15 & 
H19), 6.00 (s, 1H, H2), 4.20 (s, 2H, H20), 3.15 (q, J = 7.2 Hz, 
2H, H21), 1.38 (t, J = 7.3 Hz, 3H, H22); 13C-NMR (101 MHz, 
DMSO-d6) δ 202.61, 177.70, 164.23, 153.77, 149.97, 134.09, 132.80, 130.73, 124.75, 
121.81, 119.46, 117.06, 113.61, 112.14, 109.00, 106.07, 101.19, 100.02, 85.65, 
45.32, 42.25, 11.31; LC-MS (ESI+): Purity 96%, (tR 2.384 min), m/z 426.2 [M + H]+. 
1-((3-((ethylamino)methyl)-5-fluoro-2-hydroxyphenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (10)  
Obtained from 3.3d (60 mg, 1.2 eq), compound 1.3a (80 mg, 
1.0 eq) and KH2PO4 (73 mg, 2 eq) to isolate 10 as a brown 
powder (31 mg, 31%), M.P. 273 – 275 °C, Rf = 0.21 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.83 (dd, J = 
8.0, 1.6 Hz, 1H, H10), 7.58 (dd, J = 8.1, 1.7 Hz, 1H, H7), 
7.35 (td, J = 8.2, 1.3 Hz, 1H, H9), 7.11 (td, J = 8.3, 1.2 Hz, 
1H, H8), 6.87 (dd, J = 9.2, 3.14 Hz, 1H, H17), 6.84 (dd, J = 
10.3, 3.11 Hz, 1H, H15), 5.74 (s, 1H, H2), 4.14 (s, 2H, H20), 
3.03 (q, J = 7.2 Hz, 2H, H21), 1.24 (t, J = 7.2 Hz, 3H, H22); 
13C-NMR (151 MHz, DMSO-d6) δ 156.47, 154.91, 152.17, 151.66, 145.58, 145.09, 
140.15 (d, CJF), 134.95 (q, CJF), 131.21, 124.85, 124.51, 119.20 (d, CJF), 118.91, 
118.54, 117.77, 116.38, 109.96 (d, CJF), 109.50 (d, CJF), 87.90, 45.43, 42.61, 11.39; 





(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (11)  
Obtained from 3.3e (57 mg, 1.2 eq), compound 1.3a (70 mg, 
1.0 eq) and KH2PO4 (65 mg, 2 eq) to isolate 11 as a yellow 
powder (9.8 mg, 9%), M.P. 274 – 275 °C Rf = 0.14 (8% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.84 (dd, J = 
8.1, 2.0 Hz, 1H, H10), 7.58 (dd, J = 8.0, 1.7 Hz, 1H, H7), 7.35 
(td, J = 8.5, 1.3 Hz, 1H, H9), 7.11 (td, J = 8.2, 0.9 Hz, 1H, 
H8), 7.06 – 6.96 (m, 2H, H15/H16), 5.73 (s, 1H, H2), 4.26 (s, 
2H, H20), 3.07 (q, J = 7.2 Hz, 2H, H21), 1.26 (t, J = 7.2 Hz, 
3H, H22); 13C-NMR (151 MHz, DMSO-d6) δ 152.23, 151.66, 
150.51, 145.54, 138.13, 134.88, 131.22, 126.98, 124.85, 124.51, 123.79, 123.03, 
120.44, 118.91, 118.54, 117.80, 116.94, 116.33, 87.99, 49.06, 43.14, 11.35; LC-MS 
(ESI+): Purity 98%, (tR 2.573 min), m/z 460.0 [M + H]+. 
 
1-((5-chloro-3-((ethylamino)methyl)-2-hydroxyphenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (12)  
Obtained from 3.3f (65 mg, 1.2 eq), compound 1.3a (80 mg, 
1.0 eq) and KH2PO4 (73 mg, 2 eq) to isolate 12 as a brown 
powder (21.8 mg, 18%). M.P. 274 – 276 °C, Rf = 0.37 (20% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.82 (dd, J 
= 8.0, 2.0 Hz, 1H, H10), 7.58 (dd, J = 8.0, 1.8 Hz, 1H, H7), 
7.35 (td, J = 8.3, 1.3 Hz, 1H, H9), 7.11 (td, J = 7.4, 1.2 Hz, 
1H, H8), 7.10 – 7.09 (m, 1H, H19), 6.99 (d, J = 2.6 Hz, 1H, 
H17), 5.69 (s, 1H, H2), 4.12 (s, 2H, H20), 3.02 (q, J = 7.2 
Hz, 2H, H21), 1.24 (t, J = 7.2 Hz, 3H, H22); 13C-NMR (151 
MHz, DMSO-d6) δ 152.21, 151.63, 147.71, 145.53, 140.53, 135.00), 131.22, 125.31, 
124.51, 123.70, 123.01, 122.58, 122.29, 120.37, 118.93, 118.49, 117.78, 116.36, 





(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (13)  
Obtained from 3.3f (51 mg, 1.2 eq), compound 1.3a (70 mg, 
1.0 eq) and KH2PO4 (65 mg, 2 eq) to isolate 13 as a yellow 
powder (14 mg, 13%). M.P. 244–245 °C, Rf = 0.25 (15% 
MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 8.87 (dd, J 
= 8.0, 1.8 Hz, 1H, H10), 7.59 (dd, J = 8.0, 1.8 Hz, 1H, H7), 
7.36 (td, J = 8.4, 1.2 Hz, 1H, H9), 7.14 (td, J = 8.5, 1.4 Hz, 
1H, H8), 6.95 (d, J = 7.7 Hz, 1H, H17), 6.80 (d, J = 7.8 Hz, 
1H, H18), 5.31 (s, 1H, H2), 4.1 (s, 2H, H21), 2.99 (q, J = 7.3 
Hz, 2H, H22), 2.03 (s, 3H, H20), 1.23 (t, J = 7.2 Hz, 3H, 
H23); 13C-NMR (101 MHz, DMSO-d6) δ 151.58, 151.29, 147.72, 144.88, 137.11, 
134.56, 131.34, 127.96, 126.64, 124.81, 124.47, 122.99, 121.34, 119.12, 118.59, 
117.76, 116.13, 115.94, 89.16, 45.73, 42.27, 18.18, 11.29; LC-MS (ESI+): Purity 98%, 
(tR 2.492 min), m/z 440.1 [M + H]+. 
1-((3-((ethylamino)methyl)-2-hydroxy-5-methylphenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (14)  
Obtained from 3.3g (47 mg, 1.2 eq), compound 1.3a (65 mg, 
1.0 eq) and KH2PO4 (60 mg, 2 eq) to isolate 14 as a red 
powder (31 mg, 32%). M.P. 266–268 °C, Rf = 0.33 (15% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.84 (dd, J = 
8.1, 2.2 Hz, 1H, H10), 77.57 (dd, J = 8.2, 1.7 Hz, 1H, H7), 
7.34 (td, J = 8.3, 1.3 Hz, 1H, H9), 7.10 (td, J = 8.1, 1.0 Hz, 
1H, H8), 6.84 (d, J = 2.1 Hz, 1H, H17), 6.80 (d, J = 2.0 Hz, 
1H, H19), 5.73 (s, 1H, H2), 4.09 (s, 2H, H20), 3.01 (q, J = 7.2 
Hz, 2H, H21), 2.24 (s, 3H, H23), 1.24 (t, J = 7.2 Hz, 3H, H22); 
13C-NMR (151 MHz, DMSO-d6) δ 151.82, 146.10, 145.27, 
138.50, 134.80, 134.49, 131.26, 128.49, 125.36, 125.15, 124.40, 123.63, 122.64, 
118.87, 118.69, 118.39, 117.64, 116.13, 88.62, 45.73, 42.47, 20.76, 11.32; LC-MS 




(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (15)  
Obtained from 3.3c (71 mg, 1.2 eq), compound 1.3a 
(86 mg, 1.0 eq) and KH2PO4 (79 mg, 2 eq) to isolate 
15 as a yellow solid (31.8 mg, 26%). M.P. 275–277 °C, 
Rf = 0.31 (15% MeOH/DCM); 1H-NMR (600 MHz, 
DMSO-d6) δ 8.83 (dd, J = 8.1, 1.8 Hz, 1H, H10), 7.56 
(dd, J = 8.1, 1.8 Hz, 1H, H7), 7.34 (td, J = 8.2, 1.3 Hz, 
1H, H9), 7.11 (td, J = 8.2, 1.2 Hz, 1H, H8), 7.01 (dd, J 
= 7.6, 1.6 Hz, 1H, H17), 6.97 (dd, J = 7.7, 1.6 Hz, 1H, 
H19), 6.85 (t, J = 7.7 Hz, 1H, H18), 5.76 (s, 1H, H2), 
4.11 (s, 2H, H20), 3.00 (q, J = 7.2 Hz, 2H, H21), 1.22 (t, J = 7.3 Hz, 3H, H22); 13C-
NMR (151 MHz, DMSO-d6) δ 151.59, 148.52, 144.33, 138.30, 134.68, 131.00, 125.09, 
124.73, 123.15, 122.93, 120.52, 119.94, 119.29, 118.82, 118.32, 117.77, 117.30, 
115.88, 114.35, 45.66, 42.51, 11.31; LC-MS (ESI+): Purity 97%, (tR 2.460 min), m/z 
426.2 [M + H]+. 
 
General synthetic procedure and characterization of target compounds 16-28 
The appropriate amine/Mannich base (1.5 eq) was dissolved in EtOH (2 mL) and 
added to the appropriate chlorinated PBI intermediate 1.3a-1.3d (1.0 eq) and KH2PO4 
(2.0 eq). The reaction mixture was allowed to stir at 23 °C for 12 h. The reaction 
mixture was diluted in EtOH (5 mL) and reduced in vacuo. The resulting residue was 
purified using column chromatography (DCM/MeOH) and reduced in vacuo. The 









Obtained from 3.3g (106 mg, 1.5 eq), compound 1.3a (100 
mg, 1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 16 as a 
yellow solid (41.3 mg, 26%). M.P. 268–269 °C Rf = 0.54 (9% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.85 (d, J = 
8.2 Hz, 1H, H10), 7.63 (d, J = 8.0 Hz, 1H, H7), 7.46 (t, J = 7.7 
Hz, 1H, H9), 7.25 (t, J = 7.7 Hz, 1H, H8), 7.00 (d, J = 2.1 Hz, 
1H, H19), 6.88 (d, J = 2.1 Hz, 1H, H17), 5.80 (s, 1H, H2), 
4.24 (s, 2H, H20), 3.12 (q, J = 7.2 Hz, 4H, H21), 2.26 (s, 3H, 
H23), 1.27 (t, J = 7.2 Hz, 6H, H22); 13C-NMR (151 MHz, 
DMSO-d6) δ 151.08, 149.99, 146.68, 139.24, 135.94, 
135.56, 133.67, 133.54, 130.37, 127.99, 126.67, 125.21, 123.58, 121.41, 118.84, 
117.78, 117.65, 114.64, 92.29, 51.24, 46.42 (2C), 19.21, 10.29 (2C); LC-MS (ESI+): 
Purity 98%, (tR 2.151 min), m/z 468.2 [M + H]+. 
1-((3-((ethylamino)methyl)-4-hydroxyphenyl)amino)-3-methylbenzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (17) 
Obtained from 3.3a (85 mg, 1.5 eq), compound 1.3b (100 
mg, 1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 17 as a 
yellow solid (42 mg, 33%). M.P. 227–228 °C, Rf = 0.09 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.47 (d, J = 
8.3 Hz, 1H, H10), 7.72 (d, J = 8.3 Hz, 1H, H7), 7.47 (t, J = 7.7 
Hz, 1H, H9), 7.30 (s, 1H, H15), 7.25 (t, J = 8.4 Hz, 1H, H8), 
7.17 (d, J = 8.1 Hz, 3H, H19), 7.01 (d, J = 8.5 Hz, 1H, H18), 
5.95 (s, 1H, H2), 4.02 (s, 2H, H20), 2.91 (q, J = 7.3 Hz, 2H, 
H21), 2.38 (s, 3H, H13), 1.19 (t, J = 7.2 Hz, 3H, H22); 13C-
NMR (151 MHz, DMSO-d6) δ 153.84, 150.20, 149.40, 
149.09, 129.00, 128.79, 127.22, 126.38, 125.99 (2C), 120.40, 119.80, 117.43, 116.82 
(2C), 116.66, 116.37, 95.65, 45.10, 42.21, 21.02, 11.36; LC-MS (ESI+): Purity 98%, 





Obtained from 3.3i (98 mg, 1.5 eq), compound 1.3b (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 18 as a yellow 
solid (46 mg, 34%). M.P. 243–244 °C, Rf = 0.48 (9% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 10.10 (s, 1H, 
OH), 8.52 (d, J = 8.4 Hz, 1H, H10), 7.78 (d, J = 8.3 Hz, 1H, 
H7), 7.59 (t, J = 7.8 Hz, 1H, H9), 7.49 (d, J = 2.7 Hz, 1H, H15), 
7.38 (t, J = 7.9 Hz, 1H, H8), 7.28 (dd, J = 8.6, 2.7 Hz, 1H, 
H19), 7.13 (d, J = 8.6 Hz, 1H, H18), 6.27 (s, 1H, H2), 4.17 (d, 
J = 5.2 Hz, 2H, H20), 3.11 – 2.97 (m, 3H, H21), 2.46 (s, 3H, 
H13), 1.23 (t, J = 7.2 Hz, 6H, H22); 13C-NMR (151 MHz, 
DMSO-d6) δ 155.26, 152.62, 148.87, 147.75, 130.64, 129.09, 128.00, 127.53, 127.39, 
121.81, 119.88, 117.91, 117.32 (2C), 116.86, 116.40, 115.98, 98.52, 49.82, 46.72 
(2C), 21.09, 8.96 (2C); LC-MS (ESI+): Purity 98%, (tR 2.071 min), m/z 400.3 [M + H]+. 
1-((3-((ethylamino)methyl)-2-hydroxy-5-methylphenyl)amino)-3-
methylbenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (19) 
Obtained from 3.3g (92 mg, 1.5 eq), compound 1.3b (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 19 as a yellow 
solid (33 mg, 25%). M.P. 217–218 °C, Rf = 0.1 (10% 
MeOH/DCM), 1H-NMR (400 MHz, DMSO-d6) δ 8.52 (d, J = 
8.1 Hz, 1H, H10), 7.57 – 7.49 (m, 2H, H7 / H19), 7.48 (t, J = 
7.6 Hz, 1H, H9), 7.37 – 7.27 (m, 2H, H8 / H17), 5.86 (s, 1H, 
H2), 4.16 (s, 1H, H20), 3.06 (q, J = 7.2 Hz, 2H, H21), 2.34 (s, 
3H, H13), 1.27 (t, J = 7.2 Hz, 3H, H22); 13C-NMR (101 MHz, 
DMSO-d6) δ 159.24, 151.58, 149.35, 148.97, 133.95, 
129.00, 128.48, 126.65, 126.25, 122.39, 122.25, 120.85, 
119.36, 117.30, 116.77, 116.41, 112.51, 104.11, 42.97, 42.72, 20.79, 19.56, 11.28; 






Obtained from 3.3j (106 mg, 1.5 eq), compound 1.3b 
(100mg, 1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 20 as 
a yellow solid (55 mg, 39%). M.P. 234–235 °C, Rf = 0.48 
(10% MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 10.12 
(s, 1H, OH), 8.68 (d, J = 8.4 Hz, 1H, H10), 7.76 (d, J = 8.2 
Hz, 1H, H7), 7.59 (t, J = 7.7 Hz, 1H, H9), 7.38 (t, J = 7.8 Hz, 
1H, H8), 7.36 (s, 1H, H19), 7.13 (s, 1H, H17), 4.25 (s, 2H, 
H20), 3.10 – 3.02 (m, 4H, H21), 2.40 (s, 3H, H13), 2.24 (s, 
3H, H23), 1.26 (t, J = 7.2 Hz, 6H, H22); 13C-NMR (151 MHz, 
DMSO-d6) δ 151.75, 149.25, 148.99, 147.61, 145.83, 
131.99, 129.59, 129.21, 128.30, 127.23, 123.85, 121.79, 119.47, 118.97, 117.31, 
116.17, 115.86, 97.79, 50.18, 46.64 (2C), 21.03, 20.49, 8.94 (2C); LC-MS (ESI+): 




Obtained from 3.3a (90 mg, 1.5 eq), compound 1.3d (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 21 as a yellow 
solid (33 mg, 22%). M.P. 269–270 °C, Rf = 0.12 (10 % 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.58 (dd, J = 
11.6, 7.6 Hz, 1H, H10), 7.70 (dd, J = 11.2, 7.7 Hz, 1H, H7), 
7.23 (d, J = 2.6 Hz, 1H, H15), 7.13 (dd, J = 8.7, 2.6 Hz, 1H, 
H19), 6.98 (d, J = 8.6 Hz, 1H, H18), 5.84 (s, 1H, H2), 4.03 
(s, 2H, H20), 2.93 (q, J = 7.3 Hz, 2H, H21), 2.33 (s, 3H, H13), 
1.19 (t, J = 7.2 Hz, 3H, H22); 13C-NMR (151 MHz, DMSO-d6) 
δ 153.46, 151.65, 149.51, 149.14, 147.91, 147.81, 145.12, 
143.55, 141.19, 127.27, 126.48, 124.40, 119.57, 117.81, 116.73, 104.97, 104.81, 
95.13, 45.10, 42.27, 21.05, 11.29; 19F NMR (377 MHz, DMSO-d6) δ -140.10, -146.56; 




methylbenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (22)  
Obtained from 3.3i (100 mg, 1.2 eq), compound 1.3d 
(100mg, 1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 22 as 
a yellow solid (45 mg, 29%). M.P. 289–290 °C, Rf = 0.44 
(10% MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.55 
(dd, J = 11.4, 7.3 Hz, 1H, H10), 7.82 (dd, J = 11.0, 7.6 Hz, 
1H, H7), 7.43 (d, J = 2.7 Hz, 1H, H15), 7.28 (dd, J = 7.7, 2.6 
Hz, 1H, H19), 7.08 (d, J = 8.6 Hz, 1H, H18), 6.03 (s, 1H, H2), 
4.18 (s, 2H, H20), 3.06 (q, J = 7.24 Hz, 4H, H21), 2.41 (s, 3H, 
H13), 1.23 (t, J = 7.2 Hz, 6H, H22); 13C-NMR (151 MHz, 
DMSO-d6) δ 155.05, 151.43, 150.63, 149.93, 148.14, 
145.66, 144.18, 129.11, 127.71, 123.73, 123.66, 117.95, 117.15, 116.59, 105.61, 
105.15, 104.98, 96.44, 50.15, 46.92 (2C), 21.03, 9.00 (2C); LC-MS (ESI+): Purity 98%, 
(tR 2.322 min), m/z 436.2 [M + H]+. 
1-((3-((ethylamino)methyl)-2-hydroxy-5-methylphenyl)amino)-7,8-difluoro-3-
methylbenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (23) 
Obtained from 3.3g (98 mg, 1.5 eq), compound 1.3d (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 23 as a yellow 
solid (45 mg, 29%). M.P. 257–258 °C, Rf = 0.47 (10% 
MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 8.77 (dd, J = 
11.8, 7.4 Hz, 1H, H10), 7.88 – 7.79 (m, 1H, H7), 7.23 (d, J = 
2.3 Hz, 1H, H19), 6.89 (d, J = 2.4 Hz, 1H, H17), 5.60 (s, 1H, 
H2), 4.15 (s, 2H, H20), 3.05 (q, J = 7.2 Hz, 2H, H21), 2.44 (s, 
3H, H13), 2.39 (s, 3H, H23), 1.27 (t, J = 7.3 Hz, 3H, H22); 
13C-NMR (101 MHz, DMSO-d6) δ 152.21, 150.71, 150.16, 
148.48, 147.87, 146.02, 143.81, 143.67, 138.81, 129.13, 
124.14, 124.03, 122.49, 119.87, 116.80, 105.64, 105.39, 94.81, 42.88, 42.44, 21.05, 
19.78, 11.29; 19F NMR (377 MHz, DMSO-d6) δ -139.04 (d, J = 22.1 Hz), -145.75 (d, J 





Obtained from 3.3j (105 mg, 1.2 eq), compound 1.3d (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 24 as a yellow 
solid (41 mg, 25%). M.P. 205–206 °C, Rf = 0.47 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.69 (dd, J = 
11.6, 7.3 Hz, 1H, H10), 7.79 (dd, J = 11.6, 7.3 Hz, 1H, H7), 
7.27 (s, 1H, H19), 7.14 (s, 1H, H17), 5.59 (s, 1H, H2), 4.23 
(s, 2H, H20), 3.08 (q, J = 7.2 Hz, 4H, H21), 2.35 (s, 3H, H13), 
2.24 (s, 3H, H23), 1.24 (t, J = 7.2 Hz, 6H, H22); 13C-NMR 
(151 MHz, DMSO-d6) δ 150.99, 150.57, 149.88, 149.65, 
148.05, 145.73, 144.17, 131.97, 129.76, 129.53, 124.04, 
123.97, 119.29, 116.76, 105.51, 105.34, 105.08, 95.30, 50.57, 46.90 (2C), 21.00, 




Obtained from 3.3a (75 mg, 1.5 eq), compound 1.3c (100mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 25 as a yellow 
solid (25 mg, 18%). M.P. 265–266 °C, Rf = 0.13 (10% 
MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6) δ 8.80 (dd, J = 
11.5, 7.7 Hz, 1H, H10), 7.79 (dd, J = 10.9, 7.4 Hz, 1H, H7), 
7.24 (d, J = 2.6 Hz, 1H, H15), 7.14 (dd, J = 8.6, 2.6 Hz, 1H, 
H19), 7.04 (d, J = 8.5 Hz, 1H, H18), 6.04 (s, 1H, H2), 4.10 (s, 
2H, H20), 3.15 – 3.04 (m, 2H, H21), 1.23 (t, J = 7.3 Hz, 3H, 
H22); 13C-NMR (101 MHz, DMSO-d6) δ 164.70, 153.68, 
151.17, 149.67, 143.98, 139.51, 135.53, 127.99, 127.05, 
126.06, 124.61, 121.65, 119.70, 116.89, 115.87, 105.53, 105.27, 46.17, 45.12, 42.32, 
11.24, 9.04; 19F NMR (377 MHz, DMSO-d6) δ -62.33, -138.74, -144.74; LC-MS (ESI+): 





Obtained from 3.3i (44 mg, 1.2 eq), compound 1.3c (50mg, 
1.0 eq) and KH2PO4 (46 mg, 2 eq) to isolate 26 as a yellow 
solid (8.7 mg, 12%). M.P. 150–151 °C, Rf = 0.49 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.70 (dd, J = 
11.5, 8.2 Hz, 1H, H10), 7.51 (dd, J = 11.4, 7.5 Hz, 1H, H7), 
7.01 (d, J = 2.5 Hz, 1H, H15), 6.93 (d, J = 8.5 Hz, 1H, H18), 
6.89 (dd, J = 8.5, 2.5 Hz, 1H, H19), 5.70 (s, 1H, H2), 4.17 (s, 
2H, H20), 3.08 (q, J = 7.2 Hz, 4H, H21), 1.21 (t, J = 7.2 Hz, 
6H, H22); 13C-NMR (151 MHz, DMSO-d6) δ 153.48, 152.12, 
150.44, 147.20, 142.41, 141.60, 134.86, 134.66, 126.12, 
125.95, 124.72, 122.91, 118.33, 117.73, 116.95, 104.90, 103.25, 88.59, 70.22, 50.91, 
47.08 (2C), 8.99 (2C); LC-MS (ESI+): Purity 98%, (tR 2.445 min), m/z 490.2 [M + H]+. 
1-((3-((ethylamino)methyl)-2-hydroxy-5-methylphenyl)amino)-7,8-difluoro-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (27) 
Obtained from 3.3g (82 mg, 1.5 eq), compound 1.3c (100 
mg, 1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 27 as a 
yellow solid (17 mg, 12%). M.P. >300 °C, Rf = 0.41 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.75 (dd, J = 
11.6, 8.1 Hz, 1H, H10), 7.54 (dd, J = 11.1, 7.4 Hz, 1H, H7), 
6.84 (s, 1H, H19), 6.79 (s, 1H, H17), 5.69 (s, 1H, H2), 4.06 
(s, 2H, H20), 3.00 – 2.96 (m, 2H, H21), 2.20 (s, 3H, H23), 
1.20 (t, J = 7.3 Hz, 3H, H22); 13C-NMR (151 MHz, DMSO-d6) 
δ 152.86, 151.06, 149.06, 146.33, 144.72, 135.00, 134.80, 
128.59, 126.00, 124.57, 124.19, 122.75, 118.88, 117.82, 
105.83, 105.66, 103.19, 89.22, 46.27, 45.69, 42.49, 20.66, 11.29; 19F NMR (377 MHz, 
DMSO-d6) δ -62.34, -141.54, -147.82; LC-MS (ESI+): Purity 98%, (tR 2.607 min), m/z 





(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (28)  
Obtained from 3.3j (47 mg, 1.2 eq), compound 1.3c (50 mg, 
1.0 eq) and KH2PO4 (92 mg, 2 eq) to isolate 28 as a yellow 
solid (19 mg, 25%). M.P. 235–236 °C, Rf = 0.41 (10% 
MeOH/DCM); 1H-NMR (600 MHz, DMSO-d6) δ 8.72 (dd, J = 
11.5, 8.1 Hz, 1H, H10), 7.51 (dd, J = 11.4, 7.4 Hz, 1H, H7), 
6.86 (s, 1H, H19), 6.80 (s, 1H, H17), 5.63 (s, 1H, H2), 4.20 
(s, 2H, H20), 3.10 (q, J = 7.2 Hz, 4H, H21), 2.20 (s, 3H, H23), 
1.23 (t, J = 7.2 Hz, 6H, H22); 13C-NMR (151 MHz, DMSO-d6) 
δ 153.02, 151.19, 148.99, 147.40, 146.82, 144.63, 143.08, 
140.97, 134.96, 128.86, 126.93, 126.07, 124.76, 122.79, 
117.99, 117.29, 105.61, 103.02, 89.08, 51.17, 47.14 (2C), 20.64, 8.97 (2C); LC-MS 
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